

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

A systematic mixed studies review of treatment and health outcome priorities of multi-morbid patients and clinicians

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033445
Article Type:	Research
Date Submitted by the Author:	05-Aug-2019
Complete List of Authors:	Sathanapally, Harini; University of Leicester Diabetes Research Centre, Sidhu, Manbinder S.; University of Birmingham, Fahami, Radia; University of Leicester Diabetes Research Centre Gillies, Clare; University of Leicester Diabetes Research Centre Kadam , Umesh ; University of Leicester, Davies, Melanie; University of Leicester Diabetes Research Centre Khunti, Kamlesh; University of Leicester Diabetes Research Centre Seidu, Samuel; University of Leicester Diabetes Research Centre
Keywords:	PRIMARY CARE, GENERAL MEDICINE (see Internal Medicine), QUALITATIVE RESEARCH





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

A systematic mixed studies review of treatment and health outcome priorities of multi-morbid patients and clinicians

Harini Sathanapally¹, Manbinder Sidhu², Radia Fahami¹, Clare Gillies¹, Umesh Kadam¹, Melanie J Davies¹, Kamlesh Khunti¹ and Samuel Seidu¹

- 1. Diabetes research centre, College of Life Sciences, University of Leicester, UK
- 2. Health Services Management Centre, School of Social Policy, University of Birmingham, UK

Corresponding author: Dr Harini Sathanapally (hs333@student.le.ac.uk)

Word count excluding titles, abstract, article summary, tables, figures and references: 4414

Author contributions: HS: Design of research question and methodology, data searching, data extraction, data analysis and manuscript development; MS: Design of methodology, data extraction, data analysis and manuscript development; RF: Data searching and data extraction; CG: Data analysis and manuscript development; UK: Data analysis and manuscript development; MJD: Data analysis and manuscript development; KK: Design of research question and methodology, manuscript development; SS: Conception of the idea for this review, design of research question and methodology, data extraction, data analysis and manuscript development; All authors have approved the final manuscript.

Funding: Harini Sathanapally is funded by the NIHR academic clinical fellowship award

Competing interests: None declared

Patient consent for publication: Not required

Data sharing statement: The majority of the data extracted and analysed as part of this review has been included in this article and associated appendices. Any further data can be acquired from the corresponding author by request.

Patient and public involvement: Patient and public involvement was not applicable in the design, conduct or reporting of this review.

ABSTRACT

Objectives : To identify studies that have investigated the health outcome and treatment priorities of multi-morbid patients, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether there is a disparity between the priorities of multi-morbid patients and clinicians.

Design: Systematic review

Data sources: MEDLINE, EMBASE, CINHAL and Cochrane databases from inception to May 2019 using a pre-defined search strategy, as well as reference lists containing any relevant articles, as per PRISMA and Cochrane guidelines.

Eligibility criteria: We included studies reporting health outcome and treatment priorities of adult multimorbid patients, or of clinicians in the context of multi-morbidity, or both. There was no restriction by study design, and studies using quantitative and/or qualitative methodologies were included.

Data synthesis: We used a narrative synthesis approach to synthesise the quantitative findings, and a meta-ethnography approach to synthesise the qualitative findings.

Results: Our search resulted in the identification of 24 studies for inclusion, which comprised of 12 quantitative studies, 10 qualitative studies and 2 mixed-methods studies. Twelve studies reported the priorities of both patients and clinicians (7 quantitative, 3 qualitative and 2 mixed-methods studies), ten studies reported the priorities of patients alone (3 quantitative and 7 qualitative studies) and two studies reported the priorities of clinicians alone (2 quantitative studies).

Conclusion: Our findings have shown that there is a mostly low level of agreement between the priorities of multi-morbid patients and clinicians. We found that prioritisation by multi-morbid patients was mainly driven by their illness experiences, whilst clinicians focused on longer term risks. Recognising that there may be a disparity in prioritisation and understanding the reasons for why this might occur, can facilitate clinicians in accurately eliciting the priorities that are most important to their patients and delivering patient-centred care.

KEY WORDS: Patient-centred care, Shared decision-making, Multi-morbidity

ARTICLE SUMMARY

Strengths and limitations

- This is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both clinicians treating and patients living with multi-morbidity.
- We have included papers using both qualitative and quantitative methodologies and have been able to explore patterns and relationships in the findings, thus creating a comprehensive and well-rounded systematic review.
- Our findings facilitate clinicians in understanding both *how* and *why* the health outcome and treatment priorities of their multi-morbid patients might differ from their own priorities.
- Meta-analysis of the quantitative studies was unfeasible as there was a large variation in the tools used to ascertain priorities, and we have attempted to mitigate this by using a welldescribed and transparent method of narrative synthesis.
- A number of our included quantitative studies did not use pre-validated tools to ascertain priorities, leading to a risk of measurement bias.

INTRODUCTION

Multi-morbidity, defined as the co-existence of two or more long-term conditions [1] is a global problem [2], which has become the norm across high-income countries [2, 3][4, 5] and becoming increasingly prevalent in middle and low-income countries [6][7][2]. Guidelines for the management of chronic diseases are often single disease-orientated, and can lead to confusion and complications when applied to patients with multi-morbidity [8]. Multi-morbid patients have an increased risk of adverse drug-related events as a result of high levels of polypharmacy and receiving un-coordinated care from multiple healthcare providers [9]. These patients have a poorer health-related quality of life [10], poorer functional status [11] and greater psychological distress [12]. As a result, understanding and finding better strategies to facilitate the management of multi-morbid patients has been identified as a priority for health research [13].

Key to the effective management of multi-morbidity is using patient-centred care and shared decision-making to set management goals that are acceptable to both the patient and the clinician [14]. Incorporating the priorities of patients in relation to treatments and health outcomes is integral to this process [15-17]. However, previous research has shown that whilst doctors recognise the importance of eliciting and incorporating the priorities of their multi-morbid patients, they do not always engage with this process in real world settings, and find eliciting patients' priorities to be difficult [18] [19]. Previous research, completed in a single disease context, has shown that the treatment and health outcome priorities of patients and clinicians can differ [20-22], and some studies have highlighted a gap between what doctors' perceive to be the priorities of their patients, and the actual priorities of their patients [23-25].

This systematic review aims to identify studies that have investigated the health outcome and treatment priorities of multi-morbid patients, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether there is a disparity between the priorities of multi-morbid patients and clinicians.

METHODS

Search strategy

This systematic review has been registered on PROSPERO (ID: CRD42018076076). A comprehensive search strategy (Appendix 1), was developed using guidance for best practice [26] and input from academic librarians at the University of Leicester. The search strategy was used to search MEDLINE, EMBASE, CINHAL and COCHRANE databases from inception to May 2019, as well as searching reference lists for any relevant articles based on PRISMA and Cochrane guidelines [26-28]. Citations were stored using Refworks. We have presented our process of article selection in Figure 1.

We included studies reporting the health outcome and treatment priorities of adult patients with multimorbidity [1] and/or clinicians, in relation to patients with multi-morbidity. Studies which did not specify the definition of multi-morbidity as "two or more chronic conditions" [1] in their inclusion criteria, but had a sample patients representative of being diagnosed with multi-morbidity (i.e. with a minimum of two chronic conditions), were also included. There was no restriction by study design, and we included studies using quantitative and/or qualitative methodologies. We excluded studies not published in English language, studies with participants aged under 18 years, and studies focusing on a single disease area.

Study selection

The titles and abstracts of all articles identified by the literature search were assessed independently and in duplicate by two reviewers (HS and RF). Studies that did not meet inclusion criteria were discarded. Full text of selected articles were retrieved and assessed to determine if they met the inclusion criteria, and those studies which met the inclusion criteria were included in the review. Any discrepancies regarding eligibility of an article were discussed, and consensus reached with MS and SS.

Methodological quality assessment and data extraction

Data was extracted using standardised data extraction forms by a single reviewer (HS), and these were checked independently for accuracy by a second reviewer (SS). The reported health outcome and treatment priorities of study participants were the key outcomes that were extracted.

Quality assessment was carried out in parallel with the data extraction process. For the quantitative studies, due to the heterogeneity of study design, we used the AXIS tool for assessment for the cross-sectional studies [29], the Newcastle-Ottawa scale for assessment of the longitudinal observational and cohort studies [30], and the Cochrane collaboration's risk of bias tool for assessment of randomised controlled trials [31]. For the qualitative studies, we used the CASP checklist for appraisal of qualitative research [32]. For the two mixed-methods studies, we used the AXIS tool [29] to assess the quantitative aspects of the study (both cross-sectional in study design), and the CASP checklist for qualitative research [32], to assess the qualitative aspects of these studies.

Data synthesis

We decided *a priori* not to carry out a meta-analysis due to the heterogeneity of the quantitative studies. Therefore, we have taken a narrative synthesis approach, described by Popay et al [33] to synthesise our quantitative findings. Our approach consists of three key steps:

1) *Development of a preliminary synthesis* in which study characteristics and descriptions are collated and findings presented in a summary table

2) Exploring relationships in the data between study characteristics and their findings, as well as between the reported findings across different studies with explanations considered where relationships were identified.

c) Assessing the robustness of the synthesis using quality assessment tools to guide conclusions and identify directions for clinical practice.

Qualitative studies were synthesised using a meta-ethnography approach [34, 35], which consisted of careful reading of the papers, extracting information regarding the context of the study and findings. *Key concepts* arising from each paper were also identified, with preservation of the terminology used by the authors where possible to ensure accurate representation of the findings of the original studies. The key concepts across the papers were then *translated* using a table summarising the studies, their findings in relation to the key concepts and the *second order* interpretations of the authors, which enabled the exploration of any relationships and differences. The translations were then synthesised using a table containing the *first order* and *second order* interpretations for the key concepts across the studies, which then led to the development of further, *third order* interpretations by reviewers [34, 35].

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

RESULTS

Overall study characteristics

Our search resulted in the identification of 24 studies for inclusion, which comprised of 12 quantitative studies, 10 qualitative studies and 2 mixed-methods studies. The characteristics of all of the included studies are described in Table 1. The included studies had all been conducted in high income developed countries, including Canada [36, 37], USA[38-45], Netherlands[46, 47], Australia[48, 49], UK[50-52], Germany [53-56] and Switzerland [57-59]. Sample sizes ranged from 15 to 1169 patients and 5 to 92 clinicians in the quantitative studies, and 15 to 146 patients and 4 to 19 clinicians in the qualitative studies.

Author and year of publication	Setting	Study type	Study aims	Target group and number of participants (n)	Outcomes measured
		QUANTITAT	IVE		
Moore et al, 2014 [36]	Canada- Databases of all practising nurse practitioners, family practitioners and geriatricians in Ontario	Quantitative: Cross-sectional survey	To quantify how family physicians, nurse practitioners and geriatricians prioritize syndromes, diseases and conditions when caring for seniors	Nurse practitioners (n=68) Family practitioners (n=84) Geriatricians (n=27)	Frequency and importance rankings given by family practitioners, nurse practitioners and geriatricians to 41 health issues known to arise in elderly patients
Fried et al, 2011 [39]	USA- 3 senior centres and 1 assisted living facility	Quantitative: Cross-sectional study	To explore the use of a simple tool to elicit older persons' health outcome priorities	All volunteers included (n=357)	The prioritisation by participants of 4 universal health outcomes, namely: -keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms
Fried et al , 2011, [40]	USA- recruited from participants in a larger study, where they had been recruited from age- aggregated community housing [60]	Quantitative: Cross-sectional survey	To determine the feasibility of using a simple tool to elicit the preferences of older persons based on their prioritization of universal outcomes	Patients aged 65 and over with a known diagnosis of hypertension or use of anti-hypertensive medications, and having a known risk of falls (n=81)	 > Rankings given by participants to 4 universal health outcomes in the outcome prioritisation tool: keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms > Feasibility of the use of outcome prioritisation tool
Fried et al, 2006 [42]	USA- sub- speciality outpatient practices, a community hospital, a university teaching hospital and a veterans administration hospital.	Quantitative: Longitudinal observational study	To examine changes over time in end-of-life treatment preferences, measured in terms of willingness to undergo treatment based on the health state that would result from the treatment, in a cohort of older persons with advanced chronic illness	Patients aged 60 or over with a primary diagnosis of cancer, congestive heart failure or chronic obstructive pulmonary disease and need assistance with at least 1 instrumental activity of daily living (n=226 at baseline, 98 at follow up)	Patient reported acceptability of four health states that could result from treatment (at baseline and 4 monthly intervals over 2 years) namely: -unable to leave house -only able to get from bed to chair -Severe memory problems -Daily pain

1
2
3
4 5
5
6
7
7 8 9 10 11 12 13
a
10
10
11
12
13
14 15
15
16
17
17 18
19
20
21
ר ∠ בר
22
20 21 22 23 24 25 26 27 28 29 30
24
25
26
27
28
29
30
31
32
33
34 35
35
36
37
38
39
40
41
42
43
44
45
45 46
40 47
48
49
50
51
52
53
54
55
56
57
58
50 59
72

Zulman et al, 2010 [45]	USA- Scheduled primary care visit for patients at 9 veteran affairs facilities	Quantitative: Prospective cohort study	To understand patterns of patient-provider concordance in the prioritization of health conditions in patients with multimorbidity	Patients with diabetes and hypertension who had their primary diabetes care provider enrolled in the study (n = 1169) Primary care providers i.e. physicians, physician assistants or nurse practitioners (n= 92)	-Patient rankings given in terms of their most important health concerns and providers ranking in terms of conditions most likely to affect each patient's outcomes -Concordance between the importance ratings of patient- provider "pairs"
Van Summeren et al, 2017 [47]	Netherlands- General practice centres	Quantitative: Cross-sectional and implementation study	To determine proposed and observed medication changes when using an outcome prioritisation tool during a medication review in older patients with multimorbidity and polypharmacy. A secondary aim was to explore the relationship between the prioritized health outcome of patients and the type of medication change, such as a stop, a dose adjustment, or a switch.	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications. (n=59) General practitioners (n=17)	 >Patients' priority rankings of the four health outcomes in the outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain >Medication changes proposed by the GP, and observed in the patient records following incorporation of the priority rankings given by patients, into a medication review consultation.
Junius-Walker et al 2012 [53]	Germany- General practice centres	Quantitative: Randomised controlled trial	To investigate whether a structured priority-setting consultation reconciles the often-differing doctor-patient views on the importance of problems.	Patients aged 70 or over (n=317) General practitioners (n=40)	-Baseline importance rankings given by patients and clinicians to a list of problems generated from a geriatric assessment for each patient. - Importance rankings given again after a structured consultation incorporating the baseline problem list and importance rankings and degre of reconciliation in doctor- patient agreement after the structured consultation
Junius-Walker et al, 2011[54]	Germany- General practice centres	Quantitative: Cross-sectional survey	To gain insight into setting individual priorities with older patients using a priority definition that was coherent to the patients' life and doctors' work context	Patients aged 70 or over and living at home (n=123) General practitioners (n=11)	Importance rankings given by patients and clinicians to a list problems generated from a geriatric assessment for each patient.
Voigt et al, 2010 [55]	Germany-General practice centres	Quantitative: Cross-sectional survey	To ascertain health priorities of older patients and treatment priorities of their general practitioners (GP) on the basis of a	Patients aged 70 or over and at least one contact with the general practitioner in the preceding 3 months (n= 35)	 Importance rankings given to problems generated from a geriatric assessment by patient and clinicians Degree of agreement betweer patients and clinicians on the above

			geriatric assessment and to determine the agreement between these priorities.	General practitioners (n=9)	
Herzig et al, 2019 [57]	Switzerland- Primary data was from "Multimorbidity in Family medicine" study[61]. Patients enrolled by General practitioners during scheduled consultations.	Quantitative: Cross-sectional survey	To describe FPs' medical priority ranking of conditions relative to their prevalence in patients with multimorbidity	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International classification of primary care 2 (n=888) General Practitioners (n=100)	Importance rankings given by family practitioners to the list o chronic conditions that each patient had on the day of their inclusion in the study
Mantelli et al, 2018[58]	Switzerland- General practitioners working in Switzerland who had previously taken part in case-vignette studies	Quantitative: cross-sectional survey	To determine whether, how and why GPs de- prescribe in frail oldest-old patients with multimorbidity and polypharmacy, and to identify factors that influenced their decision to de- prescribe	General Practitioners (n=157)	 Percentage of GPs willing to de-prescribe at least one medication in the case of frail older patients with CVD and compared to frail older patients without CVD Reasons for de-prescribing Importance ratings given to factors influencing decision to de-prescribe
Déruaz-Luyet et al, 2018 [59]	Switzerland- Primary data was from "Multimorbidity in Family medicine" study [61]. Patients enrolled by General practitioners during scheduled consultations.	Quantitative: Cross-sectional survey	To evaluate whether GPs could identify the condition that their patients with multimorbidity considered most important.	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International classification of primary care 2, and receiving follow-up from their GP for at least the preceding 6 months (n= 572 for main analysis, 585 for sensitivity analysis) General Practitioners (n=100)	Whether there is agreement between what patients considered to be their most important health condition and what GPs thought patients considered to be their most important health condition
		MIXED-METH			
Van Summeren et al, 2016 [46]	Netherlands- General practice centres	Mixed-methods: Cross-sectional survey pilot and qualitative interviews to assess acceptability (semi-structured and indepth)	To explore whether an outcome prioritization tool (OPT) is appropriate in the context of medication review in family practice, focusing on its acceptability and practicality	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications (n=60) General practitioners (n=13)	 >Patients' prioritisation of the four domains of the outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain > Family practitioners views on the acceptability and practicalit of using the outcome prioritisation tool for medicatio review

Caughey et al, 2017 [48]	Australia- Multi- disciplinary ambulatory consulting service clinics at tertiary teaching hospitals	Mixed-methods: Structured quantitative interviews with patients then semi-structured qualitative interviews with patients and clinicians	To investigate how older patients with multi-morbidity balance the benefits and harms associated with medication for prevention of CVD, and in the presence of competing health outcomes. To investigate the	Patients aged 65 or older with 2 or more chronic conditions (n=15) Clinicians (n=5)	 Patient willingness to take a medication when presented with different scenarios with variable degree of benefit, impact on daily living, adverse outcomes and impact on othe comorbid conditions Patient-reported data during semi-structured interviews where they were asked about their treatment preferences, medication effects and shared decision making
			factors that clinicians consider when making treatment decisions for older, multimorbid particets		-Clinician reported data during semi-structured interviews on treatment decisions, patient preferences and polypharmac
		QUALITATI	patients. VF		
Kuluski et a, 2013 [37]	Canada- A Family Health Team in Ontario	Qualitative: Semi- structured interviews	To examine patient goals of care from the perspectives of older persons with multi-morbidities, their family physicians and informal caregivers (i.e., family member or friend who provides ongoing support) and then examine the extent of alignment between these three perspectives	Patients aged 65 or older with a diagnosis of at least two chronic health conditions (n=28) Informal Caregivers of included patients (n=28) Family physicians (n=4)	 Patient, caregiver and physician reported data on go of care for the patients Degree of alignment of goals care across patient, caregiver and physician "triads"
Schoenberg et al, 2009 [38]	USA- Senior centres, Low income senior housing complexes, churches and a civic meeting hall	Qualitative: In- depth interviews	To understand how vulnerable older adults with multimorbidity prioritize and manage their chronic conditions	Patients aged 55 or older with a diagnosis of at least two chronic illnesses, from low- income backgrounds (n= 41)	Patient-reported data from in- depth interviews, regarding their previous health, perceptions and self-care procedures in relation to their multi-morbidity
Fried et al, 2008 [41]	USA- Senior centres, Doctors' practices and a congregate housing site	Qualitative: Focus groups	To examine the ways in which older persons with multiple conditions think about potentially competing outcomes, in order to gain insight into how processes to elicit values regarding these outcomes can be grounded in the patient's perspective	Patients aged 65 or older and were taking 5 or more medications (participants also had a minimum of 3 chronic conditions)	Patient-reported data regardin their perceptions of the interactions between their different illnesses and treatmen regimens, goals of treatment and decisions regarding treatment

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Naik et al, 2016 [43]	USA- Qualitative data from the VETCARES study [62] , in which participants recruited from the VA tumour registry	Qualitative: Open-ended questions as part of mixed methods interviews which also included structured questions	To identify a taxonomy of health-related values that frame goals of care of older, multi- morbid adults who recently faced cancer diagnosis and treatment	Veterans with a diagnosis of head and neck, gastric, oesophageal, or colorectal cancer, and diagnosis fell one month prior to the study's opening eligibility window (6 months) (n=146)	Patient-reported data regarding their priorities or concerns regarding their future healthcare decisions
Elliott et al, 2007 [44]	USA- Harvard Pilgrim Health Centre, a HMO (health maintenance organisation) in New England	Qualitative: Semi- structured interviews	To explore how older adults with multiple illnesses make choices about medicines	Patients taking more than three medicines with purposive sampling to reflect symptomatic comorbidities and asymptomatic comorbidities and mental health issues (participants had a minimum of 3 comorbidities) (n=20)	Patient-reported data regarding beliefs about medicines, medicine-taking behaviour, historical vs potential choices between different medicines, and factors influencing these choices
Turner et al, 2016 [49]	Australia- Long term care facilities in South Australia	Qualitative: Nominal group technique	To use nominal group technique to generate then rank factors that general medical practitioners, nurses, pharmacists and residents or their representatives perceive are most important when deciding whether or not to de- prescribe medication	Residents/representatives of residents (n=11) General Practitioners (n=19) Nurses (n=12) Pharmacists (n=14)	-Generated factors important for de-prescribing according to residents/resident representatives, general practitioners, nurses and pharmacists -Priority rankings given by groups containing representatives from all of the above, to the list of priorities generated previously.
Lindsay, 2009 [50]	UK- Participants recruited from CHD registries in Greater Manchester as part of a larger RCT[63]	Qualitative: Focus groups and two interviews	To use the concepts of "chronic illness trajectory" and "biographical disruption" to examine how patients self- manage multiple chronic conditions and especially how they prioritize their conditions	Participants from the parent study who had more than one chronic condition (i.e. at least two) (n=53)	Patient-reported data regarding how they prioritised their multiple conditions, what strategies they used to cope with their conditions and barriers in being able to manage their illnesses
Cheraghi-Sohi et al, 2013 [51]	UK- secondary analysis of qualitative data from four other studies [64-67]	Qualitative: In- depth interviews	To explore how and why people with multimorbidity prioritise some long-term conditions over others and what the potential implications may be for self- management activity, and in turn, suggest how such information may help clinicians negotiate the management of	Participants from original studies who had two or more long term conditions, and had given data regarding prioritisation (n=41)	Patient-reported data pertainin to prioritisation of their long term conditions

			multimorbidity patients		
Morris et al [52]	UK- General Practices in North-West England	Qualitative: Semi- structured interviews	To examine what influences self- management priorities for individuals with multiple long- term conditions and how this changes over time	Patients with more than one chronic condition and at least one of COPD, IBS or Diabetes (n=21)	Patient-reported data on management strategies and experiences with primary health care, and data from follow-up interviews on any changes in their illness management.
Hansen et al, 2015 [56]	Germany- Participants recruited from the "Multicare cohort study" [68]	Qualitative: Focus groups	To identify reasons for disagreement regarding illnesses between patients and their GPs	Patients who had 3 or more chronic conditions from a list of 29 conditions (n=21) General Practitioners of the recruited patients (n=15)	Data from separate focus groups for patients and clinicians in which any communication problems and reasons for disagreement between patients and clinicians were explored

Table 1 Characteristics of all of the included studies in order of reference

Summary of quality assessment

The outcome of quality assessment based on each of the afore-mentioned tools is summarised in Appendix 2. The majority of the quantitative studies were cross-sectional in design [36, 39, 40, 46, 47, 54, 55, 57-59] [48], including the quantitative elements of the two mixed-methods studies. The other studies included one longitudinal observational study [42], one cohort study [45] and one randomised controlled trial [53]. The cross-sectional studies were of moderate quality, with a number of studies having small sample sizes [40, 46, 47, 55]. The sample sizes of clinicians in most of the cross-sectional studies were particularly small, ranging from of 9 to 157 clinicians [46, 47, 55, 58], which impacts upon the generalisability and application of their findings. We noted that a number of the studies did not use pre-validated questions and tools to ascertain priorities [36, 55, 57-59], leading to a degree of subjectivity in the way in which priorities were ascertained, and the risk of measurement bias which again impacts on the generalisability of their findings.

The majority of the qualitative studies, including the qualitative aspects of the two mixed-methods studies, used interviews for data collection (n=8). Two studies used focus groups [41, 56], one study used a combination of focus groups and interviews [50] and one study used the nominal group technique [49]. The qualitative studies were of good quality, with appropriate use of qualitative methodology and transparent descriptions of the data analysis processes. Three studies only gave a limited description of their analytic process [48, 49], with two of these studies not presenting any quotes [48, 49].

QUANTITATIVE SYNTHESIS

Within our quantitative synthesis, we found that the studies focused either on the overall state of the patients' health, the problems posed by different chronic disease groups, or the patients' treatment regimens. Some of the quantitative studies elicited patient and/or clinician priorities as part of an intervention [53] [47]. Therefore, in order to reduce the risk of bias from the interventions, we included only the pre-intervention results from these studies.

Health outcome priorities

Four studies reported patient priorities of overall health outcomes using a "health outcome prioritisation tool" [39, 40, 46], which is a visual analogue scale requiring the following health

outcomes to be given a score out of 100: "Maintaining independence"; "Staying alive"; "Pain relief"; "Symptom relief". Maintaining independence was the outcome that had the highest importance after a pooling of the *most important* rankings from the four studies, followed by "Staying alive" (Table 2). For clinicians' priorities, one study reported that 98% of a sample of 157 general practitioners identified the "quality of life for the patient", and 96% identified the "life expectancy of the patient", as the most important factors in influencing their clinical decision-making to deprescribe for elderly, multi-morbid patients [58].

Study	Health outcome prioritisation as a tool for decision making among older persons with multiple chronic conditions[39]	Health outcome prioritisation to elicit preferences of older persons with multiple health conditions[40]	Outcome prioritisation tool for medication review in older patients with multimorbidity: A pilot study in general practice[47]	Eliciting Preferences of multi-morbid Elderly Adults in Family Practice Using an Outcome Prioritisation Tool[46]	Aggregate ranking as most important (%)
Maintaining independence	270 (75.6%)	34 (42.0%)	7 (36.8%)	19 (35.8%)	330 (64.7%)
Staying alive	40 (11.2%)	22 (27.2%)	6 (31.6%)	18 (34.0%)	86 (16.9%)
Pain relief	26 (7.3%)	17 (21.0%)	1 (5.3 %)	6 (11.3%)	50 (9.8%)
Symptom relief	21 (5.9%)	8 (9.8%)	5 (26.3%)	10 (18.9%)	44 (8.6%)
Total number of participants	357	81	19ª	53	510

Table 2-Summary of most important rankings for studies using the Outcome Prioritisation Tool *a* = although there were 59 patients included in this study [47] priorities were only reported for 19 patients

Priorities based on health problems

Three studies reported patient and general practitioners' priorities based on various health *problems*, following a geriatric assessment [53-55]. These problems were then categorised into domains, and the importance rankings for each of the domains were presented. Problems in the domains of "Social" "Mood" and "Function" recurrently featured in the top four of the most highly ranked priorities by patients across all three studies. In terms of the importance rankings by clinicians, problems in the domains of "Mood" and "Function" also featured in the top four importance rankings across all three studies, whilst "Social" problems were rated highly in one study [54] and problems in the domain of "Medication" were ranked highly in the other two studies [53, 55]. Interestingly, the authors in one study[54] found that patients feeling "Emotionally affected" was the strongest predictor for a problem being rated as important (OR 11.1 Cl 6.73 to 18.33), whereas "Poor prognosis" was the strongest predictor for clinicians (OR 6.39 Cl 4.61 TO 8.87)

Disease-specific priorities

Two studies reported patient priorities in relation to specific diseases or disease groups [45, 59]. Zulman et al. reported that "Diabetes/glycaemic control" was most frequently ranked as "most important", with "Hypertension" coming second [45]. However, the sample of patients included in this study were all diabetic, hypertensive patients. Deruaz-luyet et al. found that musculoskeletal conditions including back pain, were most frequently reported to be the most important conditions for their patients, however endocrine/metabolic conditions (including obesity) were second and cardiovascular conditions were third [59].

Three studies reported disease-specific, or disease-group-specific priorities of clinicians. Herzig et al. reported the priorities of general practitioners alone [57], and found that "multiple sclerosis", "mental retardation", and "bronchus lung neoplasm" were all highly prioritised by their participants. Zulman et al. reported the priorities of "primary care providers" who consisted of physicians, physician assistants or nurse practitioners [45], and found that diabetes was the top priority for primary care providers, with hypertension coming second, in alignment with their previously described patient priorities [45]. Moore et al. examined the priorities of different types of clinicians, including family physicians, geriatricians and nurse practitioners [36], and as with Zulman et al., found that diabetes was the top priority for family physicians and also nurse practitioners, whereas dementia was the top priority for geriatricians [36]. In addition, heart failure, atrial fibrillation and hypertension formed three of the top five conditions considered to be most important by the family practitioners in the study [36].

Treatment priorities

Fried et al. examined patient-ratings as *acceptable vs unacceptable* for four adverse outcomes from treatment, namely 'unable to leave house'; 'only able to get from bed to chair'; 'severe memory problems'; and 'daily pain', at baseline and over the course of a two year follow-up period [42]. They found that participants were more likely to find the health states relating to functional ability (i.e. 'unable to leave house' and 'only able to get from bed to chair') as *acceptable* at baseline and throughout the study, whereas 'severe memory problems' and 'daily pain' were more likely to be rated as *unacceptable*, at baseline and throughout the study.

As part of a study to examine the influence of the risks and benefits of medications on treatment preferences of patients, Caughey et al. also examined the priorities of patients in the face of "competing outcomes" [48]. They found that 80% of participants would not be willing to take medication to reduce "joint pain", if the medication increased their risk of a myocardial infarction by 10%. However, this was deduced from a sample of only 15 patients [48].

Agreement between patients and clinicians

Five of the included studies investigated the level of agreement in priority rankings between patients and their clinicians [45, 53-55, 59]. Three studies reported a low level of agreement between patient and clinicians' priority rankings [53-55]. Two of these studies used a Cohen's Kappa calculation to estimate the degree of agreement between the importance ratings of patients and clinicians, and the values of which were 0.18 and 0.11 respectively, indicating "slight agreement" after allowing for chance [54][55]. One study used a weighted kappa calculation to measure the degree of agreement, which, at a pre-intervention point in this study, was low at 6% [53].

Two studies reported that there was a "high" level of agreement [45, 59]. Deruaz-Luyet et al. found that in the case of 54.9% (n=314) of their patients, the condition that their GP had considered to be either the first or second most important, was in the same disease-group as the condition that the patient considered to be most important [59].

Zulman et al. reported that 60% of "patient-provider pairs" had a "high concordance", meaning that the same three conditions had been rated as top three priorities by both parties, or that two of the same conditions had been rated in the top three priorities by both parties [45]. In this case, given that the sample of patients were all diabetic and hypertensive could have led to a narrowing of the range of chronic diseases across the sample, which in turn could have led to an increased likelihood of agreement. However, the participant characteristics reported by the authors state that the

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

patients had a mean of eight health conditions (SD 3.00), suggesting that the patients did not have a narrow range of chronic diseases.

QUALITATIVE SYNTHESIS

Whilst our quantitative synthesis allowed us to investigate *which* health outcomes, diseases or treatments were important to multi-morbid patients and their clinicians, our qualitative analysis enabled us to explore *how* prioritisation occurs. Below, we describe the key findings from our qualitative analysis.

Mechanisms of prioritisation

In the qualitative studies that approached prioritisation from a disease-specific perspective, patients were able to identify an illness as their main priority [50, 51]. For many patients, prioritisation appeared to be driven by their experience of the illness, which formed part of its "meaning as consequence" [51] as phrased by Cheraghi-Sohi et al. The 'consequences' of an illness consisted of the *impact* that the illness was having on the patients' everyday lives, which included functional limitation and the symptomatic burden of the illness, including its "unpredictability" (Table 3) [50]. For others, prioritisation appeared to be driven by their perception of the risk now and in the future with respect to functional deterioration and mortality.

In other studies, patients framed their priorities between *quality of life vs length of life* (Table 3) [43]. Patients in the study by Naik et al. who were multi-morbid adults with cancer, prioritised "quality of life" more highly than "length of life" [43]. This was also reflected in the findings of Fried et al., who found that when considering medication with competing outcomes in terms of extending life compared to quality of life, participants appeared to prioritise preserving quality of life [41].

Van Summeren et al. found that prioritisation was "difficult" when there was no "specific need" for a treatment decision to be made [46]. This concept of a difference in prioritisation based on hypothetical, or experiential levels, was also shared in the findings of Elliott et al [44] and Fried et al [41].

Where clinicians' perspectives were explored alongside patients, clinicians reported that exploring patients' priorities was "extremely important" when managing "competing interests" [48] and beneficial in providing patient-centred care [46]. Some clinicians in the mixed-methods study carried out by Van Summeren et al. reported that exploring their patients' priorities allowed them to have a "deeper understanding" of the patient, helped with making patient-centred treatment decisions and advance care planning (Table 3) [46]. However, other clinicians in the same study found exploring patient priorities to be difficult due its "novelty" and the fact that it represented a change to their usual consultations [46].

	Concept	Examples from included studies
Mechanisms of	Unpredictability of symptoms	"My final issue is diverticulitis. In many ways that is the thing that makes the most impact on my life because of the unreliability of it. You make plans to do something to go somewhere and at the last minute you don't dare leave the house because you don't leave the loo. In itself it's not an important medical issue. It's the social
prioritisation	Quality of life vs length of life	problem more than anything else." – Lindsay et al [50] "If you don't feel good, you can't take care of yourself and you have to depend on somebody else, what's the good of living another 10 years?"- Fried et al [41]

Facilitat	ing "In future, I'll	be happier to be more decisive in keeping an eye on
clinician	s' decision what we do ar	nd do not do as regards this patient." Van Summeren
making	et al [46]	

Table 3- Examples from included studies for key concepts relating to mechanisms of prioritisation

Factors influencing prioritisation:

Our analysis revealed that there were a number of factors that appeared to influence how both patients and clinicians arrived at their priorities, and which priorities they chose.

i. Functional ability

Preserving functional ability as a priority for patients was a dominant concept across the majority of the qualitative studies [37, 38, 50, 52] [43][48][41]. Preserving independence emerged as the most significant reason for prioritising functional ability for patients, and maintaining the ability to engage in activities of daily living, mobility, maintaining cognitive ability and wanting to avoid being a "burden" or lacking social support to help them cope with functional deterioration (Table 4) [38, 50, 51].

Conditions which caused limitation to patients' ability to self-manage their health conditions, led to a "tension" between the patients' expectations of themselves and what they were physically able to do [52]. Lifestyle management, particularly reduced ability to exercise and the adverse impact of this on weight, was cited as part of patients' ability to self-manage [50].

Maintaining patients' functional ability was reported as a priority by some clinicians [37] [48]. Clinicians considered the wider implications of the patients' functional deterioration, particularly cognitive deterioration, and spoke of wanting to reduce the risk of "burnout" for the patients' family members/caregivers [37]. Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ii. Mortality

Reducing the risk of mortality emerged as a recurrent priority for clinicians [48, 56]. Caughey et al found that clinicians prioritised mortality in younger (less than 65 years) multi-morbid patients rather than older multi-morbid patients, as they felt they could be more "aggressive" in their treatment [48]. Reducing the risk of mortality also emerged as a priority for patients across a number of studies [37, 38, 44, 51, 52] [43]. Some patients found the asymptomatic nature of hypertension to be concerning; hence, the consequences of hypertension could be unpredictable, compared to some other chronic illnesses where symptoms can give warning of onset and severity (Table 4) [38, 44].

iii. Symptom control

The symptomatic burden of a condition contributed to its "meaning as consequence" for patients [51]. Symptoms were cited as being a cause of functional limitation [38, 50], and in some cases their "unpredictability" could cause significant disruption to patients' daily lives [50]. Symptom control was reported to be a priority by some clinicians [37][48]. However, clinicians in one study considered symptom control to be less important, particularly when there was no risk of mortality [56]. In these cases, clinicians seemed to be aware that patients may still be prioritising symptom control highly, even if the clinicians did not (Table 4).

iv. Treatment burden

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Factors related to the treatment burden of an illness appeared to adversely impact prioritisation for patients, leading to *de-prioritisation* of certain medications and treatments [38, 41, 44, 49]. Elliot et al. reported that cost and distressing side effects, were factors which led patients to stop taking a medication [44]. Similarly, Fried et al. found that patients reported unpleasant side effects to be a "competing outcome", which negatively influenced their decision regarding continuing a medication [41]. However, difficulty with achieving control over the management of an illness, as well as requirement for high levels of engagement with self-management, emerged as factors that contributed to the prioritisation of an illness by some patients (Table 4) [50].

	Concept	Examples from included studies
	Functional ability	"I mean, because I have to be mobile, I am living on my own, no one is going to take care of me, I have got to look after myself" Cheraghi-Sohi et al [51]
	Mortality	"Well I really do worry the most about the high blood pressure. 'Cause see you know you got arthritis and you can tell when it's coming on. But you can't hardly tell about high blood pressure. It can just hit you like that [snaps fingers]"" Lindsay et al [50]
Factors influencing	Symptom control	"I would not want to live with pain. I won't allow that to happen"- Naik et al [43]
prioritisation	Disparity in prioritisation of symptom control	" I talk [to her] for a quarter of an hour about this and that every time after which she replies, "but my vertigo," and I answer every time, well, unfortunately there is nothing I can do about it, we have already tried and done everything. But it is probably the first diagnosis she will mention: "What are you suffering from?". "Vertigo". For me, this would be somewhere all the way at the bottom." – Hansen et al [56]
	Treatment burden	"It's the knee that's the most concerning because everything else is controlled by tablets. The knee is a problem because if I have one little slip I'm in plaster again for 6 weeks." Lindsay et al [50]

Table 4- Examples from included studies for key concepts relating to factors influencing prioritisation

DISCUSSION

Health outcome and treatment priorities

From our findings, patients' prioritisation appeared to be driven by weighing up the empirical compared to the hypothetical impact of a disease, whereby the empirical impact of a disease, which included its impact on function, symptomatic and treatment burden, was the most dominant driver of prioritisation. This is consistent with the findings of previous literature showing patients with rheumatoid arthritis who had reported experiencing higher levels of pain, were more likely to report pain as a priority [69].

Amongst empirical factors, preserving functionality emerged as most highly prioritised by patients amongst the quantitative studies that took a health outcome approach[39, 40, 47], whilst "function" was a domain that was prioritised highly by both patients and clinicians in the studies where prioritisation of various health *problems* were investigated [53-55]. From our qualitative findings, functional ability formed a key part of the preservation of various aspects of the patients'

independence and their quality of life, as well as their ability to self-manage. Existing evidence shows that the prevalence of multi-morbidity is highest in those aged over 65 years [70], and the population for the majority of the included studies were older multi-morbid adults. This could provide an explanation for why preserving functionality was highly prioritised.

Prioritisation was not a static process and was subject to change, based on factors such as illness exacerbations, life events, whether there was a need for a treatment decision to be made, and whether the priority related to retrospective or prospective healthcare [50, 52]. When considering the hypothetical impact of an illness, perceptions of future risk came into play, and in particular, the risk of mortality [44]. This was particularly evident in relation to cardiovascular disease, where patients appeared to perceive the risk of mortality to be high [38].

Risk of mortality was a dominant driver for prioritisation amongst clinicians. This was shown in our quantitative synthesis, where amongst studies assessing disease-specific priorities, conditions with a higher risk of mortality, such as cardiovascular disease and diabetes, recurrently emerged as being highly prioritised by clinicians [36, 45, 57] and differentiated by age [48]. This age-based consideration could explain why clinicians prioritised "quality of life for the patient" as higher, albeit marginally, than "life expectancy of the patient" in their clinical decision-making for de-prescribing for elderly, multi-morbid patients [58].

Our findings show a varying degree of agreement between the priorities of multi-morbid patients and clinicians. Previous studies carried out in the context of diabetes[71], and psoriasis[72] have found a low level of agreement on health outcome and treatment priorities between patients and clinicians, which correlates with the findings of some studies included in this review [53-55], but not others [45]. The nature of the patients' illnesses emerged as a factor for concordance or discordance of priorities with their clinicians [37]. Patients and clinicians were in agreement in situations where patients were currently experiencing an exacerbation of a particular condition, or had a "stable" state of health. However, in patients who suffered from illnesses with more complex courses, discordance of priorities tended to occur between patients and clinicians [37]. Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Strengths and limitations

To our knowledge, this is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both patients and clinicians for patients living with multi-morbidities. In this review, we have been able to add a novel line of argument to the ongoing discussion on this subject. By incorporating papers using both qualitative and quantitative methodologies, we have been able to explore patterns and relationships in the findings of a wide range of studies, thus creating a comprehensive and well-rounded systematic review.

There are noteworthy limitations. We did not include the term "comorbidity", in our search terms, and whilst "comorbidity" is distinctive from multi-morbidity, there is also some conceptual overlap between the two terms. We felt that including "comorbidity" in our search strategy would identify studies focusing on a specific condition rather than multi-morbidity.

A number of the quantitative studies did not use pre-validated tools to ascertain priorities [36, 55, 57-59], leading to a risk of measurement bias, which could limit the generalisability of findings in this review. We also detected a large variation in the tools used to ascertain priorities, which meant that carrying out a meta-analysis to synthesise the findings of the quantitative studies was not possible. Yet, we have tried to mitigate the lack of meta-analysis by using a well-described and well-established method of narrative synthesis [33], in order to maintain rigour and transparency.

Recommendations for the future

We recommend that future guidelines developed for clinicians in the management of multimorbidity highlight the need to elicit and consider both short term and long term priorities for their patients', and review these priorities continually, and particularly when exacerbations, changes to illness course or treatment regimens, or other wider socially-contextualised changes occur in their patients' lives.

There was a large variation in how priorities were ascertained, and in the tools used to ascertain priorities. The relative lack of standardised and validated tools for use to ascertain patient priorities in everyday clinical practice has also been described in previous literature [73]. We highlight a need for the development of a standardised and validated tool that is acceptable to both patients and clinicians, and can be used to ascertain patient-priorities in the multiple dimensions described in this review. Such a tool would a valuable aid to treatment decision-making, advance care planning and achieving patient-centeredness for patients living with multi-morbidity.

Conclusion

The findings from this review show the priorities of patients and clinicians can have varying degrees of concordance, being mostly low [53, 55], in alignment with previous findings in single disease contexts [71, 72]. We have found that the mechanisms of prioritisation can also differ between our two groups, in that patients are driven by illness experiences, whereas clinicians may be focused on managing longer term risks. Understanding these differences can help clinicians to better recognise situations where the patients' priorities may be different to theirs and elicit the most important priorities for their patients.

REFERENCES

1 van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature, *The European Journal of General Practice* 1996;2:65-70.

2 Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study, *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences* 2015;71:205-14.

3 Rijken M, Struckmann V, Dyakova M, et al. ICARE4EU: Improving care for people with multiple chronic conditions in Europe. 2013.

4 Roberts KC, Rao DP, Bennett TL, et al. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada, *Health Promot Chronic Dis Prev Can* 2015;35:87-94.

5 Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. 2014;89:1336-49.

6 Arokiasamy P, Uttamacharya U, Jain K, et al. The impact of multimorbidity on adult physical and mental health in low-and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? *BMC medicine* 2015;13:178.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

7 Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global ageing: a crosssectional study of 28 countries using the World Health Surveys, *BMC Public Health* 2015;15:776.

8 Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions, *N Engl J Med* 2004;351:2870-4.

9 Calderon-Larranaga A, Poblador-Plou B, Gonzalez-Rubio F, et al. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? *Br J Gen Pract* 2012;62:e821-6.

10 Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care, *Quality of Life Research* 2006;15:83-91.

11 Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature, *Ageing research reviews* 2011;10:430-9.

12 Fortin M, Bravo G, Hudon C, et al. Psychological distress and multimorbidity in primary care, *Ann Fam Med* 2006;4:417-22.

13 Academy of Medical Sciences. Multimorbidity: a priority for global health research, 2018.

14 Muth C, van den Akker M, Blom JW, et al. The Ariadne principles: how to handle multimorbidity in primary care consultations. *BMC Medicine* 2014;12:223.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

15 Azad NA, Mielniczuk L. A call for collaboration: improving cardiogeriatric care, *Can J Cardiol* 2016;32:1041-4.

16 Roland M, Paddison C. Better management of patients with multimorbidity, *BMJ: British Medical Journal (Online)* 2013;346.

17 Bierman AS, Tinetti ME. Precision medicine to precision care: managing multimorbidity, *Lancet* 2016;388:2721-3.

18 Mc Namara KP, Breken BD, Alzubaidi HT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia, *Age & Ageing* 2017;46:291-9.

19 Sinnott C, Mc Hugh S, Browne J, et al. GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research, *BMJ Open* 2013;3:e003610,2013-003610.

20 Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis, *BMJ* 1997;314:1580-3.

21 Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? *Qual Health Care* 2001;10 Suppl 1:i39-43.

22 Thomson S, Doody G. Parallel paths? Patient and doctor priorities in psychiatric outpatient consultations, *Journal of Mental Health* 2010;19:461-9.

23 Lee CN, Hultman CS, Sepucha K. Do patients and providers agree about the most important facts and goals for breast reconstruction decisions? *Ann Plast Surg* 2010;64:563-6.

24 Volandes AE, Paasche-Orlow MK, Barry MJ, et al. Video decision support tool for advance care planning in dementia: randomised controlled trial, *BMJ* 2009;338:b2159.

25 Pager CK, McCluskey PJ. Surgeons' perceptions of their patients' priorities, *Journal of Cataract & Refractive Surgery* 2004;30:591-7.

26 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons 2011.

27 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement, *Systematic reviews* 2015;4:1.

28 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement, *Ann Intern Med* 2009;151:264-9.

29 Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS), *BMJ Open* 2016;6:e011458,2016-011458.

30 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, *Eur J Epidemiol* 2010;25:603-5.

31 Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, *BMJ* 2011;343:d5928.

32 Critical Appraisal Skills Programme UK. CASP qualitative research checklist. *CASP checklists* 13/03/2017.

33 Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews, *A product from the ESRC methods programme Version* 2006;1:b92.

34 Noblit GW, Hare RD. Meta-ethnography: Synthesizing qualitative studies: sage 1988.

35 Britten N, Campbell R, Pope C, et al. Using meta ethnography to synthesise qualitative research: a worked example, *J Health Serv Res Policy* 2002;7:209-15.

36 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, family physicians and geriatricians when caring for the elderly. *Journal of interprofessional care* 2015;29:401-3.

37 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between older persons with multi-morbidities, their family physicians and informal caregivers. *BMC Family Practice* 2013;14:133.

38 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and accommodating multiple morbidities by vulnerable older adults, *J Health Care Poor Underserved* 2009;20:134-51.

39 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions, *Arch Intern Med* 2011;171:1856-8.

40 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with multiple health conditions, *Patient Educ Couns* 2011;83:278-82.

41 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, *J Am Geriatr Soc* 2008;56:1839-44.

42 Fried TR, Byers AL, Gallo WT, et al. Prospective study of health status preferences and changes in preferences over time in older adults, *Arch Intern Med* 2006;166:890-5.

43 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing Life-Threatening Illness. *J Am Geriatr Soc* 2016;64:625-31.

44 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness, *Journal of General Internal Medicine* 2007;22:805-10.

45 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *Journal of General Internal Medicine* 2010;25:408-14.

46 Summeren JJ, Haaijer-Ruskamp FM, Schuling J. Eliciting preferences of multimorbid elderly adults in family practice using an outcome prioritization tool, *J Am Geriatr Soc* 2016;64.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

47 van Summeren JJ, Schuling J, Haaijer-Ruskamp FM, et al. Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice, *Br J Gen Pract* 2017;67:e501-6.

48 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. *Patient Preference and Adherence* 2017;11:131-40.

49 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. *BMJ Open* 2016;6:Arte Number: e009781. ate of Pubaton: 2016.

50 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEASES, CANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.

51 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimorbidity: A qualitative secondary analysis. *SAGE Open Medicine* 2013;1:2050312113503955.

52 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. *Chronic Illness* 2011;7:147-61.

53 Junius-Walker U, Wrede J, Voigt I, et al. Impact of a priority-setting consultation on doctor-patient agreement after a geriatric assessment: cluster randomised controlled trial in German general practices. *Quality in primary care* 2012;20.

54 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general practitioners: a cross-sectional study. *Quality in primary care* 2011;19.

55 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patients differ from treatment priorities of their physicians, *Croat Med J* 2010;51:483-92.

56 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older patients with multimorbidity and their GPs - a qualitative study. *BMC family practice* 2015;16:68.

57 Herzig L, Mueller Y, Haller DM, et al. Family practitioners' top medical priorities when managing patients with multimorbidity: a cross-sectional study, *BJGP open* 2019;3:bjgpopen18X101622.

58 Mantelli S, Jungo KT, Rozsnyai Z, et al. How general practitioners would deprescribe in frail oldestold with polypharmacy—the LESS study, *BMC family practice* 2018;19:169.

59 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, *BMC family practice* 2018;19:66.

60 Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes, *J Am Geriatr Soc* 2008;56:1409-16.

61 DeruazLuyet A., Alexandra N'Goran A., Tandjung R., et al. Multimorbidity in primary care: Protocol of a national cross-sectional study in Switzerland. *BMJ Open* 2015;5:Arte Number: e009165. ate of Pubaton: 2015.

62 Martin LA, Moye J, Street Jr RL, et al. Reconceptualizing cancer survivorship through veterans' lived experiences, *J Psychosoc Oncol* 2014;32:289-309.

63 Lindsay S, Bellaby P, Smith S, et al. Enabling healthy choices: is ICT the highway to health improvement? *Health:* 2008;12:313-31.

64 Hurley MV, Walsh N, Bhavnani V, et al. Health beliefs before and after participation on an exercised-based rehabilitation programme for chronic knee pain: doing is believing, *BMC Musculoskeletal Disorders* 2010;11:31.

65 Bower P, Harkness E, Macdonald W, et al. Illness representations in patients with multimorbid long-term conditions: Qualitative study, *Psychol Health* 2012;27:1211-26.

66 Grime J, Richardson JC, Ong BN. Perceptions of joint pain and feeling well in older people who reported being healthy: a qualitative study, *Br J Gen Pract* 2010;60:597-603.

67 Nio Ong B, Jinks C, Morden A. The hard work of self-management: Living with chronic knee pain, *International journal of qualitative studies on health and well-being* 2011;6:7035.

68 Hansen H., Schafer I., Schon G., et al. Agreement between self-reported and general practitionerreported chronic conditions among multimorbid patients in primary care - results of the MultiCare Cohort Study. *BMC family practice* 2014;15:39.


69 Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority, *Arthritis Care & Research* 2002;47:391-7.

70 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, *The Lancet* 2012;380:37-43.

71 Heisler M, Vijan S, Anderson RM, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? *Journal of general internal medicine* 2003;18:893-902.

72 Okubo Y, Tsuruta D, Tang A, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians, *Journal of the European Academy of Dermatology and Venereology* 2018;32:606-14.

73 Mangin D., Stephen G., Bismah V., et al. Making patient values visible in healthcare: A systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity. *BMJ Open* 2016;6:Arte Number: e010903. ate of Pubaton: 01 Jun 2016.



1. Patient*.	mp.
2. Patients/	1
3. 1 or 2	
keyword he	np. [mp=title, abstract, original title, name of substance word, subject heading word, eading word, protocol supplementary concept word, rare disease supplementary concept ue identifier, synonyms]
5. Choice*.	mp.
6. Preferen	ce*.mp.
7. Aim*.mp).
8. Goal*.mj	p.
9. 4 or 5 or	6 or 7 or 8
10. Doctor*	f.mp.
11. Physicia	ans/
12. Clinicia	n*.mp.
13. Primary	Health Care/ or Physicians, Family/ or Family Practice/ or General Practitioners/
14. General	practitioner*.mp.
15. 10 or 11	L or 12 or 13 or 14
keyword he	orbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading wore eading word, protocol supplementary concept word, rare disease supplementary concept ue identifier, synonyms]
word, keyw	norbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading yord heading word, protocol supplementary concept word, rare disease supplementary ord, unique identifier, synonyms]
word, keyw	e morbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading yord heading word, protocol supplementary concept word, rare disease supplementary ord, unique identifier, synonyms]
19. 16 or 17	7 or 18
20. 3 and 9	and 15 and 19
keyword he	oorbid*.mp. [mp=title, abstract, original title, name of substance word, subject heading word eading word, protocol supplementary concept word, rare disease supplementary concept ue identifier, synonyms]
22. 16 or 17	7 or 18 or 21
23. 3 and 9	and 15 and 22

		Cheraghi -Sohi et al [3]	Naik et al [4]	Lindsay et al [5]	Hansen et al [6]	Morris et al [7]	Elliott et al [8]	Friegen-2019-([9] right, in	Turner et al [10]	Van Summeren et al [11]	Caughey et al [12]
Was there a YES clear statement of the aims of	YES	YES	YES	YES	YES	YES	YES	njoppen-2019-033445 on 12 Februa t Frig 9 19 19 19 19 19 19 19 19 19 19 19 10 12 Februa Frig 19 19 19 19 19 19 19 19 19 19 19 19 19	YES	YES	YES
the research? Is a YES qualitative methodology appropriate?	YES	YES	YES	YES	YES	YES	YES	bruary 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 202 Erasmushogeschool . s related to text and data mining, Al training, and similar technologies. YE	NO- Quantitative or mixed methods methodology would have been more appropriate as the aim was to rank factors, although data collected using a qualitative technique, it lacks richness and appears to be presented in a quantitative manner	YES	YES
Was the YES research design appropriate to the aims of the research?	YES	YES	YES	YES	YES	YES	YES	bmj.com/ on May g.similar technol YE	YES	YES	YES
Was the YES recruitment strategy	YES	YES	YES	YES	YES	NO- no explanation given as to	YES	12, 2025 at Department GEZ-LTA ogies.	YES	YES	YES

26 of 44

3

Page	27	of	44
------	----	----	----

- 44			

44						BMJ Ope	n		6/bmjopen-2019-033445 4 by copyright, including			
appropriate to the aims of the research							why the specific conditions were chosen (COPD, IBS etc)		on 12 g for u			
Were the data collected in a way that addressed the research issue?	YES	YES	YES	YES	YES	YES	YES	YES	9bruary 2020. [Erasmushd S related to tey	YES	YES	YES
Has the relationship between researcher and participants been adequately considered?	YES	YES	YES	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point.	NO- There is no background information given on the researcher (sole in this case) and there has been no evidence of any consideration of researcher bias at any point during the study.	NO- there has been no evidence of any consideration of researcher bias at any point during the study	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point. However there was some evidence of reflexivity during the data collection process when emerging areas of interest that could be incorporated into future interviews	NO- background of RAE who conducted interviews and main aspect of analysis not specified and no consideration has been given to any possibility of researcher bias	YES, related to text and the profinition of the profession of the	NO- no mention of the background of the researchers or how this may have influenced the results	NO- role of second interviewer carrying out the in-depth interviews not mentioned, and there has been no consideration given to the possibility of bias from the interviewers. One of the interviewers was a FP, which could have led to bias with the interviewees responses.	NO- there has been no consideratio n given to the role of the researcher and the potential for researcher bias at any point.

						BMJ Ope	en		/bmjopen-201: by copyright,			Ρ
							were		9-033			
Have ethical issues been taken into consideration ?	YES	YES	YES- in the original studies, however further ethical issues regarding secondary qualitative analysis were not taken into account.	YES	YES	YES	considered. YES	YES	445 on 12 February 2020. Downloaded Erasmushogeschool . YE YE	YES	YES	YES
Was the data analysis sufficiently rigorous?	YES	YES	YES	YES	NO- superficial description of analytic process and no information given on how many researchers analysed the transcripts- assumed one as there is only one author- risk of bias not taken into account for the analytic process	YES	YES	YES	6/bmjopen-2019-033445 on 12 February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Depaid by copyright, including for uses related to text and data mining, Al training, and similar technologies.	NO- the data analysis process is very ambiguous and the qualitative analysis has not been described in sufficient depth.	YES- clear description of the analytic process with two researchers independentl y analysing the data for rigour. However no description of the interpretation phase from the data.	NO- there i only a superficial description of the data analysis process, an there is ver little detail given on how the themes wer derived fro the data. There is no presentation at all of quotes fron the data to support the authors interpretation n of the data
Is there a clear	YES	YES	YES	YES	YES	YES	YES	YES	at Department GEZ-LTA	YES	YES- however the qualitative	YES- however no quotes give

Page 29 (of 44						BMJ Ope	en		6/bmjopen-2019- 1 by copyright, in			
1 2 3 4 5 6 7 8	statement of findings?									033445 on cluding fo		data from the patient interviews has only been summarised- no direct	to support findings
9 10 11	How valuable is the research?	Valuable	0	Valuable	quotes given Valuable	Valuable							
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46							Valuable			125 at Department GEZ-LTA			

				BMJ Open and observatio Demonstration that outcome of interest was not present at start of study N/A		6/bmjopen-2019-033445 on 12 Februar			
	Newcastle	e-ottawa scale	for cohort	and observatio	nal studies sun	in ary	y table)	
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis controlled for confounders	D20AD6wnloaded f 020AD6wnloaded f 04AD6wnloaded f	essment utcome	Was follow- up long enough for outcomes to occur	Adequacy of follow-up of cohorts
Zulman et al [13]	Somewhat representative (one star) *	Drawn from the same community as the exposed cohort (one star) *	Secure record (one star) *	N/A	The study controls for age, sex and marital status (one star)*	tp://b		N/A	No statement
Fried et al [14]	Somewhat representative (one star) *	N/A	Secure record (one star) *	N/A	Cohorts are not comparable on the basis of the design	njøpen.bmj.c	-report	Yes (one star)	Follow up rate less that 80%
					The study controls for age, sex and marital status (one star)*	om/ on May 12, 2025 at Department GEZ-LTA	-report		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

of 44				A	xis tool f	or cross	-sectional	studies	summary	y table इ	op Mantelli et al		
	Intro	duction	Junius- Walker et al [15]	Fried et al[16]	Fried et al [17]	Moore et al [18]	Van Summeren et al [19]	Voigt et al [20]	Van Summeren et al [11]	Caughey & ight	822]	Deruaz- Luyet et al [23]	Herzig et al [24]
	1	Were the aims/objectives of the study clear?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes includir	19-033445 01	Yes	Yes
	Meth									D.	50		
	2	Was the study design appropriate for the stated aim(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes or uses re	1Yes 12 Feb	Yes	Yes
	3	Was the sample size justified?	No- convenien ce sampling used, small sample size, however no explanatio n for sample size given	No- no justificatio n for sample size given, convenien ce sampling used	No- recruitme nt strategy described clearly but no justificatio n for sample size given	Yes	No	No- sampling strategy described well but no justificati on for sample size given	No- purposive sampling used, however no justificatio n for sample size given	data mining, Al tr	Tasmus convenience ampling Second and no second and second and second and second and second and second and second and second and second and second a	Yes- in the parent study [25]	Yes- in the parent study [25]
	4	Was the target/reference population clearly defined? (Is it clear who the research was about?)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes aining, and sir	bmjopen.bmj.	Yes	Yes
	5	Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?	Yes	Yes- However assumptio n made that participant s will have multiple chronic conditions	Yes	Yes	Yes	Yes	Yes	Yes filar technologies.	Yes- Ithough only GP's who Add Previously Caken part in Other case- Studies were Thy ited, Previously Caken part in Other case- Studies were Thy ited, Pristore Pristore Case- Construction Case- Construction Case- Construction Case- Construction Case- Construction Case- Construction Case- Construction Case- Construction Case- Case- Construction Case- Case- Construction Case-	Yes	Yes

						BMJ Ope	n		y copyright,	6/bmjopen-2019-		
6	Was the selection process likely to select subjects/participan ts that were representative of the target/reference population under investigation?	Yes	Yes- as above	Yes	Yes	Yes	Yes	Yes	by copyright, including for uses relate	03345 03345 012 Febru	Yes	Yes
7	Were measures undertaken to address and categorise non- responders?	Yes	Don't know- not reported	Yes	No	No	No	Yes- Purposive sampling used with efforts made to address gaps in participant types	Don't d tax know- noto text and data mining, Al training, and sim Yes	200n't know- 2020 reported 2020 Downloaded from http://br	Yes in the parent study [26]. Characteristi cs of participants who were not included due to missing data, were described in this study	Yes in the parent stue [26]
8	Were the risk factor and outcome variables measured appropriate to the aims of the study?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes ing, and sim	jõpen.bmj.ce	Yes	Yes
9	Were the risk factor and outcome variables measured correctly using instruments/measu rements that had been trialled, piloted or published previously?	Yes	Yes- piloted in a previous study	No- Tested in this study as it was a feasibility study	No- Pre- tested in this study but only using 2 FP's and 1 NP	Yes	No- STEP assessme nt previousl y published however no testing done of measure used to collect importan ce ratings	Yes	Yes llar technologies.	Yes- the Instruments Insed were Within this Study using 5 Sip's as Authad not Deen Published Previously Mithing Mithin	No- instruments designed through "internal consensus discussions".	No

	BMJ Open												
									y 11911, 1	6/bmjopen-2019			
10	Is it clear what was used to determined statistical significance and/or precision estimates? (e.g. p- values, confidence intervals)	Yes	N/A	Yes	Yes	N/A	Yes	N/A		es -033445 on 12 Februa Er	Yes	Yes	
11	Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	کلهmjopen-2019-033445 on 12 February 2020. Downloaded from Erasmushogeschool . - Erasmushogeschool .	Yes	Yes	
Rest	ults					-							
12	Were the basic data adequately described?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	Sector 2015 All training and sim	Yes	Yes	
13	Does the response rate raise concerns about non- response bias?	No	Don't know- response rate not reported	No	No	No	Don't know- response rate not reported	No	Don't know- response rate not reported No	in technolo	No	No	
14	If appropriate, was information about non-responders described?	Yes	No	Yes	No	Yes	No	Yes	No T	⊙ 27,2025 at Department GEZ-LTA	Yes in the parent study[26] Characteristi cs of participants who were not included	Yes in th parent study[26	

						BMJ Ope	า			y copyright,	6/bmjopen-2019-		
										cluding for u	033445 on 12	due to missing data, were described in this study	
15	Were the results internally consistent?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ises rel	Trebru	Yes	Yes
16	Were the results presented for all the analyses described in the methods?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	rasmushogeschool . ated to text and data n	ల గాebruary 2020. Downloaded	Yes	Yes
Discu	ission				2					nin	fro		
17	Were the authors' discussions and conclusions justified by the results?	No- very small sample of GP's compared to patients therefore generaliza ble conclusion s regarding concordan ce between doctors and patients cannot accurately be drawn from this study	Yes	Yes	Yes	Yes	Yes	Yes- Small sample size for quantitativ e aspect of study taken into account	No- very small sample siz across patients ai clinicians meaning results are not generaliza e	ng, Aktraining, and similar technologies.	ങ് http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA	Yes	Yes

18	Were the limitations of the study discussed?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	9-033445	Yes	Y
Othe										fo n		
19	Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?	No	o February 202t Erasmus r uses related to	No	N							
20	Was ethical approval or consent of participants attained?	Yes	text and data	Yes	Ye							
										om http://bmjo hing, Al training		
						r.				ق 6/bmjopen-2019-033445 on 12 February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 202 Erasmushogeschool . by copyright, including for uses related to text and data mining, Al training, and similar technologies.		

Page 35 of 44

26

33 34

	BMJ Open	6/bmjopen-2019 1 by copyright, i
The Cochrane Collaboration's to	ol for assessing risk of bias in rando	6/bmjopen-2019-0019-0019-0019-0019-0019-0019-0019
Study	Junius-Walker et al [27]	ing control of the second of t
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Participating doctors were allocated 1:1 into the intervention and control group using random block sizes of Burg
Allocation concealment (selection bias)	Unclear risk	No information given regarding any efforts to concea the allocation sequence
Blinding of participants and researchers (performance bias)	Low risk	Participate were only informed of the procedures of their ow A gararm.
Blinding of outcome assessment (detection bias)	Low risk	Participation Series blinded to the pre-intervention importance and an
Incomplete outcome data (attrition bias)	High risk	25 patients dependent out prior to baseline ratings and 5 further patients dropped out prior to final ratings, thes patients dere excluded from analysis, however intention to treat analysis cannot be carried out in this context the to the nature of the intervention
Selective reporting (reporting bias)	Low risk	Adequate reporting on all of the specified outcomes
		jopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA ing, and similar technologies.
For peer	review only - http://bmjopen.bmj.com/site/about/	

Page 37 of 44	BMJ Open BMJ Open
5	copy pe
1 2 3 4 5 6	BMJ Open 2019-033445 on N References References
7 8 9	1 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between of the second s
10 11 12	2 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and the prioritize of the prioritize of the priority of the prior
13 14 15	3 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimotion by the secondary analysis. SAGE Open Medicine 2013;1:2050312113503955.
16 17 18 19	4 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing Life Threatening Illness. J Am Geriatr Soc 2016;64:625-31.
20 21 22	5 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEASES, CANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.
23 24 25 26	6 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older patients with multimorbidity and their GPs - a qualitative study. <i>BMC family practice</i> 2015;16:68.
27 28 29	7 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. <i>Chronic Illness</i> 2011;7:147-61.
30 31 32	8 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among other adults with chronic illness, <i>Journal of General Internal Medicine</i> 2007;22:805-10.
33 34 35 26	9 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, <i>J Am Geriatr Soc</i> 2008;56:1839-44.
36 37 38 39 40 41	10 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term categories facilities? Perspectives of residents and health professionals. <i>BMJ Open</i> 2016;6:Arte Number: e009781. ate of Pubaton: 2016.
42 43 44	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

12 Caughey G.E., Huynh E., Shakib S., et al. Influence of medication risks and benefits on patient and clinician preferences for treatment in multimorbidity: A discrete-choice experiment. 2017.

13 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health condition and hypertensive diabetes patients. Journal of General Internal Medicine 2010;25:408-14.

14 Fried TR, Byers AL, Gallo WT, et al. Prospective study of health status preferences and changes in preferences $\frac{1}{2000}$ time in older adults, *Arch Intern Med* 2006;166:890-5.

15 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general attioners: a cross-sectional study. Quality in primary care 2011;19.

16 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions, Arch Intern Med 2011;171:1856-8.

17 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with multiple health conditions, *Patient Educ* Couns 2011;83:278-82. and

18 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, aming physicians and geriatricians when caring for the elderly. Journal of interprofessional care 2015;29:401-3. lla

19 Van Summeren J.J.G.T., Schuling J., HaaijerRuskamp F.M., et al. Outcome prioritisation tool for medication regieve in older patients with multimorbidity: A pilot study in general practice. British Journal of General Practice 2017;67:e501-6. nolog

20 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patients of their from treatment priorities of their physicians, Croat Med J 2010;51:483-92.

21 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. Patient Preference and Adherence 2017;11:131-40. tment GEZ-LTA

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 family practice 2018;19:169. 23 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, *BMC family practice* 2018;19:66.

24 Herzig L, Mueller Y, Haller DM, et al. Family practitioners' top medical priorities when managing patients with a cross-sectional study, *BJGP open* 2019;3:bjgpopen18X101622.
25 DeruazLuyet A., Alexandra N'Goran A., Tandjung R., et al. Multimorbidity in primary care: Protocol of a nation of the protocol of the protocol of a nation of the protocol of the proto

1, ..., 19:169.
A, N'Goran AA, Pasquier J, et al. Mu... ational cross-sectional study in Switzerland, Bask ______.
Mueller Y, Haller DM, et al. Family practitioners' top medical prioritus... 2019;3:bjgopen18X101622.
AzLuyet A, Alexandra N'Goran A., Tandjung R., et al. Multimorbidity in primary care: Protocol of a nau-per 2015;5:Arte Number: e009165. ate of Pubaton: 2015.
Deruaz-Luyet A, N'Goran AA, Senn N, et al. Multimorbidity and patterns of chronic conditions in a primary care 2015; 2019;3:bjgopen2017;7:e013664.
27 Junius-Walker U, Wrede J, Voigt I, et al. Impact of a priority-setting consultation on doctor-patient agreement for primary eare 2012;20.
2019;20: Deruar Luyet A, Voigt I, et al. Impact of a priority-setting consultation on doctor-patient agreement for primary eare 2012;20.

tp://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA

Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

		Reporting Item	Page Numbe
Title			
	<u>#1</u>	Identify the report as a systematic review, meta-	
		analysis, or both.	
Abstract			
Structured	<u>#2</u>	Provide a structured summary including, as	
summary		applicable: background; objectives; data sources;	
		study eligibility criteria, participants, and interventions;	
		study appraisal and synthesis methods; results;	
		limitations; conclusions and implications of key	
		findings; systematic review registration number	
Introduction			
Rationale	<u>#3</u>	Describe the rationale for the review in the context of	;
		what is already known.	
Objectives	<u>#4</u>	Provide an explicit statement of questions being	:
		addressed with reference to participants,	
	For	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

		interventions, comparisons, outcomes, and study design (PICOS).	
Methods			
Protocol and	<u>#5</u>	Indicate if a review protocol exists, if and where it can	3
registration		be accessed (e.g., Web address) and, if available,	
		provide registration information including the	e z
		registration number.	
Eligibility criteria	<u>#6</u>	Specify study characteristics (e.g., PICOS, length of	3
		follow-up) and report characteristics (e.g., years	ŭ
		considered, language, publication status) used as	
		criteria for eligibility, giving rational	
Information	<u>#7</u>	Describe all information sources in the search (e.g.,	3
sources		databases with dates of coverage, contact with study	
		authors to identify additional studies) and date last	
		searched.	•
Search	<u>#8</u>	Present full electronic search strategy for at least one	3, Appendix 1 4, Figure 1
		database, including any limits used, such that it could	y 1
		be repeated.	C C C C C C C C C C C C C C C C C C C
Study selection	<u>#9</u>	State the process for selecting studies (i.e., for	4, Figure 1
		screening, for determining eligibility, for inclusion in	
		the systematic review, and, if applicable, for inclusion	
		in the meta-analysis).	
	For	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Data collection	<u>#10</u>	Describe the method of data extraction from reports	4
3 4	process		(e.g., piloted forms, independently by two reviewers)	
5 6 7			and any processes for obtaining and confirming data	
8 9			from investigators.	
10 11 12	Data items	<u>#11</u>	List and define all variables for which data were	3
13 14			sought (e.g., PICOS, funding sources), and any	
15 16 17			assumptions and simplifications made.	
18 19 20	Risk of bias in	<u>#12</u>	Describe methods used for assessing risk of bias in	4
20 21 22	individual		individual studies (including specification of whether	
23 24	studies		this was done at the study or outcome level, or both),	
25 26			and how this information is to be used in any data	
27 28 29 30			synthesis.	
31 32	Summary	<u>#13</u>	State the principal summary measures (e.g., risk	N/A
33 34 35	measures		ratio, difference in means).	
36 37	Planned	<u>#14</u>	Describe the methods of handling data and combining	4
38 39	methods of		results of studies, if done, including measures of	
40 41 42	analyis		consistency (e.g., I2) for each meta-analysis.	
43 44 45	Risk of bias	<u>#15</u>	Specify any assessment of risk of bias that may affect	4
46 47	across studies		the cumulative evidence (e.g., publication bias,	
48 49 50			selective reporting within studies).	
51 52 53	Additional	<u>#16</u>	Describe methods of additional analyses (e.g.,	N/A
54 55	analyses		sensitivity or subgroup analyses, meta-regression), if	
56 57 58			done, indicating which were pre-specified.	
59 60		For	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 2	Results			BMJ Op
3 4 5	Study selection	<u>#17</u>	Give numbers of studies screened, assessed for	Figure 1
6 7			eligibility, and included in the review, with reasons for	t publi
8 9 10			exclusions at each stage, ideally with a <u>flow diagram</u> .	shed as Pro
11 12 13	Study	<u>#18</u>	For each study, present characteristics for which data	5,6,7,8,9,10 te 13
14 15	characteristics		were extracted (e.g., study size, PICOS, follow-up	(Table 1) by co
16 17 18			period) and provide the citation.	Figure 1 Figure 1 Figure 1 Figure 1 Frotected by copyright, including for uses (Table 1) Appendix 2
19 20 21	Risk of bias	<u>#19</u>	Present data on risk of bias of each study and, if	Appendix 2
21 22 23	within studies		available, any outcome-level assessment (see Item	5 on 1 ng for
24 25 26			12).	ses Fet
27 28	Results of	<u>#20</u>	For all outcomes considered (benefits and harms),	related to Frasmu N/A N/A
29 30	individual		present, for each study: (a) simple summary data for	
31 32 33	studies		each intervention group and (b) effect estimates and	nload nd dat
34 35			confidence intervals, ideally with a forest plot.	Downloaded from h ogeschool . xt and data mining,
36 37 38	Synthesis of	<u>#21</u>	Present the main results of the review. If meta-	я, р А
39 40	results		analyses are done, include for each, confidence	ning, a
41 42 43			intervals and measures of consistency.	n.bmj.cc and simi
44 45 46	Risk of bias	<u>#22</u>	Present results of any assessment of risk of bias	llar tech 10
47 48	across studies		across studies (see Item 15).	10,11,12,13,14,15 Al training, and similar technologies 10 10
49 50 51	Additional	<u>#23</u>	Give results of additional analyses, if done (e.g.,	s. 2025 at N/A at
52 53	analysis		sensitivity or subgroup analyses, meta-regression	Depar
54 55 56			[see Item 16]).	tment
56 57 58 59 60	Discussion	For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	10,11,12,13,14,15 10,11,12,13,14,15 10 10 N/A N/A

BMJ Open: first published as 10.1136/bmjopen-2019-033445 on 12 February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2	Summary of	<u>#24</u>	Summarize the main findings, including the strength	15,16
3 4	Evidence		of evidence for each main outcome; consider their	
5 6 7			relevance to key groups (e.g., health care providers,	
8 9			users, and policy makers	
10 11 12	Limitations	<u>#25</u>	Discuss limitations at study and outcome level (e.g.,	16
13 14			risk of bias), and at review level (e.g., incomplete	
15 16 17			retrieval of identified research, reporting bias).	
18 19 20	Conclusions	<u>#26</u>	Provide a general interpretation of the results in the	17
20 21 22			context of other evidence, and implications for future	
23 24 25			research.	
26 27 28	Funding			
29 30	Funding	<u>#27</u>	Describe sources of funding or other support (e.g.,	1
31 32			supply of data) for the systematic review; role of	
33 34 35			funders for the systematic review.	
36 37 38	Notes:			
39 40 41 42	• 8: 3, append	ix 1		
43 44 45	• 9: 4, Figure 7	1		
46 47 48	• 18: 5,6,7,8,9	,10 (Tab	ble 1)	
49 50 51 52 53	• 21: 10,11,12	,13,14,1	5	
54 55 56	The PRISMA	A checkl	st is distributed under the terms of the Creative Commons Attribution	
57 58 59 60	License CC-		eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

1	https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with
1 2	
3 4	Penelope.ai
5	
6 7	
8 9	
10	
11 12	
13 14	
15 16	
17	
18 19	
20 21	
22	
23 24	
25 26	
27 28	
29	
30 31	
32 33	
34 35	
36 37	
38	
39 40	
41 42	
43 44	
45	
46 47	
48 49	
50	
51 52	
53 54	
55 56	
57	
58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

BMJ Open

Priorities of clinicians and of multi-morbid patients regarding treatment and health outcome priorities: a systematic mixed studies review

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033445.R1
Article Type:	Original research
Date Submitted by the Author:	14-Nov-2019
Complete List of Authors:	Sathanapally, Harini; University of Leicester Diabetes Research Centre, Sidhu, Manbinder S.; University of Birmingham, Fahami, Radia; University of Leicester Diabetes Research Centre Gillies, Clare; University of Leicester Diabetes Research Centre Kadam, Umesh; University of Leicester, Davies, Melanie; University of Leicester Diabetes Research Centre Khunti, Kamlesh; University of Leicester Diabetes Research Centre Seidu, Samuel; University of Leicester Diabetes Research Centre
Primary Subject Heading :	General practice / Family practice
Secondary Subject Heading:	Patient-centred medicine, Communication
Keywords:	PRIMARY CARE, GENERAL MEDICINE (see Internal Medicine), QUALITATIVE RESEARCH





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Priorities of clinicians and of multi-morbid patients regarding treatment and health outcome priorities: a systematic mixed studies review

Harini Sathanapally¹, Manbinder Sidhu², Radia Fahami¹, Clare Gillies¹, Umesh Kadam¹, Melanie J Davies¹, Kamlesh Khunti¹ and Samuel Seidu¹

- 1. Diabetes research centre, College of Life Sciences, University of Leicester, UK
- 2. Health Services Management Centre, School of Social Policy, University of Birmingham, UK

Corresponding author: Dr Harini Sathanapally (hs333@student.le.ac.uk)

Word count excluding titles, abstract, article summary, tables, figures and references: 4992

Author contributions: HS: Design of research question and methodology, data searching, data extraction, data analysis and manuscript development; MS: Design of methodology, data extraction, data analysis and manuscript development; RF: Data searching and data extraction; CG: Data analysis and manuscript development; UK: Data analysis and manuscript development; MJD: Data analysis and manuscript development; KK: Design of research question and methodology, manuscript development; SS: Conception of the idea for this review, design of research question and methodology, data extraction, data analysis and manuscript development; All authors have approved the final manuscript.

Funding: Harini Sathanapally is funded by the NIHR academic clinical fellowship award

Competing interests: None declared

Patient consent for publication: Not required

Data sharing statement: The majority of the data extracted and analysed as part of this review has been included in this article and associated appendices. Any further data can be acquired from the corresponding author by request.

ABSTRACT

Objectives: To identify studies that have investigated the health outcome and treatment priorities of multi-morbid patients, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether a disparity exists between the priorities of multi-morbid patients and clinicians.

Design: Systematic review

Data sources: MEDLINE, EMBASE, CINHAL and Cochrane databases from inception to May 2019 using a pre-defined search strategy, as well as reference lists containing any relevant articles, as per PRISMA and Cochrane guidelines.

Eligibility criteria: We included studies reporting health outcome and treatment priorities of adult multimorbid patients, defined as suffering from two or more chronic conditions, or of clinicians in the context of multi-morbidity, or both. There was no restriction by study design, and studies using quantitative and/or qualitative methodologies were included.

Data synthesis: We used a narrative synthesis approach to synthesise the quantitative findings, and a meta-ethnography approach to synthesise the qualitative findings.

Results: Our search identified of 24 studies for inclusion, which comprised of 12 quantitative studies, 10 qualitative studies and two mixed-methods studies. Twelve studies reported the priorities of both patients and clinicians (seven quantitative, three qualitative and two mixed-methods studies), ten studies reported the priorities of patients alone (three quantitative and seven qualitative studies) and two studies reported the priorities of clinicians alone (two quantitative studies).

Conclusion: Our findings have shown that there is a mostly low level of agreement between the priorities of multi-morbid patients and clinicians. We found that prioritisation by multi-morbid patients was mainly driven by their illness experiences, whilst clinicians focused on longer term risks. Recognising that there may be a disparity in prioritisation and understanding the reasons for why this might occur, can facilitate clinicians in accurately eliciting the priorities that are most important to their patients and delivering patient-centred care.

KEY WORDS: Patient-centred care, Shared decision-making, Multi-morbidity

ARTICLE SUMMARY

Strengths and limitations

- This is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both clinicians treating and patients living with multi-morbidity.
- We have included papers using both qualitative and quantitative methodologies and have been able to explore patterns and relationships in the findings, thus creating a comprehensive and well-rounded systematic review.
- Our findings facilitate clinicians in understanding both *how* and *why* the health outcome and treatment priorities of their multi-morbid patients might differ from their own priorities.
- Meta-analysis of the quantitative studies was unfeasible as there was a large variation in the tools used to ascertain priorities, and we have attempted to mitigate this by using a welldescribed and transparent method of narrative synthesis.
- A number of our included quantitative studies did not use pre-validated tools to ascertain priorities, leading to a risk of measurement bias.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Multi-morbidity, defined as the co-existence of two or more long-term conditions [1] is a global problem [2], which has become the norm across high-income countries [2, 3][4, 5] and becoming increasingly prevalent in middle and low-income countries [6][7][2]. Guidelines for the management of chronic diseases are often single disease-orientated, and can lead to confusion and complications when applied to patients with multi-morbidity [8]. Multi-morbid patients have an increased risk of adverse drug-related events as a result of high levels of polypharmacy and receiving un-coordinated care from multiple healthcare providers [9]. These patients have a poorer health-related quality of life [10], poorer functional status [11] and greater psychological distress [12]. As a result, understanding and finding better strategies to facilitate the management of multi-morbid patients has been identified as a priority for health research [13].

Key to the effective management of multi-morbidity is using patient-centred care and shared decision-making to set management goals that are acceptable to both the patient and the clinician [14]. Incorporating the priorities of patients in relation to treatments and health outcomes is integral to this process [15-17]. However, previous research has shown that whilst doctors recognise the importance of eliciting and incorporating the priorities of their multi-morbid patients, they do not always engage with this process in real world settings, and find eliciting patients' priorities to be difficult [18] [19]. Previous research, completed in a single disease context, has shown that the treatment and health outcome priorities of patients and clinicians can differ [20-22], and some studies have highlighted a gap between what doctors' perceive to be the priorities of their patients, and the actual priorities of their patients [23-25].

This systematic review aims to identify studies that have investigated the health outcome and treatment priorities of multi-morbid patients, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether there is a disparity between the priorities of multi-morbid patients and clinicians.

METHODS

Search strategy

This systematic review has been registered on PROSPERO (ID: CRD42018076076). A comprehensive search strategy (Appendix 1), was developed using guidance for best practice [26] and input from academic librarians at the University of Leicester. The search strategy was used to search MEDLINE, EMBASE, CINHAL and COCHRANE databases from inception to May 2019, as well as searching reference lists for any relevant articles based on PRISMA and Cochrane guidelines [26-28]. We undertook a scoping search using google scholar using our key terms (Patient*; Priorit*; Clinician, Physician, Doctor, General-practitioner, Family-practitioner; Multi-morbid*) to identify relevant grey literature. Citations were stored using Refworks. We have presented our process of article selection in Figure 1.

We included studies reporting the health outcome and treatment priorities of adult patients with multimorbidity [1] and/or clinicians, in relation to patients with multi-morbidity. Studies which did not specify the definition of multi-morbidity as "two or more chronic conditions" [1] in their inclusion criteria, but had a sample patients representative of being diagnosed with multi-morbidity (i.e. with a minimum of two chronic conditions), were also included. There was no restriction by

study design, and we included studies using quantitative and/or qualitative methodologies. We excluded studies not published in English language, studies with participants aged under 18 years, and studies focusing on a single disease area.

Patient and Public Involvement

Patient and public involvement was not applicable in the design, conduct or reporting of this review.

Study selection

The titles and abstracts of all articles identified by the literature search were assessed independently and in duplicate by two reviewers (HS and RF). Studies that did not meet inclusion criteria were discarded. Full text of selected articles were retrieved and assessed to determine if they met the inclusion criteria, and those studies which met the inclusion criteria were included in the review. Any discrepancies regarding eligibility of an article were discussed, and consensus reached with MS and SS.

Methodological quality assessment and data extraction

Data was extracted using standardised data extraction forms by a single reviewer (HS), and these were checked independently for accuracy by a second reviewer (SS). The reported health outcome and treatment priorities of study participants were the key outcomes that were extracted.

Quality assessment was carried out in parallel with the data extraction process. For the quantitative studies, due to the heterogeneity of study design, we used the AXIS tool for assessment for the cross-sectional studies [29], the Newcastle-Ottawa scale for assessment of the longitudinal observational and cohort studies [30], and the Cochrane collaboration's risk of bias tool for assessment of randomised controlled trials [31]. For the qualitative studies, we used the CASP checklist for appraisal of qualitative research [32]. For the two mixed-methods studies, we used the AXIS tool [29] to assess the quantitative aspects of the study (both cross-sectional in study design), and the CASP checklist for qualitative research [32], to assess the qualitative aspects of these studies.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Data synthesis

We decided *a priori* not to carry out a meta-analysis due to the heterogeneity of the quantitative studies. Therefore, we have taken a narrative synthesis approach, described by Popay et al [33] to synthesise our quantitative findings. Our approach consists of three key steps:

1) *Development of a preliminary synthesis* in which study characteristics and descriptions are collated and findings presented in a summary table

2) Exploring relationships in the data between study characteristics and their findings, as well as between the reported findings across different studies with explanations considered where relationships were identified.

c) Assessing the robustness of the synthesis using quality assessment tools to guide conclusions and identify directions for clinical practice.

Qualitative studies were synthesised using a meta-ethnography approach [34, 35], which consisted of careful reading of the papers, extracting information regarding the context of the study and findings. *Key concepts* arising from each paper were also identified, with preservation of the terminology used by the authors where possible to ensure accurate representation of the findings of

the original studies. The key concepts across the papers were then *translated* using a table summarising the studies, their findings in relation to the key concepts and the *second order* interpretations of the authors, which enabled the exploration of any relationships and differences. The translations were then synthesised using a table containing the *first order* and *second order* interpretations for the key concepts across the studies, which then led to the development of further, *third order* interpretations by reviewers [34, 35].

From the results of our narrative synthesis of the quantitative studies and meta-ethnography of the qualitative studies, we considered how the findings of the two syntheses complement one another, particularly where our qualitative findings may provide possible explanations for our quantitative findings. The outcome of this process is described in the discussion section.

RESULTS

Overall study characteristics

Our search resulted in the identification of 24 studies for inclusion, which comprised of 12 quantitative studies, 10 qualitative studies and two mixed-methods studies. The characteristics of all of the included studies are described in Table 1. The included studies had all been conducted in high income developed countries, including Canada [36, 37], USA[38-44], Netherlands[45, 46], Australia[47, 48], UK[49-51], Germany [52-55] and Switzerland [56-58]. Sample sizes ranged from 15 to 1169 patients and 5 to 92 clinicians in the quantitative studies, and 15 to 146 patients and 4 to 19 clinicians in the qualitative studies.

Author and year of publication	Setting	Study type	Study aims	Target group and number of participants (n)	Outcomes measured
			QUANTITATIVE		
			Health outcome prior	ities	
Fried et al, 2011 [39]	USA- 3 senior centres and 1 assisted living facility	Quantitative: Cross-sectional study	To explore the use of a simple tool to elicit older persons' health outcome priorities	All volunteers included (n=357)	The prioritisation by participants of 4 universal health outcomes, namely: -keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms
Fried et al , 2011, [40]	USA- recruited from participants in a larger study, where they had been recruited from age- aggregated community housing [59]	Quantitative: Cross-sectional survey	To determine the feasibility of using a simple tool to elicit the preferences of older persons based on their prioritization of universal outcomes	Patients aged 65 and over with a known diagnosis of hypertension or use of anti-hypertensive medications, and having a known risk of falls (n=81)	 > Rankings given by participants to 4 universal health outcomes in the outcome prioritisation tool: keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms > Feasibility of the use of outcome prioritisation tool

Mantelli et al, 2018[57]	Switzerland- General practitioners working in Switzerland who had previously taken part in case-vignette studies	Quantitative: cross-sectional survey	To determine whether, how and why GPs de- prescribe in frail oldest-old patients with multimorbidity and polypharmacy, and to identify factors that influenced their decision to de- prescribe	General Practitioners (n=157)	 Percentage of GPs willing to prescribe at least one medication in the case of frail older patients with CVD and compared to frail older patien without CVD Reasons for de-prescribing Importance ratings given to factors influencing decision to de-prescribe
Van Summeren et al, 2017 [46]	Netherlands- General practice centres	Quantitative: Cross-sectional and implementation study	To determine proposed and observed medication changes when using an outcome prioritisation tool during a medication review in older patients with multimorbidity and polypharmacy. A secondary aim was to explore the relationship between the prioritized health outcome of patients and the type of medication change, such as a stop, a dose adjustment, or a switch.	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications. (n=59) General practitioners (n=17)	 Patients' priority rankings of the four health outcomes in ti outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain >Medication changes propose by the GP, and observed in th patient records following incorporation of the priority rankings given by patients, int medication review consultation
Van Summeren et al, 2016 [45]	Netherlands- General practice centres	Mixed-methods: Cross-sectional survey pilot and qualitative interviews to assess acceptability (semi-structured and in-depth)	To explore whether an outcome prioritization tool (OPT) is appropriate in the context of medication review in family practice, focusing on its acceptability and practicality	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications (n=60) General practitioners (n=13)	 >Patients' prioritisation of the four domains of the outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain > Family practitioners views of the acceptability and practica of using the outcome prioritisation tool for medicat review
	1		Problem-based priori	ties	
Junius-Walker et al 2012 [52]	Germany- General practice centres	Quantitative: Randomised controlled trial	To investigate whether a structured priority-setting consultation reconciles the often-differing doctor-patient views on the importance of problems.	Patients aged 70 or over (n=317) General practitioners (n=40)	-Baseline importance rankings given by patients and clinician to a list of problems generate from a geriatric assessment for each patient. - Importance rankings given again after a structured consultation incorporating the baseline problem list and importance rankings and degr of reconciliation in doctor- patient agreement after the structured consultation

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Junius-Walker et al, 2011[53]	Germany- General practice centres	Quantitative: Cross-sectional survey	To gain insight into setting individual priorities with older patients using a priority definition that was coherent to the patients' life and doctors' work context	Patients aged 70 or over and living at home (n=123) General practitioners (n=11)	Importance rankings given by patients and clinicians to a list o problems generated from a geriatric assessment for each patient.
Voigt et al, 2010 [54]	Germany-General practice centres	Quantitative: Cross-sectional survey	To ascertain health priorities of older patients and treatment priorities of their general practitioners (GP) on the basis of a geriatric assessment and to determine the agreement between these priorities.	Patients aged 70 or over and at least one contact with the general practitioner in the preceding 3 months (n= 35) General practitioners (n=9)	 Importance rankings given to problems generated from a geriatric assessment by patients and clinicians Degree of agreement between patients and clinicians on the above
		C	Condition-focused prio	prities	
Moore et al, 2014 [36]	Canada- Databases of all practising nurse practitioners, family practitioners and geriatricians in Ontario	Quantitative: Cross-sectional survey	To quantify how family physicians, nurse practitioners and geriatricians prioritize syndromes, diseases and conditions when caring for seniors	Nurse practitioners (n=68) Family practitioners (n=84) Geriatricians (n=27)	Frequency and importance rankings given by family practitioners, nurse practitioner and geriatricians to 41 health issues known to arise in elderly patients
Zulman et al, 2010 [44]	USA- Scheduled primary care visit for patients at 9 veteran affairs facilities	Quantitative: Prospective cohort study	To understand patterns of patient-provider concordance in the prioritization of health conditions in patients with multimorbidity	Patients with diabetes and hypertension who had their primary diabetes care provider enrolled in the study (n = 1169) Primary care providers i.e. physicians, physician assistants or nurse practitioners (n= 92)	-Patient rankings given in terms of their most important health concerns and providers rankings in terms of conditions most likely to affect each patient's outcomes -Concordance between the importance ratings of patient- provider "pairs"
Herzig et al, 2019 [56]	Switzerland- Primary data was from "Multimorbidity in Family medicine" study [60]. Patients enrolled by General practitioners during scheduled consultations.	Quantitative: Cross-sectional survey	To describe FPs' medical priority ranking of conditions relative to their prevalence in patients with multimorbidity	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International classification of primary care 2 (n=888) General Practitioners (n=100)	Importance rankings given by family practitioners to the list of chronic conditions that each patient had on the day of their inclusion in the study
Déruaz-Luyet et al, 2018 [58]	Switzerland- Primary data was from "Multimorbidity in Family medicine" study [60].	Quantitative: Cross-sectional survey	To evaluate whether GPs could identify the condition that their patients with multimorbidity considered most important.	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International classification of primary care 2, and receiving follow-up from their GP for at least the	Whether there is agreement between what patients considered to be their most important health condition and what GPs thought patients considered to be their most important health condition

	Patients enrolled by General practitioners during scheduled consultations.			preceding 6 months (n= 572 for main analysis, 585 for sensitivity analysis) General Practitioners (n=100)	
			reatment priorities		
Caughey et al, 2017 [47]	Australia- Multi- disciplinary ambulatory consulting service clinics at tertiary teaching hospitals	Mixed-methods: Structured quantitative interviews with patients then semi-structured qualitative interviews with patients and clinicians	To investigate how older patients with multi- morbidity balance the benefits and harms associated with medication for prevention of CVD, and in the presence of competing health outcomes. To investigate the factors that clinicians consider when making treatment decisions for older, multimorbid	Patients aged 65 or older with 2 or more chronic conditions (n=15) Clinicians (n=5)	 -Patient willingness to take a medication when presented w different scenarios with variab degree of benefit, impact on daily living, adverse outcomes and impact on other comorbid conditions -Patient-reported data during semi-structured interviews where they were asked about their treatment preferences, medication effects and shared decision making -Clinician reported data during semi-structured interviews on treatment decisions, patient preferences and polypharmacy
		011	patients.		
		Q0/			
Kuluski et a, 2013 [37]	Canada- A Family Health Team in Ontario	Qualitative: Semi- structured interviews	To examine patient goals of care from the perspectives of older persons with multi-morbidities, their family physicians and informal caregivers (i.e., family member or friend who provides ongoing support) and then examine the extent of alignment between these three perspectives	Patients aged 65 or older with a diagnosis of at least two chronic health conditions (n=28) Informal Caregivers of included patients (n=28) Family physicians (n=4)	 Patient, caregiver and physici reported data on goals of care for the patients Degree of alignment of goals care across patient, caregiver and physician "triads"
Schoenberg et al, 2009 [38]	USA- Senior centres, Low income senior housing complexes, churches and a civic meeting hall	Qualitative: In- depth interviews	To understand how vulnerable older adults with multimorbidity prioritize and manage their chronic conditions	Patients aged 55 or older with a diagnosis of at least two chronic illnesses, from low-income backgrounds (n= 41)	Patient-reported data from in- depth interviews, regarding th medical history, self-care procedures, patient prioritisation by means of health-related areas of worry and health-related "expenditures" in terms of money, time and need for reliance on others.
Fried et al, 2008 [41]	USA- Senior centres, Doctors' practices and a congregate housing site	Qualitative: Focus groups	To examine the ways in which older persons with multiple conditions think about potentially competing	Patients aged 65 or older and were taking 5 or more medications (participants also had a minimum of 3 chronic conditions)	Patient-reported data regardir their perceptions of the interactions between their different illnesses and treatmen regimens, goals of treatment and decisions regarding treatment

			to gain insight into how processes to elicit values regarding these outcomes can be grounded in the patient's perspective		
Naik et al, 2016 [42]	USA- Qualitative data from the VETCARES study [61] , in which participants recruited from the VA tumour registry	Qualitative: Open-ended questions as part of mixed methods interviews which also included structured questions	To identify a taxonomy of health-related values that frame goals of care of older, multi- morbid adults who recently faced cancer diagnosis and treatment	Veterans with a diagnosis of head and neck, gastric, oesophageal, or colorectal cancer, and diagnosis fell one month prior to the study's opening eligibility window (6 months) (n=146)	Patient-reported data regarding their priorities or concerns regarding their future healthcare decisions
Elliott et al, 2007 [43]	USA- Harvard Pilgrim Health Centre, a HMO (health maintenance organisation) in New England	Qualitative: Semi- structured interviews	To explore how older adults with multiple illnesses make choices about medicines	Patients taking more than three medicines with purposive sampling to reflect symptomatic comorbidities and asymptomatic comorbidities and mental health issues (participants had a minimum of 3 comorbidities) (n=20)	Patient-reported data regarding beliefs about medicines, medicine-taking behaviour, historical vs potential choices between different medicines, and factors influencing these choices
Turner et al, 2016 [48]	Australia- Long term care facilities in South Australia	Qualitative: Nominal group technique	To use nominal group technique to generate then rank factors that general medical practitioners, nurses, pharmacists and residents or their representatives perceive are most important when deciding whether or not to de- prescribe medication	Residents/representatives of residents (n=11) General Practitioners (n=19) Nurses (n=12) Pharmacists (n=14)	-Generated factors important fo de-prescribing according to residents/resident representatives, general practitioners, nurses and pharmacists -Priority rankings given by groups containing representatives from all of the above, to the list of priorities generated previously.
Lindsay, 2009 [49]	UK- Participants recruited from CHD registries in Greater Manchester as part of a larger RCT[62]	Qualitative: Focus groups and two interviews	To use the concepts of "chronic illness trajectory" and "biographical disruption" to examine how patients self- manage multiple chronic conditions and especially how they prioritize their conditions	Participants from the parent study who had more than one chronic condition (i.e. at least two) (n=53)	Patient-reported data regarding how they prioritised their multiple conditions, what strategies they used to cope with their conditions and barriers in being able to manage their illnesses
Cheraghi-Sohi et al, 2013 [50]	UK- secondary analysis of qualitative data from four other studies [63-66]	Qualitative: In- depth interviews	To explore how and why people with multimorbidity prioritise some long-term conditions over others and what the potential implications may be for self- management activity, and in turn, suggest how	Participants from original studies who had two or more long term conditions, and had given data regarding prioritisation (n=41)	Patient-reported data pertaining to prioritisation of their long term conditions

Morris et al [51]	UK- General Practices in North-West England	Qualitative: Semi- structured interviews	such information may help clinicians negotiate the management of multimorbidity patients To examine what influences self- management priorities for individuals with multiple long-term conditions and how this changes over time	Patients with more than one chronic condition and at least one of COPD, IBS or Diabetes (n=21)	Patient-reported data on management strategies and experiences with primary health care, and data from follow-up interviews on any changes in their illness management.
Hansen et al, 2015 [55]	Germany- Participants recruited from the "Multicare cohort study" [67]	Qualitative: Focus groups	To identify reasons for disagreement regarding illnesses between patients and their GPs	Patients who had 3 or more chronic conditions from a list of 29 conditions (n=21) General Practitioners of the recruited patients (n=15)	Data from separate focus groups for patients and clinicians in which any communication problems and reasons for disagreement between patients and clinicians were explored

Table 1 Characteristics of all of the included studies in order of reference

Summary of quality assessment

The outcome of quality assessment based on each of the afore-mentioned tools is summarised in Appendix 2. The majority of the quantitative studies were cross-sectional in design [36, 39, 40, 45, 46, 53, 54, 56-58] [47], including the quantitative elements of the two mixed-methods studies. The other studies included one cohort study [44] and one randomised controlled trial [52]. The cross-sectional studies were of moderate quality, with a number of studies having small sample sizes [40, 45, 46, 54]. The sample sizes of clinicians in most of the cross-sectional studies were particularly small, ranging from of 9 to 157 clinicians [45, 46, 54, 57], which impacts upon the generalisability and application of their findings. We noted that a number of the studies did not use pre-validated questions and tools to ascertain priorities [36, 54, 56-58], leading to a degree of subjectivity in the way in which priorities were ascertained, and the risk of measurement bias which again impacts on the generalisability of their findings.

The majority of the qualitative studies, including the qualitative aspects of the two mixed-methods studies, used interviews for data collection (n=8). Two studies used focus groups [41, 55], one study used a combination of focus groups and interviews [49] and one study used the nominal group technique [48]. The qualitative studies were of good quality, with appropriate use of qualitative methodology and transparent descriptions of the data analysis processes. Three studies only gave a limited description of their analytic process [47-49], with two of these studies [47, 48] and one mixed-methods study [45], not presenting any quotes.

QUANTITATIVE SYNTHESIS

Within our quantitative synthesis, we found that the studies focused either on the overall state of the patients' health, the problems posed by different chronic disease groups, or the patients' treatment regimens. Some of the quantitative studies elicited patient and/or clinician priorities as part of an intervention [52] [46]. Therefore, in order to reduce the risk of bias from the interventions, we included only the pre-intervention results from these studies.

Health outcome priorities

Four studies reported patient priorities of overall health outcomes using a "health outcome prioritisation tool" [39, 40, 45], which is a visual analogue scale requiring the following health outcomes to be given a score out of 100: "Maintaining independence"; "Staying alive"; "Pain relief"; "Symptom relief". Maintaining independence was the outcome that had the highest importance after a pooling of the *most important* rankings from the four studies, followed by "Staying alive" (Table 2). For clinicians' priorities, one study reported that 98% of a sample of 157 general practitioners identified the "quality of life for the patient", and 96% identified the "life expectancy of the patient", as the most important factors in influencing their clinical decision-making to deprescribe for elderly, multi-morbid patients [57].

Study	Health outcome prioritisation as a tool for decision making among older persons with multiple chronic conditions[39]	Health outcome prioritisation to elicit preferences of older persons with multiple health conditions[40]	Outcome prioritisation tool for medication review in older patients with multimorbidity: A pilot study in general practice[46]	Eliciting Preferences of multi-morbid Elderly Adults in Family Practice Using an Outcome Prioritisation Tool[45]	Aggregate ranking as most important (%)
Maintaining independence	270 (75.6%)	34 (42.0%)	7 (36.8%)	19 (35.8%)	330 (64.7%)
Staying alive	40 (11.2%)	22 (27.2%)	6 (31.6%)	18 (34.0%)	86 (16.9%)
Pain relief	26 (7.3%)	17 (21.0%)	1 (5.3 %)	6 (11.3%)	50 (9.8%)
Symptom relief	21 (5.9%)	8 (9.8%)	5 (26.3%)	10 (18.9%)	44 (8.6%)
Total number of participants	357	81	19ª	53	510

Table 2-Summary of most important rankings for studies using the Outcome Prioritisation Tool a= although there were 59 patients included in this study [46] priorities were only reported for 19 patients

Priorities based on health problems

Three studies reported patient and general practitioners' priorities based on various health *problems*, following a geriatric assessment [52-54]. These problems were then categorised into domains, and the importance rankings for each of the domains were presented. Problems in the domains of "Social" "Mood" and "Function" recurrently featured in the top four of the most highly ranked priorities by patients across all three studies. In terms of the importance rankings by clinicians, problems in the domains of "Mood" and "Function" also featured in the top four importance rankings across all three studies, whilst "Social" problems were rated highly in one study [53] and problems in the domain of "Medication" were ranked highly in the other two studies [52, 54]. Interestingly, the authors in one study[53] found that patients feeling "Emotionally affected" was the strongest predictor for a problem being rated as important (OR 11.1 Cl 6.73 to 18.33), whereas "Poor prognosis" was the strongest predictor for clinicians (OR 6.39 Cl 4.61 TO 8.87)

Condition-focused priorities

Two studies reported patient priorities in relation to specific conditions or groups of conditions [44, 58], in the context of multi-morbidity. Zulman et al. reported that "Diabetes/glycaemic control" was most frequently ranked as "most important", with "Hypertension" coming second [44]. However, the sample of patients included in this study were all diabetic, hypertensive patients. Deruaz-luyet et al. found that musculoskeletal conditions including back pain, were most frequently reported to be the most important conditions for their patients, however endocrine/metabolic conditions (including obesity) were second and cardiovascular conditions were third [58].

Three studies reported condition-focused priorities of clinicians in the context of multi-morbidity. Herzig et al. reported the priorities of general practitioners alone [56], and found that "multiple sclerosis", "mental retardation", and "bronchus lung neoplasm" were all highly prioritised by their participants. Zulman et al reported the priorities of "primary care providers" who consisted of physicians, physician assistants or nurse practitioners [44], and found that diabetes was the top priority for primary care providers, with hypertension coming second, in alignment with their previously described patient priorities [44]. Moore et al. examined the priorities of different types of clinicians, including family physicians, geriatricians and nurse practitioners [36], and as with Zulman et al., found that diabetes was the top priority for family physicians and also nurse practitioners, whereas dementia was the top priority for geriatricians [36]. In addition, heart failure, atrial fibrillation and hypertension formed three of the top five conditions considered to be most important by the family practitioners in the study [36].

Treatment priorities

As part of a study to examine the influence of the risks and benefits of medications on treatment preferences of patients, Caughey et al. also examined the priorities of patients in the face of "competing outcomes" [47]. They found that 80% of participants would not be willing to take medication to reduce "joint pain", if the medication increased their risk of a myocardial infarction by 10%. However, this was deduced from a sample of only 15 patients [47].

Agreement between patients and clinicians

Five of the included studies investigated the level of agreement in priority rankings between patients and their clinicians [44, 52-54, 58]. Three studies reported a low level of agreement between patient and clinicians' priority rankings [52-54]. Two of these studies used a Cohen's Kappa calculation to estimate the degree of agreement between the importance ratings of patients and clinicians, and the values of which were 0.18 and 0.11 respectively, indicating "slight agreement" after allowing for chance [53][54]. One study used a weighted kappa calculation to measure the degree of agreement, which, at a pre-intervention point in this study, was low at 6% [52].

Two studies reported that there was a "high" level of agreement [44, 58]. Deruaz-Luyet et al. found that in the case of 54.9% (n=314) of their patients, the condition that their GP had considered to be either the first or second most important, was in the same disease-group as the condition that the patient considered to be most important [58].

Zulman et al. reported that 60% of "patient-provider pairs" had a "high concordance", meaning that the same three conditions had been rated as top three priorities by both parties, or that two of the same conditions had been rated in the top three priorities by both parties [44]. In this case, given that the sample of patients were all diabetic and hypertensive could have led to a narrowing of the

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

range of chronic diseases across the sample, which in turn could have led to an increased likelihood of agreement. However, the participant characteristics reported by the authors state that the patients had a mean of eight health conditions (SD 3.00), suggesting that the patients did not have a narrow range of chronic diseases. Furthermore, the questions posed to patients and providers were phrased differently, in that providers were asked to choose the top three most important medical concerns "that are likely to affect health outcomes for this patient", whereas patients were asked to choose their top three most important health concerns. The authors acknowledge this in their paper, and justify this difference as being due to their aim of exploring the concordance in priorities about the "most important problems facing the patient", rather which problems "providers thought the patient would have prioritised", which, they argue, is a different concept to their aim [44].

QUALITATIVE SYNTHESIS

Whilst our quantitative synthesis allowed us to investigate *which* health outcomes, diseases or treatments were important to multi-morbid patients and their clinicians, our qualitative analysis enabled us to explore *how* prioritisation occurs. Below, we describe the key findings from our qualitative analysis.

Mechanisms of prioritisation

In the qualitative studies that approached prioritisation from a disease-specific perspective, patients were able to identify an illness as their main priority [49, 50]. For many patients, prioritisation appeared to be driven by their experience of the illness, which formed part of its "meaning as consequence" [50] as phrased by Cheraghi-Sohi et al. The 'consequences' of an illness consisted of the *impact* that the illness was having on the patients' everyday lives, which included functional limitation and the symptomatic burden of the illness, including its "unpredictability" (Table 3) [49]. For others, prioritisation appeared to be driven by their perception of the risk now and in the future with respect to functional deterioration and mortality.

In other studies, patients framed their priorities between *quality of life vs length of life* (Table 3) [42]. Patients in the study by Naik et al. who were multi-morbid adults with cancer, prioritised "quality of life" more highly than "length of life" [42]. This was also reflected in the findings of Fried et al., who found that when considering medication with competing outcomes in terms of extending life compared to quality of life, participants appeared to prioritise preserving quality of life [41].

Van Summeren et al. found that prioritisation was "difficult" when there was no "specific need" for a treatment decision to be made [45]. This concept of a difference in prioritisation based on hypothetical, or experiential levels, was also shared in the findings of Elliott et al [43] and Fried et al [41].

Where clinicians' perspectives were explored alongside patients, clinicians reported that exploring patients' priorities was "extremely important" when managing "competing interests" [47] and beneficial in providing patient-centred care [45]. Some clinicians in the mixed-methods study carried out by Van Summeren et al. reported that exploring their patients' priorities allowed them to have a "deeper understanding" of the patient, helped with making patient-centred treatment decisions and advance care planning (Table 3) [45]. However, other clinicians in the same study found exploring patient priorities to be difficult due its "novelty" and the fact that it represented a change to their usual consultations [45].

	Concept	Examples from included studies
Mechanisms of	Unpredictability of symptoms	"My final issue is diverticulitis. In many ways that is the thing that makes the most impact on my life because of the unreliability of it. You make plans to do something to go somewhere and at the last minute you don't dare leave the house because you don't leave the loo. In itself it's not an important medical issue. It's the social problem more than anything else." – Lindsay et al [49]
prioritisation	Quality of life vs length of life	"If you don't feel good, you can't take care of yourself and you have to depend on somebody else, what's the good of living another 10 years?"- Fried et al [41]
	Facilitating clinicians' decision making	"In future, I'll be happier to be more decisive in keeping an eye on what we do and do not do as regards this patient." Van Summeren et al [45]

Table 3- Examples from included studies for key concepts relating to mechanisms of prioritisation

Factors influencing prioritisation:

Our analysis revealed that there were a number of factors that appeared to influence how both patients and clinicians arrived at their priorities, and which priorities they chose.

i. Functional ability

Preserving functional ability as a priority for patients was a dominant concept across the majority of the qualitative studies [37, 38, 49, 51] [42][47][41]. Preserving independence emerged as the most significant reason for prioritising functional ability for patients, and maintaining the ability to engage in activities of daily living, mobility, maintaining cognitive ability and wanting to avoid being a "burden" or lacking social support to help them cope with functional deterioration (Table 4) [38, 49, 50].

Conditions which caused limitation to patients' ability to self-manage their health conditions, led to a "tension" between the patients' expectations of themselves and what they were physically able to do [51]. Lifestyle management, particularly reduced ability to exercise and the adverse impact of this on weight, was cited as part of patients' ability to self-manage [49].

Maintaining patients' functional ability was reported as a priority by some clinicians [37] [47]. Clinicians considered the wider implications of the patients' functional deterioration, particularly cognitive deterioration, and spoke of wanting to reduce the risk of "burnout" for the patients' family members/caregivers [37].

ii. Mortality

Reducing the risk of mortality emerged as a recurrent priority for clinicians [47, 55]. Caughey et al found that clinicians prioritised mortality in younger (less than 65 years) multi-morbid patients rather than older multi-morbid patients, as they felt they could be more "aggressive" in their treatment [47]. Reducing the risk of mortality also emerged as a priority for patients across a number of studies [37, 38, 43, 50, 51] [42]. Some patients found the asymptomatic nature of hypertension to be concerning; hence, the consequences of hypertension could be unpredictable, compared to some other chronic illnesses where symptoms can give warning of onset and severity (Table 4) [38, 43].

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The symptomatic burden of a condition contributed to its "meaning as consequence" for patients [50]. Symptoms were cited as being a cause of functional limitation [38, 49], and in some cases their "unpredictability" could cause significant disruption to patients' daily lives [49]. Symptom control was reported to be a priority by some clinicians [37][47]. However, clinicians in one study considered symptom control to be less important, particularly when there was no risk of mortality [55]. In these cases, clinicians seemed to be aware that patients may still be prioritising symptom control highly, even if the clinicians did not (Table 4).

iv. Treatment burden

Factors related to the treatment burden of an illness appeared to adversely impact prioritisation for patients, leading to *de-prioritisation* of certain medications and treatments [38, 41, 43, 48]. Elliot et al. reported that cost and distressing side effects, were factors which led patients to stop taking a medication [43]. Similarly, Fried et al. found that patients reported unpleasant side effects to be a "competing outcome", which negatively influenced their decision regarding continuing a medication [41]. However, difficulty with achieving control over the management of an illness, as well as requirement for high levels of engagement with self-management, emerged as factors that contributed to the prioritisation of an illness by some patients (Table 4) [49].

	Concept	Examples from included studies
	Functional ability	"I mean, because I have to be mobile, I am living on my own, no one is going to take care of me, I have got to look after myself" Cheraghi-Sohi et al [50]
	Mortality	"Well I really do worry the most about the high blood pressure. 'Cause see you know you got arthritis and you can tell when it's coming on. But you can't hardly tell about high blood pressure. It can just hit you like that [snaps fingers]"" Lindsay et al [49]
Factors influencing	Symptom control	"I would not want to live with pain. I won't allow that to happen"- Naik et al [42]
prioritisation	Disparity in prioritisation of symptom control	" I talk [to her] for a quarter of an hour about this and that every time after which she replies, "but my vertigo," and I answer every time, well, unfortunately there is nothing I can do about it, we have already tried and done everything. But it is probably the first diagnosis she will mention: "What are you suffering from?". "Vertigo". For me, this would be somewhere all the way at the bottom." – Hansen et al [55]
	Treatment burden	"It's the knee that's the most concerning because everything else is controlled by tablets. The knee is a problem because if I have one little slip I'm in plaster again for 6 weeks." Lindsay et al [49]

Table 4- Examples from included studies for key concepts relating to factors influencing prioritisation

DISCUSSION

Prioritisation as a concept is broad, context-dependent and difficult to confine into a single definitive definition. As a result, determining what can be interpreted as a health outcome or treatment priority as part of our study selection in this review, was inherently difficult. We excluded some studies that investigated the preferences of multi-morbid patients or clinicians, in contexts that we judged to be different to the aim of this review. These included patient preferences for healthcare

 delivery [68][69], levels of engagement with self-management practices [70][71] and clinicians' experiences of the management of multi-morbid patients [18][72][73]. Whilst these studies represent very important areas of research, they were not within the scope of our aim in this review i.e. identifying studies that report the health outcome and treatment priorities of multi-morbid patients or those of clinicians in relation to multi-morbid patients. A discussion from our synthesis of findings of the included studies in this review is presented below.

Health outcome and treatment priorities

From our findings, patients' prioritisation appeared to be driven by weighing up the empirical compared to the hypothetical impact of a disease, whereby the empirical impact of a disease, which included its impact on function, symptomatic and treatment burden, was the most dominant driver of prioritisation. This is consistent with the findings of previous literature showing patients with rheumatoid arthritis who had reported experiencing higher levels of pain, were more likely to report pain as a priority [74].

Amongst empirical factors, preserving functionality emerged as most highly prioritised by patients amongst the quantitative studies that took a health outcome approach[39, 40, 46], whilst "function" was a domain that was prioritised highly by both patients and clinicians in the studies where prioritisation of various health *problems* were investigated [52-54]. From our qualitative findings, functional ability formed a key part of the preservation of various aspects of the patients' independence and their quality of life, as well as their ability to self-manage. Existing evidence shows that the prevalence of multi-morbidity is highest in those aged over 65 years [75], and the population for the majority of the included studies were older multi-morbid adults. This could provide an explanation for why preserving functionality was highly prioritised.

Prioritisation was not a static process and was subject to change, based on factors such as illness exacerbations, life events, whether there was a need for a treatment decision to be made, and whether the priority related to retrospective or prospective healthcare [49, 51]. When considering the hypothetical impact of an illness, perceptions of future risk came into play, and in particular, the risk of mortality [43]. This was particularly evident in relation to cardiovascular disease, where patients appeared to perceive the risk of mortality to be high [38].

Risk of mortality was a dominant driver for prioritisation amongst clinicians. This was shown in our quantitative synthesis, where amongst studies assessing disease-specific priorities, conditions with a higher risk of mortality, such as cardiovascular disease and diabetes, recurrently emerged as being highly prioritised by clinicians [36, 44, 56] and differentiated by age [47]. This age-based consideration could explain why clinicians prioritised "quality of life for the patient" as higher, albeit marginally, than "life expectancy of the patient" in their clinical decision-making for de-prescribing for elderly, multi-morbid patients [57].

Smith et al previously developed a "Core Outcome Set" [76] in which a Delphi consensus panel formed of 26 international health experts, identified and prioritised a set of outcomes tailored for application to research studies targeting multi-morbid patients. Mortality, mental health outcomes and quality of life featured most highly in their list of prioritised outcomes, which also emerged in this review. However, we found that relatively few studies reported the prioritisation of mental health outcomes, with the exception of the studies that took a *problem-based* approach to prioritisation, where problems with regard to "Mood" were prioritised highly by both patients and clinicians [52-54].

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Our findings show a varying degree of agreement between the priorities of multi-morbid patients and clinicians. Previous studies carried out in the context of diabetes[77], and psoriasis[78] have found a low level of agreement on health outcome and treatment priorities between patients and clinicians, which correlates with the findings of some studies included in this review [52-54], but not others [44]. The nature of the patients' illnesses emerged as a factor for concordance or discordance of priorities with their clinicians [37]. Patients and clinicians were in agreement in situations where patients were currently experiencing an exacerbation of a particular condition, or had a "stable" state of health. However, in patients who suffered from illnesses with more complex courses, discordance of priorities tended to occur between patients and clinicians [37].

In recent times, the traditional *paternalistic* model for the doctor-patient relationship has given way to an *egalitarian* model [79], where doctors and patients each play an equitable role in a shared-decision making process, which places the patient at its core and thus achieving greater *patient-centred* care [80][79]. A shared agreement between patients and doctors on treatment priorities have been highlighted to play an important part in achieving patient-centred care and creating a *therapeutic alliance*, the benefits of which can include improved treatment adherence [79, 80]. Indeed, Jowsey et al found that agreement between patients and clinicians in the formulation of care plans promoted adherence to these plans, whereas a lack of agreement led to disengagement with care plans by patients [81].

Strengths and limitations

To our knowledge, this is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both patients and clinicians for patients living with multi-morbidities. In this review, we have been able to add a novel line of argument to the ongoing discussion on this subject. By incorporating papers using both qualitative and quantitative methodologies, we have been able to explore patterns and relationships in the findings of a wide range of studies, thus creating a comprehensive and well-rounded systematic review.

There are noteworthy limitations. We did not include the term "comorbidity", in our search terms, and whilst "comorbidity" is distinctive from multi-morbidity, there is also some conceptual overlap between the two terms. We felt that including "comorbidity" in our search strategy would identify studies focusing on a specific condition rather than multi-morbidity.

A number of the quantitative studies did not use pre-validated tools to ascertain priorities [36, 54, 56-58], leading to a risk of measurement bias, which could limit the generalisability of findings in this review. We also detected a large variation in the tools used to ascertain priorities, which meant that carrying out a meta-analysis to synthesise the findings of the quantitative studies was not possible. Yet, we have tried to mitigate the lack of meta-analysis by using a well-described and well-established method of narrative synthesis [33], in order to maintain rigour and transparency.

Another limitation is that in our inclusion criteria we chose to also include studies which did not explicitly specify a definition of multi-morbidity as "two or more chronic conditions" in their inclusion criteria but had a sample of participants that were reflective of multi-morbidity (i.e. with a minimum of two chronic conditions which could be identified from participant demographic data). We chose to do this as in the absence of a universally accepted and uniform definition of multimorbidity, we sought to base our judgement on the inclusivity of each paper on its value in answering our review question. This, along with the previously discussed difficulty in defining prioritisation, may have introduced a degree of subjective interpretation in the process of study

selection, despite our attempt to mitigate this by incorporating independent review of the results of our literature searching by two reviewers in duplicate.

Recommendations for the future

We recommend that future guidelines developed for clinicians in the management of multimorbidity highlight the need to elicit and consider both short term and long term priorities for their patients', as our review has shown that patients' priorities for their current illness experiences and future risks posed by illnesses, may differ. In accordance with current NICE guidance, we also reiterate the need to review these priorities continually, and particularly when exacerbations, changes to illness course or treatment regimens, or other wider socially-contextualised changes occur in their patients' lives.

There was a large variation in how priorities were ascertained, and in the tools used to ascertain priorities. The relative lack of standardised and validated tools for use to ascertain patient priorities in everyday clinical practice has also been described in previous literature [82]. We highlight a need for the development of a standardised and validated tool that is acceptable to both patients and clinicians, and can be used to ascertain patient-priorities in the multiple dimensions described in this review. Such a tool would a valuable aid to treatment decision-making, advance care planning and achieving patient-centeredness for patients living with multi-morbidity.

Conclusion

The findings from this review show the priorities of patients and clinicians can have varying degrees of concordance, being mostly low [52, 54], in alignment with previous findings in single disease contexts [77, 78]. We have found that the mechanisms of prioritisation can also differ between our two groups, in that patients are driven by illness experiences, whereas clinicians may be focused on managing longer term risks. Understanding these differences can help clinicians to better recognise situations where the patients' priorities may be different to theirs and elicit the most important priorities for their patients.

REFERENCES

1 van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature, *The European Journal of General Practice* 1996;2:65-70.

2 Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study, *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences* 2015;71:205-14.

3 Rijken M, Struckmann V, Dyakova M, et al. ICARE4EU: Improving care for people with multiple chronic conditions in Europe. 2013.

4 Roberts KC, Rao DP, Bennett TL, et al. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada, *Health Promot Chronic Dis Prev Can* 2015;35:87-94.

5 Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. 2014;89:1336-49.

6 Arokiasamy P, Uttamacharya U, Jain K, et al. The impact of multimorbidity on adult physical and mental health in low-and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? *BMC medicine* 2015;13:178.

7 Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global ageing: a crosssectional study of 28 countries using the World Health Surveys, *BMC Public Health* 2015;15:776.

8 Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions, *N Engl J Med* 2004;351:2870-4.

9 Calderon-Larranaga A, Poblador-Plou B, Gonzalez-Rubio F, et al. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? *Br J Gen Pract* 2012;62:e821-6.

10 Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care, *Quality of Life Research* 2006;15:83-91.

11 Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature, *Ageing research reviews* 2011;10:430-9.

12 Fortin M, Bravo G, Hudon C, et al. Psychological distress and multimorbidity in primary care, *Ann Fam Med* 2006;4:417-22.

13 Academy of Medical Sciences. Multimorbidity: a priority for global health research, 2018.

14 Muth C, van den Akker M, Blom JW, et al. The Ariadne principles: how to handle multimorbidity in primary care consultations. *BMC Medicine* 2014;12:223.

15 Azad NA, Mielniczuk L. A call for collaboration: improving cardiogeriatric care, *Can J Cardiol* 2016;32:1041-4.

16 Roland M, Paddison C. Better management of patients with multimorbidity, *BMJ: British Medical Journal (Online)* 2013;346.

17 Bierman AS, Tinetti ME. Precision medicine to precision care: managing multimorbidity, *Lancet* 2016;388:2721-3.

18 Mc Namara KP, Breken BD, Alzubaidi HT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia, *Age & Ageing* 2017;46:291-9.

19 Sinnott C, Mc Hugh S, Browne J, et al. GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research, *BMJ Open* 2013;3:e003610,2013-003610.

20 Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis, *BMJ* 1997;314:1580-3.

21 Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? *Qual Health Care* 2001;10 Suppl 1:i39-43.

22 Thomson S, Doody G. Parallel paths? Patient and doctor priorities in psychiatric outpatient consultations, *Journal of Mental Health* 2010;19:461-9.

23 Lee CN, Hultman CS, Sepucha K. Do patients and providers agree about the most important facts and goals for breast reconstruction decisions? *Ann Plast Surg* 2010;64:563-6.

24 Volandes AE, Paasche-Orlow MK, Barry MJ, et al. Video decision support tool for advance care planning in dementia: randomised controlled trial, *BMJ* 2009;338:b2159.

25 Pager CK, McCluskey PJ. Surgeons' perceptions of their patients' priorities, *Journal of Cataract & Refractive Surgery* 2004;30:591-7.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

26 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons 2011.

27 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement, *Systematic reviews* 2015;4:1.

28 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement, *Ann Intern Med* 2009;151:264-9.

29 Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS), *BMJ Open* 2016;6:e011458,2016-011458.

30 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, *Eur J Epidemiol* 2010;25:603-5.

31 Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, *BMJ* 2011;343:d5928.

32 Critical Appraisal Skills Programme UK. CASP qualitative research checklist. *CASP checklists* 13/03/2017.

33 Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews, A product from the ESRC methods programme Version 2006;1:b92.

34 Noblit GW, Hare RD. Meta-ethnography: Synthesizing qualitative studies: sage 1988.

 35 Britten N, Campbell R, Pope C, et al. Using meta ethnography to synthesise qualitative research: a worked example, *J Health Serv Res Policy* 2002;7:209-15.

36 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, family physicians and geriatricians when caring for the elderly. *Journal of interprofessional care* 2015;29:401-3.

37 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between older persons with multi-morbidities, their family physicians and informal caregivers. *BMC Family Practice* 2013;14:133.

38 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and accommodating multiple morbidities by vulnerable older adults, *J Health Care Poor Underserved* 2009;20:134-51.

39 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions, *Arch Intern Med* 2011;171:1856-8.

40 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with multiple health conditions, *Patient Educ Couns* 2011;83:278-82.

41 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, *J Am Geriatr Soc* 2008;56:1839-44.

42 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing Life-Threatening Illness. *J Am Geriatr Soc* 2016;64:625-31.

43 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness, *Journal of General Internal Medicine* 2007;22:805-10.

44 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *Journal of General Internal Medicine* 2010;25:408-14.

45 Summeren JJ, Haaijer-Ruskamp FM, Schuling J. Eliciting preferences of multimorbid elderly adults in family practice using an outcome prioritization tool, *J Am Geriatr Soc* 2016;64.

46 van Summeren JJ, Schuling J, Haaijer-Ruskamp FM, et al. Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice, *Br J Gen Pract* 2017;67:e501-6.

47 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. *Patient Preference and Adherence* 2017;11:131-40.

48 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. *BMJ Open* 2016;6:Arte Number: e009781. ate of Pubaton: 2016.

49 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEASES, CANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.

50 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimorbidity: A qualitative secondary analysis. *SAGE Open Medicine* 2013;1:2050312113503955.

51 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. *Chronic Illness* 2011;7:147-61.

52 Junius-Walker U, Wrede J, Voigt I, et al. Impact of a priority-setting consultation on doctor-patient agreement after a geriatric assessment: cluster randomised controlled trial in German general practices. *Quality in primary care* 2012;20.

53 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general practitioners: a cross-sectional study. *Quality in primary care* 2011;19.

54 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patients differ from treatment priorities of their physicians, *Croat Med J* 2010;51:483-92.

55 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older patients with multimorbidity and their GPs - a qualitative study. *BMC family practice* 2015;16:68.

56 Herzig L, Mueller Y, Haller DM, et al. Family practitioners' top medical priorities when managing patients with multimorbidity: a cross-sectional study, *BJGP open* 2019;3:bjgpopen18X101622.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

57 Mantelli S, Jungo KT, Rozsnyai Z, et al. How general practitioners would deprescribe in frail oldestold with polypharmacy—the LESS study, *BMC family practice* 2018;19:169.

58 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, *BMC family practice* 2018;19:66.

59 Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes, *J Am Geriatr Soc* 2008;56:1409-16.

60 DeruazLuyet A., Alexandra N'Goran A., Tandjung R., et al. Multimorbidity in primary care: Protocol of a national cross-sectional study in Switzerland. *BMJ Open* 2015;5:Arte Number: e009165. ate of Pubaton: 2015.

61 Martin LA, Moye J, Street Jr RL, et al. Reconceptualizing cancer survivorship through veterans' lived experiences, *J Psychosoc Oncol* 2014;32:289-309.

62 Lindsay S, Bellaby P, Smith S, et al. Enabling healthy choices: is ICT the highway to health improvement? *Health:* 2008;12:313-31.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

63 Hurley MV, Walsh N, Bhavnani V, et al. Health beliefs before and after participation on an exercised-based rehabilitation programme for chronic knee pain: doing is believing, *BMC Musculoskeletal Disorders* 2010;11:31.

64 Bower P, Harkness E, Macdonald W, et al. Illness representations in patients with multimorbid long-term conditions: Qualitative study, *Psychol Health* 2012;27:1211-26.

65 Grime J, Richardson JC, Ong BN. Perceptions of joint pain and feeling well in older people who reported being healthy: a qualitative study, *Br J Gen Pract* 2010;60:597-603.

66 Nio Ong B, Jinks C, Morden A. The hard work of self-management: Living with chronic knee pain, *International journal of qualitative studies on health and well-being* 2011;6:7035.

67 Hansen H., Schafer I., Schon G., et al. Agreement between self-reported and general practitionerreported chronic conditions among multimorbid patients in primary care - results of the MultiCare Cohort Study. *BMC family practice* 2014;15:39.

68 Noel P.H., Frueh B.C., Larme A.C., et al. Collaborative care needs and preferences of primary care patients with multimorbidity. *Health Expectations* 2005;8:54-63.

69 Lechner S., Herzog W., Boehlen F., et al. Control preferences in treatment decisions among older adults - Results of a large population-based study. *J Psychosom Res* 2016;86:28-33.

70 Noel PH, Parchman ML, Williams JWJ, et al. The challenges of multimorbidity from the patient perspective. *Journal of General Internal Medicine* 2007;22:419-24.

71 Coventry PA, Fisher L, Kenning C, et al. Capacity, responsibility, and motivation: a critical qualitative evaluation of patient and practitioner views about barriers to self-management in people with multimorbidity, *BMC health services research* 2014;14:536.

72 Sinnott C., Mc Hugh S., Boyce M.B., et al. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. *British Journal of General Practice* 2015;65:e184-91.

73 Luijks HD, Loeffen MJW, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity management: a qualitative study. *British Journal of General Practice* 2012;62:e503-10.

74 Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority, *Arthritis Care & Research* 2002;47:391-7.

75 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, *The Lancet* 2012;380:37-43.

76 Smith SM, Wallace E, Salisbury C, et al. A Core Outcome Set for Multimorbidity Research (COSmm), *Ann Fam Med* 2018;16:132-8.

77 Heisler M, Vijan S, Anderson RM, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? *Journal of general internal medicine* 2003;18:893-902.

 78 Okubo Y, Tsuruta D, Tang A, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians, *Journal of the European Academy of Dermatology and Venereology* 2018;32:606-14.

79 Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature, *Soc Sci Med* 2000;51:1087-110.

80 Kaba R, Sooriakumaran P. The evolution of the doctor-patient relationship, *International Journal of Surgery* 2007;5:57-65.

81 Jowsey T, Dennis S, Yen L, et al. Time to manage: patient strategies for coping with an absence of care coordination and continuity, *Sociol Health Illn* 2016;38:854-73.


82 Mangin D., Stephen G., Bismah V., et al. Making patient values visible in healthcare: A systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity. *BMJ Open* 2016;6:Arte Number: e010903. ate of Pubaton: 01 Jun 2016.

Figure legends:

Figure 1: Flow diagram to illustrate process from literature searching to selection of studies for inclusion [28]

reziez onz

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





2. Pat	ients/
	·
3. 1 o	r 2
	prit*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
-	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
5. Ch	pice*.mp.
6. Pre	ference*.mp.
7. Air	n*.mp.
8. Go	al*.mp.
9. 4 o	r 5 or 6 or 7 or 8
10. D	octor*.mp.
11. P	nysicians/
12. Cl	inician*.mp.
13. Pı	imary Health Care/ or Physicians, Family/ or Family Practice/ or General Practitioners/
14. G	eneral practitioner*.mp.
15. 10) or 11 or 12 or 13 or 14
	ultimorbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading wo
•	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
17. N	ulti-morbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading
	, keyword heading word, protocol supplementary concept word, rare disease supplementary opt word, unique identifier, synonyms]
18. N	ultiple morbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading
	keyword heading word, protocol supplementary concept word, rare disease supplementary pt word, unique identifier, synonyms]
19. 10	5 or 17 or 18
20. 3	and 9 and 15 and 19
	ulti morbid*.mp. [mp=title, abstract, original title, name of substance word, subject heading wor
•	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
22. 10	5 or 17 or 18 or 21
23. 3	and 9 and 15 and 22

	g et al [2]	-Sohi et al [3]	[4]	al [5]	[6]	[7]	[8]	en-2019-0; 9 yright, inc	[10]	Summeren et al [11]	al [12]
YES	YES	YES	YES	YES	YES	YES	YES	33445 on 12 Feb	YES	YES	YES
YES	YES	YES	YES	YES	YES	YES	YES	ruary 2020. Downloaded from http://bmjopen.t Erasmushogeschool . 'glated to text and data mining, AI training, any YE	NO- Quantitative or mixed methods methodology would have been more appropriate as the aim was to rank factors, although data collected using a qualitative technique, it lacks richness and appears to be presented in a quantitative manner	YES	YES
YES		YES			YES	YES	017	YES similar technol	YES		YES
YES	YES	YES	YES	YES	YES	NO- no explanation given as to	YES	Cī (YES	YES	YES
	YES	YES YES YES YES	YES YES YES YES YES YES	YES YES YES YES YES YES YES YES YES YES YES YES	YES YES YES YES YES YES YES YES YES YES YES YES YES YES	YES	YES	YES	YES YES <td>CT CT</td> <td>CT CT</td>	CT CT	CT CT

 28 of 45

Page	29	of	45
------	----	----	----

of 45			

f 45						BMJ Ope	n		6/bmjopen-2019- 1 by copyright, ir			
appropriate to the aims of the research							why the specific conditions were chosen (COPD, IBS etc)		033445 on 12 ncluding for u			
Were the data collected in a way that addressed the research issue?	YES	YES	YES	YES	YES	YES	YES	YES	ebruary 2020. E Erasmusho S related to tex	YES	YES	YES
Has the relationship between researcher and participants been adequately considered?	YES	YES	YES	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point.	NO- There is no background information given on the researcher (sole in this case) and there has been no evidence of any consideration of researcher bias at any point during the study.	NO- there has been no evidence of any consideration of researcher bias at any point during the study	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point. However there was some evidence of reflexivity during the data collection process when emerging areas of interest that could be incorporated into future interviews	NO- background of RAE who conducted interviews and main aspect of analysis not specified and no consideration has been given to any possibility of researcher bias	February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA Erasmushogeschool sio for the profession of t	NO- no mention of the background of the researchers or how this may have influenced the results	NO- role of second interviewer carrying out the in-depth interviews not mentioned, and there has been no consideration given to the possibility of bias from the interviewers. One of the interviewers was a FP, which could have led to bias with the interviewees responses.	NO- there has been no consideration n given to the role of the researcher and the potential for researcher bias at any point.

						BMJ Ope	'n		6/bmjopen-2019-033445 4 by copyright, including			Pa
							were considered.		9-0334 includ			
Have ethical issues been taken into consideration ?	YES	YES	YES- in the original studies, however further ethical issues regarding secondary qualitative analysis were not taken into account.	YES	YES	YES	YES	YES	on 12 J for u	YES	YES	YES
Was the data analysis sufficiently rigorous?	YES	YES	YES	YES	NO- superficial description of analytic process and no information given on how many researchers analysed the transcripts- assumed one as there is only one author- risk of bias not taken into account for the analytic process	YES	YES	YES	February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Deparence Erasmushogeschool . ses related to text and data mining, Al training, and similar technologies.	NO- the data analysis process is very ambiguous and the qualitative analysis has not been described in sufficient depth.	YES- clear description of the analytic process with two researchers independentl y analysing the data for rigour. However no description of the interpretation phase from the data.	NO- there is only a superficial description of the data analysis process, and there is very little detail given on how the themes were derived from the data. There is no presentation at all of quotes from the data to support the authors interpretation n of the data
Is there a clear	YES	YES	YES	YES	YES	YES	YES	YES	at Department GEZ-LTA	YES	YES- however the qualitative	YES- however no quotes given

Page 31	of 45						BMJ Ope	en		6/bmjopen-2019- J by copyright, in			
1 2 3 4 5 6 7 8	statement of findings?									033445 on cluding fo		data from the patient interviews has only been summarised- no direct	to support findings
9 10 11	How valuable is the research?	Valuable	0	Valuable	quotes given Valuable	Valuable							
$\begin{array}{c} 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ \end{array}$							Valuable			125 at Department GEZ-LTA			

	Newcastle	e-ottawa scale	e for cohort	BMJ Open	Comparability of cohorts on the basis of the design or analysis controlled for confounders The study controls for age, sex and marital status (one star)*	6/bmjopen-2019-033445 on 12 February Eran	2	
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis controlled for confounders	Assessment Assessment Control of Control of Control of Control of Control of Control of Control of	Was follow- up long enough for outcomes to occur	Adequacy of follow-up of cohorts
Zulman et al [13]	Somewhat representative (one star) *	Drawn from the same community as the exposed cohort (one star) *	Secure record (one star) *	N/A	The study controls for age, sex and marital status (one star)*	Self-report	N/A	No statement
				10	The study controls for age, sex and marital status (one star)*	http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

of 45				A	xis tool f	or cross	-sectional	studies :	summar	y table \overline{s}	Mantelli et al		
	Intro	duction	Junius- Walker et al [14]	Fried et al[15]	Fried et al [16]	Moore et al [17]	Van Summeren et al [18]	Voigt et al [19]	Van Summeren et al [11]	Caughey S al [20]	Mantelli et al	Deruaz- Luyet et al [22]	Herzig et al [23]
	1	Were the aims/objectives of the study clear?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes includir		Yes	Yes
	Meth	ods								6ı	5 0		
	2	Was the study design appropriate for the stated aim(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes for uses re	1 ^Y es 12 Feb	Yes	Yes
	3	Was the sample size justified?	No- convenien ce sampling used, small sample size, however no explanatio n for sample size given	No- no justificatio n for sample size given, convenien ce sampling used	No- recruitme nt strategy described clearly but no justificatio n for sample size given	Yes	No	No- sampling strategy described well but no justificati on for sample size given	No- purposive sampling used, however no justificatio n for sample size given	data mining, Al tr	Taylo- Convenience Convenienc	Yes- in the parent study [24]	Yes- in the parent stud [24]
	4	Was the target/reference population clearly defined? (Is it clear who the research was about?)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes aining, and sir	bmjopen.bmj.	Yes	Yes
	5	Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?	Yes	Yes- However assumptio n made that participant s will have multiple chronic conditions	Yes	Yes	Yes	Yes	Yes	Yes hilar technologies.	Yes- lthough only GP's who data previously cher case- construction whether case- construction constructi	Yes	Yes

						BMJ Ope	n		y copyright	bmjopen-20		
6	Was the selection process likely to select subjects/participan ts that were representative of the target/reference population under investigation?	Yes	Yes- as above	Yes	Yes	Yes	Yes	Yes	d by copyright, including for uses relate Yes	19-03 445 on 12 Februar	Yes	Yes
7	Were measures undertaken to address and categorise non- responders?	Yes	Don't know- not reported	Yes	No	No	No	Yes- Purposive sampling used with efforts made to address gaps in participant types	Don't d	2000 't know- 2002 to reported 2020. Downloaded from http://bm	Yes in the parent study [25]. Characteristi cs of participants who were not included due to missing data, were described in this study	Yes in the parent stu [25]
8	Were the risk factor and outcome variables measured appropriate to the aims of the study?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	ies ig, and sim	s Spen.bmj.co	Yes	Yes
9	Were the risk factor and outcome variables measured correctly using instruments/measu rements that had been trialled, piloted or published previously?	Yes	Yes- piloted in a previous study	No- Tested in this study as it was a feasibility study	No- Pre- tested in this study but only using 2 FP's and 1 NP	Yes	No- STEP assessme nt previousl y published however no testing done of measure used to collect importan ce ratings	Yes	Yes Yes	Yes- the onstruments ised were within this yithin thi	No- instruments designed through "internal consensus discussions".	No

						BMJ Ope	n			bmjope		
									y 11911, 1	6/bmjopen-2019		
10	Is it clear what was used to determined statistical significance and/or precision estimates? (e.g. p- values, confidence intervals)	Yes	N/A	Yes	Yes	N/A	Yes	N/A		-033445 on 12 Februa	Yes	Yes
11	Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes Contraction of the second	کلهmjopen-2019-033445 on 12 February 2020. Downloaded from Erasmushogeschool . - Erasmushogeschool .	Yes	Yes
Rest	ults											
12	Were the basic data adequately described?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	es http://bmjopen.bmj.co	Yes	Yes
13	Does the response rate raise concerns about non- response bias?	No	Don't know- response rate not reported	No	No	No	Don't know- response rate not reported	No	Don't know- response rate not reported No	n May 1	No	No
14	If appropriate, was information about non-responders described?	Yes	No	Yes	No	Yes	No	Yes	No	् 2, 2025 at Department GEZ-LTA	Yes in the parent study[25] Characteristi cs of participants who were not included	Yes in th parent study[25

						BMJ Ope	า		-	v copyright.	6/bmiopen-2019-		
										ncluding for u	033445 on 12	due to missing data, were described in this study	
15	Were the results internally consistent?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ises rel	Tres ebru	Yes	Yes
16	Were the results presented for all the analyses described in the methods?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	Erasmushogeschool .	arv 2020. Downloaded	Yes	Yes
Discu	ission				2					nin	fro		
17	Were the authors' discussions and conclusions justified by the results?	No- very small sample of GP's compared to patients therefore generaliza ble conclusion s regarding concordan ce between doctors and patients cannot accurately be drawn from this study	Yes	Yes	Yes	Yes	Yes	Yes- Small sample size for quantitativ e aspect of study taken into account	No- very small sample siz across patients an clinicians meaning results are not generaliza e	ng. Aktraining, and similar technologies.	ස් http://bm.iopen.bmi.com/ on May 12. 2025 at Department GEZ-LTA	Yes	Yes

										6/bmjopen-2019- 4 by copyright, ir		
18	Were the limitations of the study discussed?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	6/bmjopen-2019-033445 on by copyright, including for	Yes	Y
Othe										on fo		
19	Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?	No	No	No	No	No	No	No	No	ی 12 February 2020 Erasmus r uses related to	No	N
20	Was ethical approval or consent of participants attained?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	text and data	Yes	Y
										rom http://bmjc ining, Al trainin		
						2×16				on 12 February 2020 کی Erasmushogeschool . for uses related to text and data mining, Al training, and similar technologies.		

26

33 34

	BMJ Open	6/bmjope 1 by copy
		6/bmjopen-2019-0 9 by copyright, incrolled trials summary table
I he Cochrane Collaboration's to	ool for assessing risk of blas in randor	nised controlled trials summary table
Study	Junius-Walker et al [26]	ing to
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Participating doctors were allocated 1:1 into the
		intervention and control group using random block
		sizes of 🛱 un 🗟
Allocation concealment (selection bias)	Unclear risk	No information given regarding any efforts to conceal
		the allocatizan sequence
Blinding of participants and researchers (performance	Low risk	Participate vere only informed of the procedures of
bias)		their ow the arm.
Blinding of outcome assessment (detection bias)	Low risk	Participation Server blinded to the pre-intervention
		importance and ings, when completing the final
· · · · · · · · · · · · · · · · · · ·		important dings.
Incomplete outcome data (attrition bias)	High risk	25 patients depped out prior to baseline ratings and 5
		further partiends dropped out prior to final ratings, these
		patients dere excluded from analysis, however
		intention treat analysis cannot be carried out in this context due to the nature of the intervention
Selective reporting (reporting bias)	Low risk	Adequate reporting on all of the specified outcomes
Other bias	None detected	jopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA ing, and similar technologies.
	roview only http://bmienen.hmi.com/site/about/gu	F

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 39 of 45	BMJ Open Sp jop
1 2	BMJ Open by opyright, inclus 34 References BMJ Open 2019-0334
3 4	References
5 6 7	1 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between of gersons with multi-morbidities, their family physicians and informal caregivers. <i>BMC Family Practice</i> 2013;14:133.
8 9 10 11	2 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and accommodating multiple morbidities by vulnerable older adults, <i>J Health Care Poor Underserved</i> 2009;20:134-51.
12 13 14	3 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimotion in multimotion in multimotion in secondary analysis. <i>SAGE Open Medicine</i> 2013;1:2050312113503955.
15 16 17	4 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing The Threatening Illness. J Am Geriatr Soc 2016;64:625-31.
18 19 20 21	5 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEAS ANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.
22 23 24	6 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older batter is with multimorbidity and their GPs - a qualitative study. <i>BMC family practice</i> 2015;16:68.
25 26 27	7 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. <i>Chronic Illness</i> 2011;7:147-61.
28 29 30	8 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among odder adults with chronic illness, <i>Journal of General Internal Medicine</i> 2007;22:805-10.
31 32 33 34	9 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, <i>J Am Geriatr Soc</i> 2008;56:1839-44.
34 35 36 37	10 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. <i>BMJ Open</i> 2016;6:Arte Number: e009781. ate of Pubaton: 2016.
38 39 40 41 42	11 Summeren JJ, Haaijer-Ruskamp FM, Schuling J. Eliciting preferences of multimorbid elderly adults in family practing e using an outcome prioritization tool, <i>J Am Geriatr Soc</i> 2016;64.
43	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

13 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. Journal of General Internal Medicine 2010;25:408-14.

14 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general attioners: a cross-sectional study.

2444119 In primary care 2011;19. 15 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older provide the multiple chronic conditions, Arch Intern Med 2011;171:1856-8 Arch Intern Med 2011;171:1856-8.

16 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with naile health conditions, *Patient Educ* Couns 2011;83:278-82.

17 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, Family physicians and geriatricians when caring for the elderly. Journal of interprofessional care 2015;29:401-3.

18 Van Summeren J.J.G.T., Schuling J., HaaijerRuskamp F.M., et al. Outcome prioritisation tool for medication regime in older patients with multimorbidity: A pilot study in general practice. British Journal of General Practice 2017;67:e501-6. and

19 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patient differ from treatment priorities of their physicians, Croat Med J 2010;51:483-92.

20 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in deterbatients with multimorbidity. Patient Preference and Adherence 2017;11:131-40.

family practice 2018;19:169.

22 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, BMC family practice 2018;19:66. tment GEZ-LTA

Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

	Reporting Item	Page Number
		Page Number
<u>#1</u>	Identify the report as a systematic review, meta-	1
	analysis, or both.	
<u>#2</u>	Provide a structured summary including, as applicable:	2
	background; objectives; data sources; study eligibility	
	criteria, participants, and interventions; study appraisal	
	and synthesis methods; results; limitations; conclusions	
	and implications of key findings; systematic review	
	registration number	
<u>#3</u>	Describe the rationale for the review in the context of	3
	what is already known.	
For	peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	
	#2 #3	 #1 Identify the report as a systematic review, meta- analysis, or both. #2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number #3 Describe the rationale for the review in the context of

1 2	Objectives	<u>#4</u>	Provide an explicit statement of questions being	а 3 с	
3 4			addressed with reference to participants, interventions,	open: t	
5 6 7			comparisons, outcomes, and study design (PICOS).	irst put	
8 9 10 11	Methods			BMJ Open: first published as 10.1136/bmJopen-Z019-033445 on 12 February 2020. Protected by copyright, including for uses related to te 3	יוויירייין איט א
12 13	Protocol and	<u>#5</u>	Indicate if a review protocol exists, if and where it can be	es 10.1136/bmjopen-2019-033445 on 12 February 202 Erasmu Protected by copyright, including for uses related to 3 4, 3,	1212
14 15	registration		accessed (e.g., Web address) and, if available, provide	by co	1
16 17			registration information including the registration	pen-zu pyrigh	
18 19 20			number.	t, inclu	50 020
20 21 22	Eligibility criteria	#6	Specify study characteristics (e.g., PICOS, length of	uding fo 3,4 fo	5447 2
23 24		<u>#0</u>	follow-up) and report characteristics (e.g., years	or use	; ; ; ;
25 26				s relat	, L
27 28			considered, language, publication status) used as	ed to	- 2020
29 30 31			criteria for eligibility, giving rational		
32 33	Information	<u>#7</u>	Describe all information sources in the search (e.g.,	voyeschool . xt and data mining, A ع	
34 35	sources		databases with dates of coverage, contact with study	oaded from n data mining, ℃	1
36 37			authors to identify additional studies) and date last		
38 39 40			searched.	raining,	
41 42	Search	<u>#8</u>	Present full electronic search strategy for at least one	3, Appendix 1 s	5
43 44 45			database, including any limits used, such that it could be	milar t	
46 47			repeated.	Al training, and similar technologies. 3, Appendix 1 4, Figure 1	
48 49 50	Study selection	<u>#9</u>	State the process for selecting studies (i.e., for	4, Figure 1	2 2227
51 52			screening, for determining eligibility, for inclusion in the	at Dep	1
53 54 55			systematic review, and, if applicable, for inclusion in the	artme	
56 57			meta-analysis).	יידי איז איז איז איז איז איז איז איז איז אי	100
58 59 60		For	oeer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		- + >

1 2	Data collection	<u>#10</u>	Describe the method of data extraction from reports	4
3 4 5	process		(e.g., piloted forms, independently by two reviewers)	
5 6 7			and any processes for obtaining and confirming data	
8 9 10			from investigators.	
11 12	Data items	<u>#11</u>	List and define all variables for which data were sought	3
13 14			(e.g., PICOS, funding sources), and any assumptions	
15 16 17 18			and simplifications made.	
19 20	Risk of bias in	<u>#12</u>	Describe methods used for assessing risk of bias in	4
21 22	individual		individual studies (including specification of whether this	
23 24	studies		was done at the study or outcome level, or both), and	
25 26 27			how this information is to be used in any data synthesis.	
28 29 30	Summary	<u>#13</u>	State the principal summary measures (e.g., risk ratio,	N/A
31 32 33	measures		difference in means).	
34 35	Planned	<u>#14</u>	Describe the methods of handling data and combining	4,5
36 37	methods of		results of studies, if done, including measures of	
38 39 40	analyis		consistency (e.g., I2) for each meta-analysis.	
41 42 43	Risk of bias	<u>#15</u>	Specify any assessment of risk of bias that may affect	4
43 44 45	across studies		the cumulative evidence (e.g., publication bias, selective	
46 47 48			reporting within studies).	
49 50	Additional	<u>#16</u>	Describe methods of additional analyses (e.g.,	N/A
51 52 53	analyses		sensitivity or subgroup analyses, meta-regression), if	
53 54 55			done, indicating which were pre-specified.	
56 57 58	Results			
59 60		For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Study selection	<u>#17</u>	Give numbers of studies screened, assessed for	Figure 1
3 4			eligibility, and included in the review, with reasons for	ppen: f
5 6 7			exclusions at each stage, ideally with a flow diagram.	Figure 1 Figure 1 Figure 1 Figure 1 Figure 1 Frotected by copyright, including for uses related to to Appendix 2 N/A Figure 1 N/A
8 9 10	Study	<u>#18</u>	For each study, present characteristics for which data	5,6,7,8,9,10 5 ,6,7,8,9,10
11 12	characteristics		were extracted (e.g., study size, PICOS, follow-up	(Table 1) tote
13 14			period) and provide the citation.	l36/brr ed by
15 16	Dick of high	#10	Drepart data on rick of bigs of each study and if	copyr Annordiy 2
17 18	Risk of bias	<u>#19</u>	Present data on risk of bias of each study and, if	Appendix 2 right,
19 20	within studies		available, any outcome-level assessment (see Item 12).	9-0334 includ
21 22	Results of	<u>#20</u>	For all outcomes considered (benefits and harms),	rotected by copyright, including for uses (Table 1) Appendix 2 N/A
23 24 25	individual		present, for each study: (a) simple summary data for	12 Feb ' uses
26 27	studies		each intervention group and (b) effect estimates and	related
28 29			confidence intervals, ideally with a forest plot.	
30 31				Downl gesci (t and
32 33	Synthesis of	<u>#21</u>	Present the main results of the review. If meta-analyses	11,12,13,14,15 da lo la
34 35	results		are done, include for each, confidence intervals and	togeschool ed from htt 11,12,13,14,15 11,12,13,14,15
36 37			measures of consistency.	
38 39 40	Risk of bias	<u>#22</u>	Present results of any assessment of risk of bias across	ttp://bmjopen.bmj.com/ on May 12, 2 Al training, and similar technologies 10 N/A N
41 42 43	across studies		studies (see Item 15).	n.bmj.c and sim
44 45	Additional	<u>#23</u>	Give results of additional analyses, if done (e.g.,	illar tec N/A tec
46 47 48	analysis		sensitivity or subgroup analyses, meta-regression [see	May 1: hnolog
49 50			Item 16]).	2, 2025 Jies.
51 52 53 54	Discussion			p://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA 1 training, and similar technologies. 10 N/A 16
55 56	Summary of	<u>#24</u>	Summarize the main findings, including the strength of	16 G
57 58	Evidence		evidence for each main outcome; consider their	EZ-LT
59 60		For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	>

			relevance to key groups (e.g., health care providers,
			users, and policy makers
Li	mitations	<u>#25</u>	Discuss limitations at study and outcome level (e.g., risk
			of bias), and at review level (e.g., incomplete retrieval of
			identified research, reporting bias).
C	onclusions	<u>#26</u>	Provide a general interpretation of the results in the
			context of other evidence, and implications for future
			research.
F	unding		
Fι	unding	<u>#27</u>	Describe sources of funding or other support (e.g.,
			supply of data) for the systematic review; role of funders
			for the systematic review.
No	tes:		
•	8: 3, appendix	1	
•	9: 4, Figure 1		
•	18: 5,6,7,8,9,1	0 (Tal	ble 1)
•	21: 11,12,13,1	4,15	
	The PRISMA	checkl	ist is distributed under the terms of the Creative Commons Attribution
	License CC-B	Y. Thi	s checklist was completed on 13/11/2019
		For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Priorities of patients with multimorbidity and of clinicians regarding treatment and health outcomes: a systematic mixed studies review

Journal:	BM1 Open
Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033445.R2
Article Type:	Original research
Date Submitted by the Author:	16-Dec-2019
Complete List of Authors:	Sathanapally, Harini; University of Leicester Diabetes Research Centre, Sidhu, Manbinder S.; University of Birmingham, Fahami, Radia; University of Leicester Diabetes Research Centre Gillies, Clare; University of Leicester Diabetes Research Centre Kadam , Umesh ; University of Leicester, Davies, Melanie; University of Leicester Diabetes Research Centre Khunti, Kamlesh; University of Leicester Diabetes Research Centre Seidu, Samuel; University of Leicester Diabetes Research Centre
Primary Subject Heading :	General practice / Family practice
Secondary Subject Heading:	Patient-centred medicine, Communication
Keywords:	PRIMARY CARE, GENERAL MEDICINE (see Internal Medicine), QUALITATIVE RESEARCH





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Priorities of patients with multimorbidity and of clinicians regarding treatment and health outcomes: a systematic mixed studies review

Harini Sathanapally¹, Manbinder Sidhu², Radia Fahami¹, Clare Gillies¹, Umesh Kadam¹, Melanie J Davies¹, Kamlesh Khunti¹ and Samuel Seidu¹

- 1. Diabetes research centre, College of Life Sciences, University of Leicester, UK
- 2. Health Services Management Centre, School of Social Policy, University of Birmingham, UK

Corresponding author: Dr Harini Sathanapally (hs333@student.le.ac.uk)

Word count excluding titles, abstract, article summary, tables, figures and references: 5060

Author contributions: HS: Design of research question and methodology, data searching, data extraction, data analysis and manuscript development; MS: Design of methodology, data extraction, data analysis and manuscript development; RF: Data searching and data extraction; CG: Data analysis and manuscript development; UK: Data analysis and manuscript development; MJD: Data analysis and manuscript development; KK: Design of research question and methodology, manuscript development; SS: Conception of the idea for this review, design of research question and methodology, data extraction, data analysis and manuscript development; SS: Conception of the idea for this review, design of research question and methodology, data extraction, data analysis and manuscript development. All authors have approved the final manuscript.

Funding: Harini Sathanapally is funded by the NIHR academic clinical fellowship award

Competing interests: None declared

Patient consent for publication: Not required

Data sharing statement: The majority of the data extracted and analysed as part of this review has been included in this article and associated appendices. Any further data can be acquired from the corresponding author by request.

ABSTRACT

Objectives: To identify studies that have investigated the health outcome and treatment priorities of patients with multimorbidity, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether a disparity exists between the priorities of patients with multimorbidity and clinicians.

Design: Systematic review

Data sources: MEDLINE, EMBASE, CINHAL and Cochrane databases from inception to May 2019 using a pre-defined search strategy, as well as reference lists containing any relevant articles, as per PRISMA and Cochrane guidelines.

Eligibility criteria: We included studies reporting health outcome and treatment priorities of adult patients with multimorbidity, defined as suffering from two or more chronic conditions, or of clinicians in the context of multimorbidity, or both. There was no restriction by study design, and studies using quantitative and/or qualitative methodologies were included.

Data synthesis: We used a narrative synthesis approach to synthesise the quantitative findings, and a meta-ethnography approach to synthesise the qualitative findings.

Results: Our search identified twenty four studies for inclusion, which comprised of twelve quantitative studies, ten qualitative studies and two mixed-methods studies. Twelve studies reported the priorities of both patients and clinicians, ten studies reported the priorities of patients and two studies reported the priorities of clinicians alone. Our findings have shown a mostly low level of agreement between the priorities of patients with multimorbidity and clinicians. We found that prioritisation by patients was mainly driven by their illness experiences, whilst clinicians focused on longer term risks. Preserving functional ability emerged as a key priority for patients from across our quantitative and qualitative analyses.

Conclusion: Recognising that there may be a disparity in prioritisation and understanding the reasons for why this might occur, can facilitate clinicians in accurately eliciting the priorities that are most important to their patients and delivering patient-centred care.

KEY WORDS: Patient-centred care, Shared decision-making, Multimorbidity

ARTICLE SUMMARY

Strengths and limitations

- This is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both clinicians treating and patients living with multimorbidity.
- We have included papers using both qualitative and quantitative methodologies and have been able to explore patterns and relationships in the findings, thus creating a comprehensive and well-rounded systematic review.
- Our findings facilitate clinicians in understanding both *how* and *why* the health outcome and treatment priorities of their patients with multimorbidity might differ from their own priorities.
- Meta-analysis of the quantitative studies was unfeasible as there was a large variation in the tools used to ascertain priorities, and we have attempted to mitigate this by using a welldescribed and transparent method of narrative synthesis.
- A number of our included quantitative studies did not use pre-validated tools to ascertain priorities, leading to a risk of measurement bias.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Multimorbidity, defined as the co-existence of two or more long-term conditions [1] is a global problem [2], which has become the norm across high-income countries [2, 3][4, 5] and becoming increasingly prevalent in middle and low-income countries [6][7][2]. Guidelines for the management of chronic diseases are often single disease-orientated, and can lead to confusion and complications when applied to patients with multimorbidity [8]. Patients with multimorbidity have an increased risk of adverse drug-related events as a result of high levels of polypharmacy and receiving uncoordinated care from multiple healthcare providers [9]. These patients have a poorer health-related quality of life [10], poorer functional status [11] and greater psychological distress [12]. As a result, understanding and finding better strategies to facilitate the management of patients with multimorbidity has been identified as a priority for health research [13].

Key to the effective management of multimorbidity is using patient-centred care and shared decision-making to set management goals that are acceptable to both the patient and the clinician [14]. Incorporating the priorities of patients in relation to treatments and health outcomes is integral to this process [15-17]. However, previous research has shown that whilst doctors recognise the importance of eliciting and incorporating the priorities of their patients with multimorbidity, they do not always engage with this process in real world settings, and find eliciting patients' priorities to be difficult [18] [19]. Previous research, completed in a single disease context, has shown that the treatment and health outcome priorities of patients and clinicians can differ [20-22], and some studies have highlighted a gap between what doctors' perceive to be the priorities of their patients, and the actual priorities of their patients [23-25].

This systematic review aims to identify studies that have investigated the health outcome and treatment priorities of patients with multimorbidity, clinicians, or both, in order to assess whether the priorities of the two groups are in alignment, or whether there is a disparity between the priorities of patients with multimorbidity and clinicians.

METHODS

Search strategy

This systematic review has been registered on PROSPERO (ID: CRD42018076076). A comprehensive search strategy (Appendix 1), was developed using guidance for best practice [26] and input from academic librarians at the University of Leicester. The search strategy was used to search MEDLINE, EMBASE, CINHAL and COCHRANE databases from inception to May 2019, as well as searching reference lists for any relevant articles based on PRISMA and Cochrane guidelines [26-28]. We undertook a scoping search using google scholar using our key terms (Patient*; Priorit*; Clinician, Physician, Doctor, General-practitioner, Family-practitioner; Multimorbidit*; Multi morbid*) to identify relevant grey literature. Citations were stored using Refworks. We have presented our process of article selection in Figure 1.

We included studies reporting the health outcome and treatment priorities of adult patients with multimorbidity [1] and/or clinicians, in relation to patients with multimorbidity. Studies which did not specify the definition of multimorbidity as "two or more chronic conditions" [1] in their inclusion criteria, but had a sample patients representative of being diagnosed with multimorbidity (i.e. with a minimum of two chronic conditions), were also included. There was no restriction by study design,

and we included studies using quantitative and/or qualitative methodologies. We excluded studies not published in English language, studies with participants aged under 18 years, and studies focusing on a single disease area.

Patient and Public Involvement

Patient and public involvement was not applicable in the design, conduct or reporting of this review.

Study selection

The titles and abstracts of all articles identified by the literature search were assessed independently and in duplicate by two reviewers (HS and RF). Studies that did not meet inclusion criteria were discarded. Full text of selected articles were retrieved and assessed to determine if they met the inclusion criteria, and those studies which met the inclusion criteria were included in the review. Any discrepancies regarding eligibility of an article were discussed, and consensus reached with MS and SS.

Methodological quality assessment and data extraction

Data was extracted using standardised data extraction forms by a single reviewer (HS), and these were checked independently for accuracy by a second reviewer (SS). The reported health outcome and treatment priorities of study participants were the key outcomes that were extracted.

Quality assessment was carried out in parallel with the data extraction process. For the quantitative studies, due to the heterogeneity of study design, we used the AXIS tool for assessment for the cross-sectional studies [29], the Newcastle-Ottawa scale for assessment of the longitudinal observational and cohort studies [30], and the Cochrane collaboration's risk of bias tool for assessment of randomised controlled trials [31]. For the qualitative studies, we used the CASP checklist for appraisal of qualitative research [32]. For the two mixed-methods studies, we used the AXIS tool [29] to assess the quantitative aspects of the study (both cross-sectional in study design), and the CASP checklist for qualitative research [32], to assess the qualitative aspects of these studies.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Data synthesis

We decided *a priori* not to carry out a meta-analysis due to the heterogeneity of the quantitative studies. Therefore, we have taken a narrative synthesis approach, described by Popay et al [33] to synthesise our quantitative findings. Our approach consists of three key steps:

1) *Development of a preliminary synthesis* in which study characteristics and descriptions are collated and findings presented in a summary table

2) Exploring relationships in the data between study characteristics and their findings, as well as between the reported findings across different studies with explanations considered where relationships were identified.

c) Assessing the robustness of the synthesis using quality assessment tools to guide conclusions and identify directions for clinical practice.

Qualitative studies were synthesised using a meta-ethnography approach [34, 35], which consisted of careful reading of the papers, extracting information regarding the context of the study and findings. *Key concepts* arising from each paper were also identified, with preservation of the terminology used by the authors where possible to ensure accurate representation of the findings of

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

the original studies. The key concepts across the papers were then *translated* using a table summarising the studies, their findings in relation to the key concepts and the *second order* interpretations of the authors, which enabled the exploration of any relationships and differences. The translations were then synthesised using a table containing the *first order* and *second order* interpretations for the key concepts across the studies, which then led to the development of further, *third order* interpretations by reviewers [34, 35].

From the results of our narrative synthesis of the quantitative studies and meta-ethnography of the qualitative studies, we considered how the findings of the two syntheses complement one another, particularly where our qualitative findings may provide possible explanations for our quantitative findings. The outcome of this process is described in the discussion section.

RESULTS

Overall study characteristics

Our search resulted in the identification of 24 studies for inclusion, which comprised of 12 quantitative studies, 10 qualitative studies and two mixed-methods studies. The characteristics of all of the included studies are described in Table 1. The included studies had all been conducted in high income developed countries, including Canada [36, 37], USA[38-44], Netherlands[45, 46], Australia[47, 48], UK[49-51], Germany [52-55] and Switzerland [56-58]. Sample sizes ranged from 15 to 1169 patients and 5 to 92 clinicians in the quantitative studies, and 15 to 146 patients and 4 to 19 clinicians in the qualitative studies.

Author and year of publication	Setting	Study type	Study aims	Target group and number of participants (n)	Outcomes measured			
QUANTITATIVE								
			Health outcome prior	ities				
Fried et al, 2011 [39]	USA- 3 senior centres and 1 assisted living facility	Quantitative: Cross-sectional study	To explore the use of a simple tool to elicit older persons' health outcome priorities	All volunteers included (n=357)	The prioritisation by participants of 4 universal health outcomes, namely: -keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms			
Fried et al , 2011, [40]	USA- recruited from participants in a larger study, where they had been recruited from age- aggregated community housing [59]	Quantitative: Cross-sectional survey	To determine the feasibility of using a simple tool to elicit the preferences of older persons based on their prioritization of universal outcomes	Patients aged 65 and over with a known diagnosis of hypertension or use of anti-hypertensive medications, and having a known risk of falls (n=81)	 > Rankings given by participants to 4 universal health outcomes in the outcome prioritisation tool: keeping alive - maintaining independence - reducing or eliminating pain -reducing or eliminating other symptoms > Feasibility of the use of outcome prioritisation tool 			

Mantelli et al, 2018[57]	Switzerland- General practitioners working in Switzerland who had previously taken part in case-vignette studies	Quantitative: cross-sectional survey	To determine whether, how and why GPs de- prescribe in frail oldest-old patients with multimorbidity and polypharmacy, and to identify factors that influenced their decision to de- prescribe	General Practitioners (n=157)	 Percentage of GPs willing to de-prescribe at least one medication in the case of frail older patients with CVD and compared to frail older patient without CVD Reasons for de-prescribing Importance ratings given to factors influencing decision to de-prescribe
Van Summeren et al, 2017 [46]	Netherlands- General practice centres	Quantitative: Cross-sectional and implementation study	To determine proposed and observed medication changes when using an outcome prioritisation tool during a medication review in older patients with multimorbidity and polypharmacy. A secondary aim was to explore the relationship between the prioritized health outcome of patients and the type of medication change, such as a stop, a dose adjustment, or a switch.	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications. (n=59) General practitioners (n=17)	 >Patients' priority rankings of the four health outcomes in the outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain >Medication changes proposed by the GP, and observed in the patient records following incorporation of the priority rankings given by patients, into a medication.
Van Summeren et al, 2016 [45]	Netherlands- General practice centres	Mixed-methods: Cross-sectional survey pilot and qualitative interviews to assess acceptability (semi-structured and in-depth)	To explore whether an outcome prioritization tool (OPT) is appropriate in the context of medication review in family practice, focusing on its acceptability and practicality	Patients aged 69 or over with two or more chronic diseases (one of which had to be cardiovascular disease) and daily use of five or more medications (n=60) General practitioners (n=13)	 >Patients' prioritisation of the four domains of the outcome prioritisation tool: -Maintaining independence -Remaining alive -Reducing other symptoms -Reducing pain > Family practitioners views on the acceptability and practicality of using the outcome prioritisation tool for medication review
			Problem-based prior		Product 1
Junius-Walker et al 2012 [52]	Germany- General practice centres	Quantitative: Randomised controlled trial	To investigate whether a structured priority-setting consultation reconciles the often-differing doctor-patient views on the importance of problems.	Patients aged 70 or over (n=317) General practitioners (n=40)	 Baseline importance rankings given by patients and clinicians to a list of problems generated from a geriatric assessment for each patient. Importance rankings given again after a structured consultation incorporating the baseline problem list and importance rankings and degree of reconciliation in

					doctor- patient agreement after the structured consultation
Junius-Walker et al, 2011[53]	Germany- General practice centres	Quantitative: Cross-sectional survey	To gain insight into setting individual priorities with older patients using a priority definition that was coherent to the patients' life and doctors' work context	Patients aged 70 or over and living at home (n=123) General practitioners (n=11)	Importance rankings given by patients and clinicians to a list of problems generated from a geriatric assessment for each patient.
Voigt et al, 2010 [54]	Germany- General practice centres	Quantitative: Cross-sectional survey	To ascertain health priorities of older patients and treatment priorities of their general practitioners (GP) on the basis of a geriatric assessment and to determine the agreement between these priorities.	Patients aged 70 or over and at least one contact with the general practitioner in the preceding 3 months (n= 35) General practitioners (n=9)	 Importance rankings given to problems generated from a geriatric assessment by patien and clinicians Degree of agreement betwee patients and clinicians on the above
			ondition-focused prio		
Moore et al, 2014 [36]	Canada- Databases of all practising nurse practitioners, family practitioners and geriatricians in Ontario	Quantitative: Cross-sectional survey	To quantify how family physicians, nurse practitioners and geriatricians prioritize syndromes, diseases and conditions when caring for seniors	Nurse practitioners (n=68) Family practitioners (n=84) Geriatricians (n=27)	Frequency and importance rankings given by family practitioners, nurse practitioners and geriatricians to 41 health issues known to arise in elderly patients
Zulman et al, 2010 [44]	USA- Scheduled primary care visit for patients at 9 veteran affairs facilities	Quantitative: Prospective cohort study	To understand patterns of patient-provider concordance in the prioritization of health conditions in patients with multimorbidity	Patients with diabetes and hypertension who had their primary diabetes care provider enrolled in the study (n = 1169) Primary care providers i.e. physicians, physician assistants or nurse practitioners (n= 92)	-Patient rankings given in term of their most important health concerns and providers rankings in terms of conditions most likely to affect each patient's outcomes -Concordance between the importance ratings of patient- provider "pairs"
Herzig et al, 2019 [56]	Switzerland- Primary data was from "Multimorbidity in Family medicine" study [60]. Patients enrolled by General practitioners during scheduled consultations.	Quantitative: Cross-sectional survey	To describe FPs' medical priority ranking of conditions relative to their prevalence in patients with multimorbidity	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International classification of primary care 2 (n=888) General Practitioners (n=100)	Importance rankings given by family practitioners to the list of chronic conditions that each patient had on the day of their inclusion in the study
Déruaz-Luyet et al, 2018 [58]	Switzerland- Primary data was from "Multimorbidity in Family	Quantitative: Cross-sectional survey	To evaluate whether GPs could identify the condition that their patients	Patients suffering from at least 3 of 75 chronic conditions on a pre- defined list (based on the International	Whether there is agreement between what patients considered to be their most important health condition and what GPs thought patients

Page 9 of 45

	medicine" study [60]. Patients enrolled by General practitioners during scheduled consultations.		with multimorbidity considered most important.	classification of primary care 2, and receiving follow-up from their GP for at least the preceding 6 months (n= 572 for main analysis, 585 for sensitivity analysis) General Practitioners (n=100)	considered to be their most important health condition
		Т	reatment priorities		
Caughey et al, 2017 [47]	Australia- Multi- disciplinary ambulatory consulting service clinics at tertiary teaching hospitals	Mixed-methods: Structured quantitative interviews with patients then semi-structured qualitative interviews with patients and clinicians	To investigate how older patients with multimorbidity balance the benefits and harms associated with medication for prevention of CVD, and in the presence of competing health outcomes. To investigate the factors that clinicians consider when making treatment decisions for older patients with multimochidity	Patients aged 65 or older with 2 or more chronic conditions (n=15) Clinicians (n=5)	 Patient willingness to take a medication when presented with different scenarios with variable degree of benefit, impact on daily living, adverse outcomes and impact on other comorbid conditions Patient-reported data during semi-structured interviews where they were asked about their treatment preferences, medication effects and shared decision making Clinician reported data during semi-structured interviews on treatment decisions, patient preferences and polypharmacy
		QU	multimorbidity.		
Kuluski et a, 2013 [37]	Canada- A Family Health Team in Ontario	Qualitative: Semi-structured interviews	To examine patient goals of care from the perspectives of older persons with multi- morbidities, their family physicians and informal caregivers (i.e., family member or friend who provides ongoing support) and then examine the extent of alignment between these three perspectives	Patients aged 65 or older with a diagnosis of at least two chronic health conditions (n=28) Informal Caregivers of included patients (n=28) Family physicians (n=4)	 >Patient, caregiver and physician reported data on goals of care for the patients >Degree of alignment of goals of care across patient, caregive and physician "triads"
Schoenberg et al, 2009 [38]	USA- Senior centres, Low income senior housing complexes, churches and a civic meeting hall	Qualitative: In- depth interviews	To understand how vulnerable older adults with multimorbidity prioritize and manage their chronic conditions	Patients aged 55 or older with a diagnosis of at least two chronic illnesses, from low- income backgrounds (n= 41)	Patient-reported data from in- depth interviews, regarding their medical history, self-care procedures, patient prioritisation by means of health-related areas of worry and health-related "expenditures" in terms of money, time and need for reliance on others.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Fried et al, 2008 [41]	USA- Senior centres, Doctors' practices and a congregate housing site	Qualitative: Focus groups	To examine the ways in which older persons with multiple conditions think about potentially competing outcomes, in order to gain insight into how processes to elicit values regarding these outcomes can be grounded in the patient's perspective	Patients aged 65 or older and were taking 5 or more medications (participants also had a minimum of 3 chronic conditions)	Patient-reported data regarding their perceptions of the interactions between their different illnesses and treatment regimens, goals of treatment and decisions regarding treatment
Naik et al, 2016 [42]	USA- Qualitative data from the VETCARES study [61] , in which participants recruited from the VA tumour registry	Qualitative: Open-ended questions as part of mixed methods interviews which also included structured questions	To identify a taxonomy of health-related values that frame goals of care of older adults with multimorbidity who recently faced cancer diagnosis and treatment	Veterans with a diagnosis of head and neck, gastric, oesophageal, or colorectal cancer, and diagnosis fell one month prior to the study's opening eligibility window (6 months) (n=146)	Patient-reported data regarding their priorities or concerns regarding their future healthcare decisions
Elliott et al, 2007 [43]	USA- Harvard Pilgrim Health Centre, a HMO (health maintenance organisation) in New England	Qualitative: Semi-structured interviews	To explore how older adults with multiple illnesses make choices about medicines	Patients taking more than three medicines with purposive sampling to reflect symptomatic comorbidities and asymptomatic comorbidities and mental health issues (participants had a minimum of 3 comorbidities) (n=20)	Patient-reported data regarding beliefs about medicines, medicine-taking behaviour, historical vs potential choices between different medicines, and factors influencing these choices
Turner et al, 2016 [48]	Australia- Long term care facilities in South Australia	Qualitative: Nominal group technique	To use nominal group technique to generate then rank factors that general medical practitioners, nurses, pharmacists and residents or their representatives perceive are most important when deciding whether or not to de- prescribe medication	Residents/representatives of residents (n=11) General Practitioners (n=19) Nurses (n=12) Pharmacists (n=14)	-Generated factors important for de-prescribing according to residents/resident representatives, general practitioners, nurses and pharmacists -Priority rankings given by groups containing representatives from all of the above, to the list of priorities generated previously.
Lindsay, 2009 [49]	UK- Participants recruited from CHD registries in Greater Manchester as part of a larger RCT[62]	Qualitative: Focus groups and two interviews	To use the concepts of "chronic illness trajectory" and "biographical disruption" to examine how patients self- manage multiple chronic conditions and especially how they prioritize their conditions	Participants from the parent study who had more than one chronic condition (i.e. at least two) (n=53)	Patient-reported data regarding how they prioritised their multiple conditions, what strategies they used to cope with their conditions and barriers in being able to manage their illnesses

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2 3	
4 5	
6 7	
7 8	
9 10	
10 11	
12 13	
14	
14 15 16 17	
17 10	
18 19	
20 21	
22	
19 20 21 22 23 24 25	
25 26	
26 27	
28 29	
30 31	
32 33	
34 35	
35 36	
36 37 38	
39	
40 41	
42 43	
44	
45 46	
47 48	
49	
50 51	
52 53	
54	
55 56	
57	
58 59	
60	

Cheraghi-Sohi	UK- secondary	Qualitative: In-	To explore how	Participants from original	Patient-reported data
et al, 2013 [50]	analysis of	depth interviews	and why people	studies who had two or	pertaining to prioritisation of
	qualitative data	depth interviews	with	more long term	their long term conditions
	from four other		multimorbidity	conditions, and had given	their long term conditions
	studies [63-66]		prioritise some		
	studies [63-66]			data regarding	
			long-term	prioritisation (n=41)	
			conditions over others and what		
			the potential		
			implications may		
			be for self-		
			management		
			activity, and in		
			turn, suggest how such information		
			, ,		
			may help clinicians		
			negotiate the		
			management of		
			multimorbidity patients		
Morris et al [51]	UK- General	Qualitative:	To examine what	Patients with more than	Patient-reported data on
worns et al [51]	Practices in	Semi-structured	influences self-	one chronic condition and	management strategies and
	North-West		management	at least one of COPD, IBS	experiences with primary
		interviews			
	England		priorities for individuals with	or Diabetes (n=21)	health care, and data from
					follow-up interviews on any
			multiple long-		changes in their illness
			term conditions		management.
			and how this		
			changes over		
Hansen et al.	Cormonu	Qualitative:	time To identify	Patients who had 3 or	Data from separate focus
2015 [55]	Germany- Participants		reasons for	more chronic conditions	groups for patients and
2013 [33]	recruited from	Focus groups	disagreement	from a list of 29	clinicians in which any
	the "Multicare		regarding	conditions (n=21)	communication problems and
	cohort study"		illnesses between		reasons for disagreement
	[67]		patients and their	General Practitioners of	between patients and clinicians
	[07]		GPs	the recruited patients	were explored
			GF3	-	were explored
				(n=15)	

Table 1 Characteristics of all of the included studies in order of reference

Summary of quality assessment

The outcome of quality assessment based on each of the afore-mentioned tools is summarised in Appendix 2. The majority of the quantitative studies were cross-sectional in design [36, 39, 40, 45, 46, 53, 54, 56-58] [47], including the quantitative elements of the two mixed-methods studies. The other studies included one cohort study [44] and one randomised controlled trial [52]. The cross-sectional studies were of moderate quality, with a number of studies having small sample sizes [40, 45, 46, 54]. The sample sizes of clinicians in most of the cross-sectional studies were particularly small, ranging from of 9 to 157 clinicians [45, 46, 54, 57], which impacts upon the generalisability and application of their findings. We noted that a number of the studies did not use pre-validated questions and tools to ascertain priorities [36, 54, 56-58], leading to a degree of subjectivity in the way in which priorities were ascertained, and the risk of measurement bias which again impacts on the generalisability of their findings.

The majority of the qualitative studies, including the qualitative aspects of the two mixed-methods studies, used interviews for data collection (n=8). Two studies used focus groups [41, 55], one study used a combination of focus groups and interviews [49] and one study used the nominal group technique [48]. The qualitative studies were of good quality, with appropriate use of qualitative methodology and transparent descriptions of the data analysis processes. Three studies only gave a limited description of their analytic process [47-49], with two of these studies [47, 48] and one mixed-methods study [45], not presenting any quotes.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

QUANTITATIVE SYNTHESIS

Within our quantitative synthesis, we found that the studies focused either on the overall state of the patients' health, the problems posed by different chronic disease groups, or the patients' treatment regimens. Some of the quantitative studies elicited patient and/or clinician priorities as part of an intervention [52] [46]. Therefore, in order to reduce the risk of bias from the interventions, we included only the pre-intervention results from these studies.

Health outcome priorities

Four studies reported patient priorities of overall health outcomes using a "health outcome prioritisation tool" [39, 40, 45], which is a visual analogue scale requiring the following health outcomes to be given a score out of 100: "Maintaining independence"; "Staying alive"; "Pain relief"; "Symptom relief". Maintaining independence was the outcome that had the highest importance after a pooling of the *most important* rankings from the four studies, followed by "Staying alive" (Table 2). For clinicians' priorities, one study reported that 98% of a sample of 157 general practitioners identified the "quality of life for the patient", and 96% identified the "life expectancy of the patient", as the most important factors in influencing their clinical decision-making to deprescribe for elderly, patients with multimorbidity [57].

Study	Health outcome prioritisation as a tool for decision making among older persons with multiple chronic conditions[39]	Health outcome prioritisation to elicit preferences of older persons with multiple health conditions[40]	Outcome prioritisation tool for medication review in older patients with multimorbidity: A pilot study in general practice[46]	Eliciting Preferences of multi-morbid Elderly Adults in Family Practice Using an Outcome Prioritisation Tool[45]	Aggregate ranking as most important (%)
Maintaining independence	270 (75.6%)	34 (42.0%)	7 (36.8%)	19 (35.8%)	330 (64.7%)
Staying alive	40 (11.2%)	22 (27.2%)	6 (31.6%)	18 (34.0%)	86 (16.9%)
Pain relief	26 (7.3%)	17 (21.0%)	1 (5.3 %)	6 (11.3%)	50 (9.8%)
Symptom relief	21 (5.9%)	8 (9.8%)	5 (26.3%)	10 (18.9%)	44 (8.6%)
Total number of participants	357	81	19ª	53	510

Table 2-Summary of most important rankings for studies using the Outcome Prioritisation Tool a= although there were 59 patients included in this study [46] priorities were only reported for 19 patients

Priorities based on health problems

Three studies reported patient and general practitioners' priorities based on various health *problems*, following a geriatric assessment [52-54]. These problems were then categorised into domains, and the importance rankings for each of the domains were presented. Problems in the domains of "Social" "Mood" and "Function" recurrently featured in the top four of the most highly

ranked priorities by patients across all three studies. In terms of the importance rankings by clinicians, problems in the domains of "Mood" and "Function" also featured in the top four importance rankings across all three studies, whilst "Social" problems were rated highly in one study [53] and problems in the domain of "Medication" were ranked highly in the other two studies [52, 54]. Interestingly, the authors in one study[53] found that patients feeling "Emotionally affected" was the strongest predictor for a problem being rated as important (OR 11.1 Cl 6.73 to 18.33), whereas "Poor prognosis" was the strongest predictor for clinicians (OR 6.39 Cl 4.61 TO 8.87)

Condition-focused priorities

Two studies reported patient priorities in relation to specific conditions or groups of conditions [44, 58], in the context of multimorbidity. Zulman et al. reported that "Diabetes/glycaemic control" was most frequently ranked as "most important", with "Hypertension" coming second [44]. However, the sample of patients included in this study were all diabetic, hypertensive patients. Deruaz-luyet et al. found that musculoskeletal conditions including back pain, were most frequently reported to be the most important conditions for their patients, however endocrine/metabolic conditions (including obesity) were second and cardiovascular conditions were third [58].

Three studies reported condition-focused priorities of clinicians in the context of multimorbidity. Herzig et al. reported the priorities of general practitioners alone [56], and found that "multiple sclerosis", "mental retardation", and "bronchus lung neoplasm" were all highly prioritised by their participants. Zulman et al reported the priorities of "primary care providers" who consisted of physicians, physician assistants or nurse practitioners [44], and found that diabetes was the top priority for primary care providers, with hypertension coming second, in alignment with their previously described patient priorities [44]. Moore et al. examined the priorities of different types of clinicians, including family physicians, geriatricians and nurse practitioners [36], and as with Zulman et al., found that diabetes was the top priority for family physicians and also nurse practitioners, whereas dementia was the top priority for geriatricians [36]. In addition, heart failure, atrial fibrillation and hypertension formed three of the top five conditions considered to be most important by the family practitioners in the study [36]. Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Treatment priorities

As part of a study to examine the influence of the risks and benefits of medications on treatment preferences of patients, Caughey et al. also examined the priorities of patients in the face of "competing outcomes" [47]. They found that 80% of participants would not be willing to take medication to reduce "joint pain", if the medication increased their risk of a myocardial infarction by 10%. However, this was deduced from a sample of only 15 patients [47].

Agreement between patients and clinicians

Five of the included studies investigated the level of agreement in priority rankings between patients and their clinicians [44, 52-54, 58]. Three studies reported a low level of agreement between patient and clinicians' priority rankings [52-54]. Two of these studies used a Cohen's Kappa calculation to estimate the degree of agreement between the importance ratings of patients and clinicians, and the values of which were 0.18 and 0.11 respectively, indicating "slight agreement" after allowing for chance [53][54]. One study used a weighted kappa calculation to measure the degree of agreement, which, at a pre-intervention point in this study, was low at 6% [52].

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Two studies reported that there was a "high" level of agreement [44, 58]. Deruaz-Luyet et al. found that in the case of 54.9% (n=314) of their patients, the condition that their GP had considered to be either the first or second most important, was in the same disease-group as the condition that the patient considered to be most important [58].

Zulman et al. reported that 60% of "patient-provider pairs" had a "high concordance", meaning that the same three conditions had been rated as top three priorities by both parties, or that two of the same conditions had been rated in the top three priorities by both parties [44]. In this case, given that the sample of patients were all diabetic and hypertensive could have led to a narrowing of the range of chronic diseases across the sample, which in turn could have led to an increased likelihood of agreement. However, the participant characteristics reported by the authors state that the patients had a mean of eight health conditions (SD 3.00), suggesting that the patients did not have a narrow range of chronic diseases. Furthermore, the questions posed to patients and providers were phrased differently, in that providers were asked to choose the top three most important medical concerns "that are likely to affect health outcomes for this patient", whereas patients were asked to choose their top three most important health concerns. The authors acknowledge this in their paper, and justify this difference as being due to their aim of exploring the concordance in priorities about the "most important problems facing the patient", rather which problems "providers thought the patient would have prioritised", which, they argue, is a different concept to their aim [44].

QUALITATIVE SYNTHESIS

Whilst our quantitative synthesis allowed us to investigate *which* health outcomes, diseases or treatments were important to patients with multimorbidity and their clinicians, our qualitative analysis enabled us to explore *how* prioritisation occurs. Below, we describe the key findings from our qualitative analysis.

Mechanisms of prioritisation

In the qualitative studies that approached prioritisation from a disease-specific perspective, patients were able to identify an illness as their main priority [49, 50]. For many patients, prioritisation appeared to be driven by their experience of the illness, which formed part of its "meaning as consequence" [50] as phrased by Cheraghi-Sohi et al. The 'consequences' of an illness consisted of the *impact* that the illness was having on the patients' everyday lives, which included functional limitation and the symptomatic burden of the illness, including its "unpredictability" (Table 3) [49]. For others, prioritisation appeared to be driven by their perception of the risk now and in the future with respect to functional deterioration and mortality.

In other studies, patients framed their priorities between *quality of life vs length of life* (Table 3) [42]. Patients in the study by Naik et al who were adults with multimorbidity and suffering from cancer, prioritised "quality of life" more highly than "length of life" [42]. This was also reflected in the findings of Fried et al., who found that when considering medication with competing outcomes in terms of extending life compared to quality of life, participants appeared to prioritise preserving quality of life [41].

Van Summeren et al. found that prioritisation was "difficult" when there was no "specific need" for a treatment decision to be made [45]. This concept of a difference in prioritisation based on hypothetical, or experiential levels, was also shared in the findings of Elliott et al [43] and Fried et al [41].

Where clinicians' perspectives were explored alongside patients, clinicians reported that exploring patients' priorities was "extremely important" when managing "competing interests" [47] and beneficial in providing patient-centred care [45]. Some clinicians in the mixed-methods study carried out by Van Summeren et al. reported that exploring their patients' priorities allowed them to have a "deeper understanding" of the patient, helped with making patient-centred treatment decisions and advance care planning (Table 3) [45]. However, other clinicians in the same study found exploring patient priorities to be difficult due its "novelty" and the fact that it represented a change to their usual consultations [45].

	Concept	Examples from included studies
Mechanisms of	Unpredictability of symptoms	"My final issue is diverticulitis. In many ways that is the thing that makes the most impact on my life because of the unreliability of it. You make plans to do something to go somewhere and at the last minute you don't dare leave the house because you don't leave the loo. In itself it's not an important medical issue. It's the social problem more than anything else." – Lindsay et al [49]
prioritisation	Quality of life vs length of life	"If you don't feel good, you can't take care of yourself and you have to depend on somebody else, what's the good of living another 10 years?"- Fried et al [41]
	Facilitating clinicians' decision making	"In future, I'll be happier to be more decisive in keeping an eye on what we do and do not do as regards this patient." Van Summeren et al [45]

Table 3- Examples from included studies for key concepts relating to mechanisms of prioritisation

Factors influencing prioritisation:

Our analysis revealed that there were a number of factors that appeared to influence how both patients and clinicians arrived at their priorities, and which priorities they chose.

i. Functional ability

Preserving functional ability as a priority for patients was a dominant concept across the majority of the qualitative studies [37, 38, 49, 51] [42][47][41]. Preserving independence emerged as the most significant reason for prioritising functional ability for patients, and maintaining the ability to engage in activities of daily living, mobility, maintaining cognitive ability and wanting to avoid being a "burden" or lacking social support to help them cope with functional deterioration (Table 4) [38, 49, 50].

Conditions which caused limitation to patients' ability to self-manage their health conditions, led to a "tension" between the patients' expectations of themselves and what they were physically able to do [51]. Lifestyle management, particularly reduced ability to exercise and the adverse impact of this on weight, was cited as part of patients' ability to self-manage [49].

Maintaining patients' functional ability was reported as a priority by some clinicians [37] [47]. Clinicians considered the wider implications of the patients' functional deterioration, particularly cognitive deterioration, and spoke of wanting to reduce the risk of "burnout" for the patients' family members/caregivers [37].

ii. Mortality

Reducing the risk of mortality emerged as a recurrent priority for clinicians [47, 55]. Caughey et al found that clinicians prioritised mortality in younger (less than 65 years) patients with

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

multimorbidity rather than older patients with multimorbidity, as they felt they could be more "aggressive" in their treatment [47]. Reducing the risk of mortality also emerged as a priority for patients across a number of studies [37, 38, 43, 50, 51] [42]. Some patients found the asymptomatic nature of hypertension to be concerning; hence, the consequences of hypertension could be unpredictable, compared to some other chronic illnesses where symptoms can give warning of onset and severity (Table 4) [38, 43].

iii. Symptom control

The symptomatic burden of a condition contributed to its "meaning as consequence" for patients [50]. Symptoms were cited as being a cause of functional limitation [38, 49], and in some cases their "unpredictability" could cause significant disruption to patients' daily lives [49]. Symptom control was reported to be a priority by some clinicians [37][47]. However, clinicians in one study considered symptom control to be less important, particularly when there was no risk of mortality [55]. In these cases, clinicians seemed to be aware that patients may still be prioritising symptom control highly, even if the clinicians did not (Table 4).

iv. Treatment burden

Factors related to the treatment burden of an illness appeared to adversely impact prioritisation for patients, leading to *de-prioritisation* of certain medications and treatments [38, 41, 43, 48]. Elliot et al. reported that cost and distressing side effects, were factors which led patients to stop taking a medication [43]. Similarly, Fried et al. found that patients reported unpleasant side effects to be a "competing outcome", which negatively influenced their decision regarding continuing a medication [41]. However, difficulty with achieving control over the management of an illness, as well as requirement for high levels of engagement with self-management, emerged as factors that contributed to the prioritisation of an illness by some patients (Table 4) [49].

	Concept	Examples from included studies
	Functional ability	"I mean, because I have to be mobile, I am living on my own, no one is going to take care of me, I have got to look after myself" Cheraghi-Sohi et al [50]
	Mortality	"Well I really do worry the most about the high blood pressure. 'Cause see you know you got arthritis and you can tell when it's coming on. But you can't hardly tell about high blood pressure. It can just hit you like that [snaps fingers]"" Lindsay et al [49]
Factors influencing	Symptom control	"I would not want to live with pain. I won't allow that to happen"- Naik et al [42]
prioritisation	Disparity in prioritisation of symptom control	" I talk [to her] for a quarter of an hour about this and that every time after which she replies, "but my vertigo," and I answer every time, well, unfortunately there is nothing I can do about it, we have already tried and done everything. But it is probably the first diagnosis she will mention: "What are you suffering from?". "Vertigo". For me, this would be somewhere all the way at the bottom." – Hansen et al [55]
	Treatment burden	"It's the knee that's the most concerning because everything else is controlled by tablets. The knee is a problem because if I have one little slip I'm in plaster again for 6 weeks." Lindsay et al [49]

Table 4- Examples from included studies for key concepts relating to factors influencing prioritisation

DISCUSSION

Prioritisation as a concept is broad, context-dependent and difficult to confine into a single definitive definition. As a result, determining what can be interpreted as a health outcome or treatment priority as part of our study selection in this review, was inherently difficult. We excluded some studies that investigated the preferences of patients with multimorbidity or clinicians, in contexts that we judged to be different to the aim of this review. These included patient preferences for healthcare delivery [68][69], levels of engagement with self-management practices [70][71] and clinicians' experiences of the management of patients with multimorbidity [18][72][73]. Whilst these studies represent very important areas of research, they were not within the scope of our aim in this review i.e. identifying studies that report the health outcome and treatment priorities of patients with multimorbidity or those of clinicians in relation to patients with multimorbidity. A discussion from our synthesis of findings of the included studies in this review is presented below.

Health outcome and treatment priorities

From our findings, patients' prioritisation appeared to be driven by weighing up the empirical compared to the hypothetical impact of a disease, whereby the empirical impact of a disease, which included its impact on function, symptomatic and treatment burden, was the most dominant driver of prioritisation. This is consistent with the findings of previous literature showing patients with rheumatoid arthritis who had reported experiencing higher levels of pain, were more likely to report pain as a priority [74].

Amongst empirical factors, preserving functionality emerged as most highly prioritised by patients amongst the quantitative studies that took a health outcome approach[39, 40, 46], whilst "function" was a domain that was prioritised highly by both patients and clinicians in the studies where prioritisation of various health *problems* were investigated [52-54]. From our qualitative findings, functional ability formed a key part of the preservation of various aspects of the patients' independence and their quality of life, as well as their ability to self-manage. Existing evidence shows that the prevalence of multimorbidity is highest in those aged over 65 years [75], and the population for the majority of the included studies were older adults with multimorbidity. This could provide an explanation for why preserving functionality was highly prioritised.

Prioritisation was not a static process and was subject to change, based on factors such as illness exacerbations, life events, whether there was a need for a treatment decision to be made, and whether the priority related to retrospective or prospective healthcare [49, 51]. When considering the hypothetical impact of an illness, perceptions of future risk came into play, and in particular, the risk of mortality [43]. This was particularly evident in relation to cardiovascular disease, where patients appeared to perceive the risk of mortality to be high [38].

Risk of mortality was a dominant driver for prioritisation amongst clinicians. This was shown in our quantitative synthesis, where amongst studies assessing disease-specific priorities, conditions with a higher risk of mortality, such as cardiovascular disease and diabetes, recurrently emerged as being highly prioritised by clinicians [36, 44, 56] and differentiated by age [47]. This age-based consideration could explain why clinicians prioritised "quality of life for the patient" as higher, albeit marginally, than "life expectancy of the patient" in their clinical decision-making for de-prescribing for elderly, patients with multimorbidity [57].

Smith et al previously developed a "Core Outcome Set" [76] in which a Delphi consensus panel formed of 26 international health experts, identified and prioritised a set of outcomes tailored for

application to research studies targeting patients with multimorbidity. Mortality, mental health outcomes and quality of life featured most highly in their list of prioritised outcomes, which also emerged in this review. However, we found that relatively few studies reported the prioritisation of mental health outcomes, with the exception of the studies that took a *problem-based* approach to prioritisation, where problems with regard to "Mood" were prioritised highly by both patients and clinicians [52-54].

Our findings show a varying degree of agreement between the priorities of patients with multimorbidity and clinicians. Previous studies carried out in the context of diabetes[77], and psoriasis[78] have found a low level of agreement on health outcome and treatment priorities between patients and clinicians, which correlates with the findings of some studies included in this review [52-54], but not others [44]. The nature of the patients' illnesses emerged as a factor for concordance or discordance of priorities with their clinicians [37]. Patients and clinicians were in agreement in situations where patients were currently experiencing an exacerbation of a particular condition, or had a "stable" state of health. However, in patients who suffered from illnesses with more complex courses, discordance of priorities tended to occur between patients and clinicians [37].

In recent times, the traditional *paternalistic* model for the doctor-patient relationship has given way to an *egalitarian* model [79], where doctors and patients each play an equitable role in a shared-decision making process, which places the patient at its core and thus achieving greater *patient-centred* care [80][79]. A shared agreement between patients and doctors on treatment priorities have been highlighted to play an important part in achieving patient-centred care and creating a *therapeutic alliance*, the benefits of which can include improved treatment adherence [79, 80]. Indeed, Jowsey et al found that agreement between patients and clinicians in the formulation of care plans promoted adherence to these plans, whereas a lack of agreement led to disengagement with care plans by patients [81].

Strengths and limitations

To our knowledge, this is the first systematic review to assimilate and compare the findings of existing literature on the health outcome and treatment priorities of both patients and clinicians for patients living with multi-morbidities. In this review, we have been able to add a novel line of argument to the ongoing discussion on this subject. By incorporating papers using both qualitative and quantitative methodologies, we have been able to explore patterns and relationships in the findings of a wide range of studies, thus creating a comprehensive and well-rounded systematic review.

There are noteworthy limitations. We did not include the term "comorbidity", in our search terms, and whilst "comorbidity" is distinctive from multimorbidity, there is also some conceptual overlap between the two terms. We felt that including "comorbidity" in our search strategy would identify studies focusing on a specific condition rather than multimorbidity.

A number of the quantitative studies did not use pre-validated tools to ascertain priorities [36, 54, 56-58], leading to a risk of measurement bias, which could limit the generalisability of findings in this review. All of the included studies were conducted in developed, western countries, which limits the global generalisability of our findings, as the priorities of patients with multimorbidity and of clinicians in developing and/or eastern countries may differ to the findings of this review.

We also detected a large variation in the tools used to ascertain priorities, which meant that carrying out a meta-analysis to synthesise the findings of the quantitative studies was not possible. Yet, we

have tried to mitigate the lack of meta-analysis by using a well-described and well-established method of narrative synthesis [33], in order to maintain rigour and transparency.

Another limitation is that in our inclusion criteria we chose to also include studies which did not explicitly specify a definition of multimorbidity as "two or more chronic conditions" in their inclusion criteria but had a sample of participants that were reflective of multimorbidity (i.e. with a minimum of two chronic conditions which could be identified from participant demographic data). We chose to do this as in the absence of a universally accepted and uniform definition of multimorbidity, we sought to base our judgement on the inclusivity of each paper on its value in answering our review question. This, along with the previously discussed difficulty in defining prioritisation, may have introduced a degree of subjective interpretation in the process of study selection, despite our attempt to mitigate this by incorporating independent review of the results of our literature searching by two reviewers in duplicate.

Recommendations for the future

We recommend that future guidelines developed for clinicians in the management of multimorbidity highlight the need to elicit and consider both short term and long term priorities for their patients', as our review has shown that patients' priorities for their current illness experiences and future risks posed by illnesses, may differ. In accordance with current NICE guidance, we also reiterate the need to review these priorities continually, and particularly when exacerbations, changes to illness course or treatment regimens, or other wider socially-contextualised changes occur in their patients' lives.

There was a large variation in how priorities were ascertained, and in the tools used to ascertain priorities. The relative lack of standardised and validated tools for use to ascertain patient priorities in everyday clinical practice has also been described in previous literature [82]. We highlight a need for the development of a standardised and validated tool that is acceptable to both patients and clinicians, and can be used to ascertain patient-priorities in the multiple dimensions described in this review. Such a tool would a valuable aid to treatment decision-making, advance care planning and achieving patient-centeredness for patients living with multimorbidity.

Conclusion

The findings from this review show the priorities of patients and clinicians can have varying degrees of concordance, being mostly low [52, 54], in alignment with previous findings in single disease contexts [77, 78]. We have found that the mechanisms of prioritisation can also differ between our two groups, in that patients are driven by illness experiences, whereas clinicians may be focused on managing longer term risks. Understanding these differences can help clinicians to better recognise situations where the patients' priorities may be different to theirs and elicit the most important priorities for their patients.

REFERENCES

1 van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature, *The European Journal of General Practice* 1996;2:65-70.

2 Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study, *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences* 2015;71:205-14.

3 Rijken M, Struckmann V, Dyakova M, et al. ICARE4EU: Improving care for people with multiple chronic conditions in Europe. 2013.

4 Roberts KC, Rao DP, Bennett TL, et al. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada, *Health Promot Chronic Dis Prev Can* 2015;35:87-94.

5 Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. 2014;89:1336-49.

6 Arokiasamy P, Uttamacharya U, Jain K, et al. The impact of multimorbidity on adult physical and mental health in low-and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? *BMC medicine* 2015;13:178.

7 Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global ageing: a crosssectional study of 28 countries using the World Health Surveys, *BMC Public Health* 2015;15:776.

8 Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions, *N Engl J Med* 2004;351:2870-4.

9 Calderon-Larranaga A, Poblador-Plou B, Gonzalez-Rubio F, et al. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? *Br J Gen Pract* 2012;62:e821-6.

10 Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care, *Quality of Life Research* 2006;15:83-91.

11 Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature, *Ageing research reviews* 2011;10:430-9.

12 Fortin M, Bravo G, Hudon C, et al. Psychological distress and multimorbidity in primary care, *Ann Fam Med* 2006;4:417-22.

13 Academy of Medical Sciences. Multimorbidity: a priority for global health research, 2018.

14 Muth C, van den Akker M, Blom JW, et al. The Ariadne principles: how to handle multimorbidity in primary care consultations. *BMC Medicine* 2014;12:223.

15 Azad NA, Mielniczuk L. A call for collaboration: improving cardiogeriatric care, *Can J Cardiol* 2016;32:1041-4.

16 Roland M, Paddison C. Better management of patients with multimorbidity, *BMJ: British Medical Journal (Online)* 2013;346.

17 Bierman AS, Tinetti ME. Precision medicine to precision care: managing multimorbidity, *Lancet* 2016;388:2721-3.

18 Mc Namara KP, Breken BD, Alzubaidi HT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia, *Age & Ageing* 2017;46:291-9.

19 Sinnott C, Mc Hugh S, Browne J, et al. GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research, *BMJ Open* 2013;3:e003610,2013-003610.

20 Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis, *BMJ* 1997;314:1580-3.

21 Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? *Qual Health Care* 2001;10 Suppl 1:i39-43.

22 Thomson S, Doody G. Parallel paths? Patient and doctor priorities in psychiatric outpatient consultations, *Journal of Mental Health* 2010;19:461-9.

23 Lee CN, Hultman CS, Sepucha K. Do patients and providers agree about the most important facts and goals for breast reconstruction decisions? *Ann Plast Surg* 2010;64:563-6.

24 Volandes AE, Paasche-Orlow MK, Barry MJ, et al. Video decision support tool for advance care planning in dementia: randomised controlled trial, *BMJ* 2009;338:b2159.

25 Pager CK, McCluskey PJ. Surgeons' perceptions of their patients' priorities, *Journal of Cataract & Refractive Surgery* 2004;30:591-7.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

26 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons 2011.

27 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement, *Systematic reviews* 2015;4:1.

28 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement, *Ann Intern Med* 2009;151:264-9.

29 Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS), *BMJ Open* 2016;6:e011458,2016-011458.

30 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, *Eur J Epidemiol* 2010;25:603-5.

31 Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, *BMJ* 2011;343:d5928.

32 Critical Appraisal Skills Programme UK. CASP qualitative research checklist. *CASP checklists* 13/03/2017.

33 Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews, A product from the ESRC methods programme Version 2006;1:b92.

34 Noblit GW, Hare RD. Meta-ethnography: Synthesizing qualitative studies: sage 1988.

 35 Britten N, Campbell R, Pope C, et al. Using meta ethnography to synthesise qualitative research: a worked example, *J Health Serv Res Policy* 2002;7:209-15.

36 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, family physicians and geriatricians when caring for the elderly. *Journal of interprofessional care* 2015;29:401-3.

37 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between older persons with multi-morbidities, their family physicians and informal caregivers. *BMC Family Practice* 2013;14:133.

38 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and accommodating multiple morbidities by vulnerable older adults, *J Health Care Poor Underserved* 2009;20:134-51.

39 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions, *Arch Intern Med* 2011;171:1856-8.

40 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with multiple health conditions, *Patient Educ Couns* 2011;83:278-82.

41 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, *J Am Geriatr Soc* 2008;56:1839-44.

42 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing Life-Threatening Illness. *J Am Geriatr Soc* 2016;64:625-31.

43 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness, *Journal of General Internal Medicine* 2007;22:805-10.

44 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *Journal of General Internal Medicine* 2010;25:408-14.

45 Summeren JJ, Haaijer-Ruskamp FM, Schuling J. Eliciting preferences of multimorbid elderly adults in family practice using an outcome prioritization tool, *J Am Geriatr Soc* 2016;64.

46 van Summeren JJ, Schuling J, Haaijer-Ruskamp FM, et al. Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice, *Br J Gen Pract* 2017;67:e501-6.

47 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. *Patient Preference and Adherence* 2017;11:131-40.

48 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. *BMJ Open* 2016;6:Arte Number: e009781. ate of Pubaton: 2016.

49 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEASES, CANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.

50 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimorbidity: A qualitative secondary analysis. *SAGE Open Medicine* 2013;1:2050312113503955.

51 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. *Chronic Illness* 2011;7:147-61.

52 Junius-Walker U, Wrede J, Voigt I, et al. Impact of a priority-setting consultation on doctor-patient agreement after a geriatric assessment: cluster randomised controlled trial in German general practices. *Quality in primary care* 2012;20.

53 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general practitioners: a cross-sectional study. *Quality in primary care* 2011;19.

54 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patients differ from treatment priorities of their physicians, *Croat Med J* 2010;51:483-92.

55 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older patients with multimorbidity and their GPs - a qualitative study. *BMC family practice* 2015;16:68.

56 Herzig L, Mueller Y, Haller DM, et al. Family practitioners' top medical priorities when managing patients with multimorbidity: a cross-sectional study, *BJGP open* 2019;3:bjgpopen18X101622.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

57 Mantelli S, Jungo KT, Rozsnyai Z, et al. How general practitioners would deprescribe in frail oldestold with polypharmacy—the LESS study, *BMC family practice* 2018;19:169.

58 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, *BMC family practice* 2018;19:66.

59 Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes, *J Am Geriatr Soc* 2008;56:1409-16.

60 DeruazLuyet A., Alexandra N'Goran A., Tandjung R., et al. Multimorbidity in primary care: Protocol of a national cross-sectional study in Switzerland. *BMJ Open* 2015;5:Arte Number: e009165. ate of Pubaton: 2015.

61 Martin LA, Moye J, Street Jr RL, et al. Reconceptualizing cancer survivorship through veterans' lived experiences, *J Psychosoc Oncol* 2014;32:289-309.

62 Lindsay S, Bellaby P, Smith S, et al. Enabling healthy choices: is ICT the highway to health improvement? *Health:* 2008;12:313-31.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

63 Hurley MV, Walsh N, Bhavnani V, et al. Health beliefs before and after participation on an exercised-based rehabilitation programme for chronic knee pain: doing is believing, *BMC Musculoskeletal Disorders* 2010;11:31.

64 Bower P, Harkness E, Macdonald W, et al. Illness representations in patients with multimorbid long-term conditions: Qualitative study, *Psychol Health* 2012;27:1211-26.

65 Grime J, Richardson JC, Ong BN. Perceptions of joint pain and feeling well in older people who reported being healthy: a qualitative study, *Br J Gen Pract* 2010;60:597-603.

66 Nio Ong B, Jinks C, Morden A. The hard work of self-management: Living with chronic knee pain, *International journal of qualitative studies on health and well-being* 2011;6:7035.

67 Hansen H., Schafer I., Schon G., et al. Agreement between self-reported and general practitionerreported chronic conditions among multimorbid patients in primary care - results of the MultiCare Cohort Study. *BMC family practice* 2014;15:39.

68 Noel P.H., Frueh B.C., Larme A.C., et al. Collaborative care needs and preferences of primary care patients with multimorbidity. *Health Expectations* 2005;8:54-63.

69 Lechner S., Herzog W., Boehlen F., et al. Control preferences in treatment decisions among older adults - Results of a large population-based study. *J Psychosom Res* 2016;86:28-33.

70 Noel PH, Parchman ML, Williams JWJ, et al. The challenges of multimorbidity from the patient perspective. *Journal of General Internal Medicine* 2007;22:419-24.

71 Coventry PA, Fisher L, Kenning C, et al. Capacity, responsibility, and motivation: a critical qualitative evaluation of patient and practitioner views about barriers to self-management in people with multimorbidity, *BMC health services research* 2014;14:536.

72 Sinnott C., Mc Hugh S., Boyce M.B., et al. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. *British Journal of General Practice* 2015;65:e184-91.

73 Luijks HD, Loeffen MJW, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity management: a qualitative study. *British Journal of General Practice* 2012;62:e503-10.

74 Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority, *Arthritis Care & Research* 2002;47:391-7.

75 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, *The Lancet* 2012;380:37-43.

76 Smith SM, Wallace E, Salisbury C, et al. A Core Outcome Set for Multimorbidity Research (COSmm), *Ann Fam Med* 2018;16:132-8.

77 Heisler M, Vijan S, Anderson RM, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? *Journal of general internal medicine* 2003;18:893-902.

 78 Okubo Y, Tsuruta D, Tang A, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians, *Journal of the European Academy of Dermatology and Venereology* 2018;32:606-14.

79 Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature, *Soc Sci Med* 2000;51:1087-110.

80 Kaba R, Sooriakumaran P. The evolution of the doctor-patient relationship, *International Journal of Surgery* 2007;5:57-65.

81 Jowsey T, Dennis S, Yen L, et al. Time to manage: patient strategies for coping with an absence of care coordination and continuity, *Sociol Health Illn* 2016;38:854-73.


82 Mangin D., Stephen G., Bismah V., et al. Making patient values visible in healthcare: A systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity. *BMJ Open* 2016;6:Arte Number: e010903. ate of Pubaton: 01 Jun 2016.

Figure legends:

Figure 1: Flow diagram to illustrate process from literature searching to selection of studies for inclusion [28]

reziez onz

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





2. Pat	ients/
	·
3. 1 o	r 2
	prit*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
-	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
5. Ch	pice*.mp.
6. Pre	ference*.mp.
7. Air	n*.mp.
8. Go	al*.mp.
9. 4 o	r 5 or 6 or 7 or 8
10. D	octor*.mp.
11. P	nysicians/
12. Cl	inician*.mp.
13. Pı	imary Health Care/ or Physicians, Family/ or Family Practice/ or General Practitioners/
14. G	eneral practitioner*.mp.
15. 10) or 11 or 12 or 13 or 14
	ultimorbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading wo
•	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
17. N	ulti-morbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading
	, keyword heading word, protocol supplementary concept word, rare disease supplementary opt word, unique identifier, synonyms]
18. N	ultiple morbidit*.mp. [mp=title, abstract, original title, name of substance word, subject heading
	keyword heading word, protocol supplementary concept word, rare disease supplementary pt word, unique identifier, synonyms]
19. 10	5 or 17 or 18
20. 3	and 9 and 15 and 19
	ulti morbid*.mp. [mp=title, abstract, original title, name of substance word, subject heading wor
•	ord heading word, protocol supplementary concept word, rare disease supplementary concept , unique identifier, synonyms]
22. 10	5 or 17 or 18 or 21
23. 3	and 9 and 15 and 22

	g et al [2]	-Sohi et al [3]	[4]	al [5]	[6]	[7]	[8]	en-2019-0; 9 yright, inc	[10]	Summeren et al [11]	al [12]
YES	YES	YES	YES	YES	YES	YES	YES	33445 on 12 Feb	YES	YES	YES
YES	YES	YES	YES	YES	YES	YES	YES	ruary 2020. Downloaded from http://bmjopen.t Erasmushogeschool . 'glated to text and data mining, AI training, any YE	NO- Quantitative or mixed methods methodology would have been more appropriate as the aim was to rank factors, although data collected using a qualitative technique, it lacks richness and appears to be presented in a quantitative manner	YES	YES
YES		YES			YES	YES	017	YES similar technol	YES		YES
YES	YES	YES	YES	YES	YES	NO- no explanation given as to	YES	Cī (YES	YES	YES
	YES	YES YES YES YES	YES YES YES YES YES YES	YES YES YES YES YES YES YES YES YES YES YES YES	YES YES YES YES YES YES YES YES YES YES YES YES YES YES	YES	YES	YES	YES YES <td>CT CT</td> <td>CT CT</td>	CT CT	CT CT

 28 of 45

Page	29	of	45
------	----	----	----

of 45			

f 45						BMJ Ope	n		6/bmjopen-2019- 1 by copyright, ir			
appropriate to the aims of the research							why the specific conditions were chosen (COPD, IBS etc)		033445 on 12 ncluding for u			
Were the data collected in a way that addressed the research issue?	YES	YES	YES	YES	YES	YES	YES	YES	ebruary 2020. E Erasmusho S related to tex	YES	YES	YES
Has the relationship between researcher and participants been adequately considered?	YES	YES	YES	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point.	NO- There is no background information given on the researcher (sole in this case) and there has been no evidence of any consideration of researcher bias at any point during the study.	NO- there has been no evidence of any consideration of researcher bias at any point during the study	NO- no information given on background of main researcher and no consideration given to possibility of researcher bias at any point. However there was some evidence of reflexivity during the data collection process when emerging areas of interest that could be incorporated into future interviews	NO- background of RAE who conducted interviews and main aspect of analysis not specified and no consideration has been given to any possibility of researcher bias	February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA Erasmushogeschool sio for the profession of t	NO- no mention of the background of the researchers or how this may have influenced the results	NO- role of second interviewer carrying out the in-depth interviews not mentioned, and there has been no consideration given to the possibility of bias from the interviewers. One of the interviewers was a FP, which could have led to bias with the interviewees responses.	NO- there has been no consideration n given to the role of the researcher and the potential for researcher bias at any point.

						BMJ Ope	'n		6/bmjopen-2019-033445 4 by copyright, including			Pa
							were considered.		9-0334 includ			
Have ethical issues been taken into consideration ?	YES	YES	YES- in the original studies, however further ethical issues regarding secondary qualitative analysis were not taken into account.	YES	YES	YES	YES	YES	on 12 J for u	YES	YES	YES
Was the data analysis sufficiently rigorous?	YES	YES	YES	YES	NO- superficial description of analytic process and no information given on how many researchers analysed the transcripts- assumed one as there is only one author- risk of bias not taken into account for the analytic process	YES	YES	YES	February 2020. Downloaded from http://bmjopen.bmj.com/ on May 12, 2025 at Deparence Erasmushogeschool . ses related to text and data mining, Al training, and similar technologies.	NO- the data analysis process is very ambiguous and the qualitative analysis has not been described in sufficient depth.	YES- clear description of the analytic process with two researchers independentl y analysing the data for rigour. However no description of the interpretation phase from the data.	NO- there is only a superficial description of the data analysis process, and there is very little detail given on how the themes were derived from the data. There is no presentation at all of quotes from the data to support the authors interpretation n of the data
Is there a clear	YES	YES	YES	YES	YES	YES	YES	YES	at Department GEZ-LTA	YES	YES- however the qualitative	YES- however no quotes given

Page 31	of 45						BMJ Ope	en		6/bmjopen-2019- J by copyright, in			
1 2 3 4 5 6 7 8	statement of findings?									033445 on cluding fo		data from the patient interviews has only been summarised- no direct	to support findings
9 10 11	How valuable is the research?	Valuable	0	Valuable	quotes given Valuable	Valuable							
$\begin{array}{c} 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ \end{array}$							Valuable			125 at Department GEZ-LTA			

	Newcastle	e-ottawa scale	e for cohort	BMJ Open	Comparability of cohorts on the basis of the design or analysis controlled for confounders The study controls for age, sex and marital status (one star)*	6/bmjopen-2019-033445 on 12 February Eray	2	
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis controlled for confounders	Assessment Assessment Control of Control of Control of Control of Control of Control of Control of	Was follow- up long enough for outcomes to occur	Adequacy of follow-up of cohorts
Zulman et al [13]	Somewhat representative (one star) *	Drawn from the same community as the exposed cohort (one star) *	Secure record (one star) *	N/A	The study controls for age, sex and marital status (one star)*	Self-report	N/A	No statement
				10	The study controls for age, sex and marital status (one star)*	http://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

of 45				A	xis tool f	or cross	-sectional	studies :	summar	y table \overline{s}	Mantelli et al		
	Intro	duction	Junius- Walker et al [14]	Fried et al[15]	Fried et al [16]	Moore et al [17]	Van Summeren et al [18]	Voigt et al [19]	Van Summeren et al [11]	Caughey S al [20]	Mantelli et al	Deruaz- Luyet et al [22]	Herzig et al [23]
	1	Were the aims/objectives of the study clear?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes includir		Yes	Yes
	Meth	ods								6ı	5 0		
	2	Was the study design appropriate for the stated aim(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes for uses re	1 ^Y es 12 Feb	Yes	Yes
	3	Was the sample size justified?	No- convenien ce sampling used, small sample size, however no explanatio n for sample size given	No- no justificatio n for sample size given, convenien ce sampling used	No- recruitme nt strategy described clearly but no justificatio n for sample size given	Yes	No	No- sampling strategy described well but no justificati on for sample size given	No- purposive sampling used, however no justificatio n for sample size given	data mining, Al tr	Taylo- Convenience Convenienc	Yes- in the parent study [24]	Yes- in the parent stud [24]
	4	Was the target/reference population clearly defined? (Is it clear who the research was about?)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes aining, and sir	bmjopen.bmj.	Yes	Yes
	5	Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?	Yes	Yes- However assumptio n made that participant s will have multiple chronic conditions	Yes	Yes	Yes	Yes	Yes	Yes hilar technologies.	Yes- lthough only GP's who data previously cher case- construction whether case- construction constructi	Yes	Yes

						BMJ Ope	n		y copyright	bmjopen-20		
6	Was the selection process likely to select subjects/participan ts that were representative of the target/reference population under investigation?	Yes	Yes- as above	Yes	Yes	Yes	Yes	Yes	d by copyright, including for uses relate Yes	19-03 445 on 12 Februar	Yes	Yes
7	Were measures undertaken to address and categorise non- responders?	Yes	Don't know- not reported	Yes	No	No	No	Yes- Purposive sampling used with efforts made to address gaps in participant types	Don't d	2000 't know- 2002 to reported 2020. Downloaded from http://bm	Yes in the parent study [25]. Characteristi cs of participants who were not included due to missing data, were described in this study	Yes in the parent stu [25]
8	Were the risk factor and outcome variables measured appropriate to the aims of the study?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	ies ig, and sim	S Spen.bmj.co	Yes	Yes
9	Were the risk factor and outcome variables measured correctly using instruments/measu rements that had been trialled, piloted or published previously?	Yes	Yes- piloted in a previous study	No- Tested in this study as it was a feasibility study	No- Pre- tested in this study but only using 2 FP's and 1 NP	Yes	No- STEP assessme nt previousl y published however no testing done of measure used to collect importan ce ratings	Yes	Yes Yes	Yes- the onstruments ised were within this yithin thi	No- instruments designed through "internal consensus discussions".	No

						BMJ Ope	n			bmjope		
									y 11911, 1	6/bmjopen-2019		
10	Is it clear what was used to determined statistical significance and/or precision estimates? (e.g. p- values, confidence intervals)	Yes	N/A	Yes	Yes	N/A	Yes	N/A		-033445 on 12 Februa	Yes	Yes
11	Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	کلهmjopen-2019-033445 on 12 February 2020. Downloaded from Erasmushogeschool . - Erasmushogeschool .	Yes	Yes
Rest	ults											
12	Were the basic data adequately described?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	es http://bmjopen.bmj.co	Yes	Yes
13	Does the response rate raise concerns about non- response bias?	No	Don't know- response rate not reported	No	No	No	Don't know- response rate not reported	No	Don't know- response rate not reported No	n May 1	No	No
14	If appropriate, was information about non-responders described?	Yes	No	Yes	No	Yes	No	Yes	No	् 2, 2025 at Department GEZ-LTA	Yes in the parent study[25] Characteristi cs of participants who were not included	Yes in th parent study[25

						BMJ Ope	า		-	v copyright.	6/bmiopen-2019-		
										ncluding for u	033445 on 12	due to missing data, were described in this study	
15	Were the results internally consistent?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ises rel	Tres ebru	Yes	Yes
16	Were the results presented for all the analyses described in the methods?	Yes	Yes	Yes	Yes	No- No reporting of prioritisation of patients for whom no medication changes were proposed	Yes	Yes	Yes	Erasmushogeschool .	arv 2020. Downloaded	Yes	Yes
Discu	ission				2					nin	fro		
17	Were the authors' discussions and conclusions justified by the results?	No- very small sample of GP's compared to patients therefore generaliza ble conclusion s regarding concordan ce between doctors and patients cannot accurately be drawn from this study	Yes	Yes	Yes	Yes	Yes	Yes- Small sample size for quantitativ e aspect of study taken into account	No- very small sample siz across patients an clinicians meaning results are not generaliza e	ng. Aktraining, and similar technologies.	ස් http://bm.iopen.bmi.com/ on May 12. 2025 at Department GEZ-LTA	Yes	Yes

										6/bmjopen-2019- 4 by copyright, ir		
18	Were the limitations of the study discussed?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	6/bmjopen-2019-033445 on by copyright, including for	Yes	Y
Othe										on fo		
19	Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?	No	No	No	No	No	No	No	No	ی 12 February 2020 Erasmus r uses related to	No	N
20	Was ethical approval or consent of participants attained?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	text and data	Yes	Y
										rom http://bmjc ining, Al trainin		
						2×16				on 12 February 2020 کی Erasmushogeschool . for uses related to text and data mining, Al training, and similar technologies.		

26

33 34

	BMJ Open ol for assessing risk of bias in random	6/bmjopen 1 by copyri
		ght, inc
The Cochrane Collaboration's to	ol for assessing risk of bias in random	nised controlled trials summary table
Study	Junius-Walker et al [26]	ng f
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Participating doctors were allocated 1:1 into the intervention and control group using random block
		sizes of Buig
Allocation concealment (selection bias)	Unclear risk	No information given regarding any efforts to conceal the allocation equence
Blinding of participants and researchers (performance	Low risk	Participate vere only informed of the procedures of
bias) Blinding of outcome assessment (detection bias)	Low risk	Participate Sere blinded to the pre-intervention
	$\rho_{\rm o}$	importance and a second s
Incomplete outcome data (attrition bias)	High risk	25 patients depend out prior to baseline ratings and 5 further patients dropped out prior to final ratings, these patients dere excluded from analysis, however intention to treat analysis cannot be carried out in this context due to the nature of the intervention
Selective reporting (reporting bias)	Low risk	Adequate reperting on all of the specified outcomes
Other bias	None detected	
		jopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA ing, and similar technologies.
For moor	raviou anly http://bmianan.hmi.com/sita/about/gui	F Contraction of the second seco

Page 39 of 45	BMJ Open Sp jop
1 2	BMJ Open by opyright, inclus 34 References BMJ Open 2019-0334
3 4	References
5 6 7	1 Kuluski K, Gill A, Naganathan G, et al. A qualitative descriptive study on the alignment of care goals between of gersons with multi-morbidities, their family physicians and informal caregivers. <i>BMC Family Practice</i> 2013;14:133.
8 9 10 11	2 Schoenberg NE, Leach C, Edwards W. "It's a toss up between my hearing, my heart, and my hip": prioritizing and accommodating multiple morbidities by vulnerable older adults, <i>J Health Care Poor Underserved</i> 2009;20:134-51.
12 13 14	3 Cheraghi-Sohi S, Morden A, Bower P, et al. Exploring patient priorities among long-term conditions in multimotion in multimotion in multimotion in secondary analysis. <i>SAGE Open Medicine</i> 2013;1:2050312113503955.
15 16 17	4 Naik A.D., Martin L.A., Moye J., et al. Health Values and Treatment Goals of Older, Multimorbid Adults Facing The Threatening Illness. J Am Geriatr Soc 2016;64:625-31.
18 19 20 21	5 LINDSAY S. PRIORITIZING ILLNESS: LESSONS IN SELFa MANAGING MULTIPLE CHRONIC DISEAS ANADIAN JOURNAL OF SOCIOLOGY/CAHIERS CANADIENS DE SOCIOLOGIE 2009;34:983.
22 23 24	6 Hansen H., Pohontsch N., van den Bussche H., et al. Reasons for disagreement regarding illnesses between older batter is with multimorbidity and their GPs - a qualitative study. <i>BMC family practice</i> 2015;16:68.
25 26 27	7 Morris R.L., Sanders C., Kennedy A.P., et al. Shifting priorities in multimorbidity: A longitudinal qualitative study of patient's prioritization of multiple conditions. <i>Chronic Illness</i> 2011;7:147-61.
28 29 30	8 Elliott RA, Ross-Degnan D, Adams AS, et al. Strategies for coping in a complex world: adherence behavior among odder adults with chronic illness, <i>Journal of General Internal Medicine</i> 2007;22:805-10.
31 32 33 34	9 Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making, <i>J Am Geriatr Soc</i> 2008;56:1839-44.
34 35 36 37	10 Turner J.P., Edwards S., Stanners M., et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. <i>BMJ Open</i> 2016;6:Arte Number: e009781. ate of Pubaton: 2016.
38 39 40 41 42	11 Summeren JJ, Haaijer-Ruskamp FM, Schuling J. Eliciting preferences of multimorbid elderly adults in family practing e using an outcome prioritization tool, <i>J Am Geriatr Soc</i> 2016;64.
43	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

13 Zulman D.M., Kerr E.A., Hofer T.P., et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. Journal of General Internal Medicine 2010;25:408-14.

14 Junius-Walker U, Stolberg D, Steinke P, et al. Health and treatment priorities of older patients and their general attioners: a cross-sectional study.

2444119 In primary care 2011;19. 15 Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older provide the multiple chronic conditions, Arch Intern Med 2011;171:1856-8 Arch Intern Med 2011;171:1856-8.

16 Fried TR, Tinetti M, Agostini J, et al. Health outcome prioritization to elicit preferences of older persons with naile health conditions, *Patient Educ* Couns 2011;83:278-82.

17 Moore A., Patterson C., Nair K., et al. Minding the gap: Prioritization of care issues among nurse practitioners, Family physicians and geriatricians when caring for the elderly. Journal of interprofessional care 2015;29:401-3.

18 Van Summeren J.J.G.T., Schuling J., HaaijerRuskamp F.M., et al. Outcome prioritisation tool for medication regime in older patients with multimorbidity: A pilot study in general practice. British Journal of General Practice 2017;67:e501-6. and

19 Voigt I, Wrede J, Diederichs-Egidi H, et al. Priority setting in general practice: health priorities of older patient differ from treatment priorities of their physicians, Croat Med J 2010;51:483-92.

20 Caughey G.E., Tait K., Vitry A.I., et al. Influence of medication risks and benefits on treatment preferences in deterbatients with multimorbidity. Patient Preference and Adherence 2017;11:131-40.

family practice 2018;19:169.

22 Déruaz-Luyet A, N'Goran AA, Pasquier J, et al. Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland, BMC family practice 2018;19:66. tment GEZ-LTA

Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

		Reporting Item	Page Number
Title			Page Number
	<u>#1</u>	Identify the report as a systematic review, meta-	1
		analysis, or both.	
Abstract			
Structured	<u>#2</u>	Provide a structured summary including, as applicable:	2
summary		background; objectives; data sources; study eligibility	
		criteria, participants, and interventions; study appraisal	
		and synthesis methods; results; limitations; conclusions	
		and implications of key findings; systematic review	
		registration number	
Introduction			
Rationale	<u>#3</u>	Describe the rationale for the review in the context of	3
		what is already known.	
	For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Objectives	<u>#4</u>	Provide an explicit statement of questions being	а 3 с	
3 4			addressed with reference to participants, interventions,	open: t	
5 6 7			comparisons, outcomes, and study design (PICOS).	irst put	
8 9 10 11	Methods			BMJ Open: first published as 10.1136/bmJopen-Z019-033445 on 12 February 2020. Protected by copyright, including for uses related to te 3	יוויירייין איט א
12 13	Protocol and	<u>#5</u>	Indicate if a review protocol exists, if and where it can be	es 10.1136/bmjopen-2019-033445 on 12 February 202 Erasmu Protected by copyright, including for uses related to 3 4, 3,	1212
14 15	registration		accessed (e.g., Web address) and, if available, provide	by co	1
16 17			registration information including the registration	pen-zu pyrigh	
18 19 20			number.	t, inclu	10 020
20 21 22	Eligibility criteria	#6	Specify study characteristics (e.g., PICOS, length of	uding fo 3,4 fo	5447 2
23 24		<u>#0</u>	follow-up) and report characteristics (e.g., years	or use	; ; ; ;
25 26				s relat	, L
27 28			considered, language, publication status) used as	ed to	- 2020
29 30 31			criteria for eligibility, giving rational		
32 33	Information	<u>#7</u>	Describe all information sources in the search (e.g.,	voyeschool . xt and data mining, A ع	
34 35	sources		databases with dates of coverage, contact with study	oaded from n data mining, ℃	1
36 37			authors to identify additional studies) and date last		
38 39 40			searched.	raining,	
41 42	Search	<u>#8</u>	Present full electronic search strategy for at least one	3, Appendix 1 s	5
43 44 45			database, including any limits used, such that it could be	milar t	
46 47			repeated.	Al training, and similar technologies. 3, Appendix 1 4, Figure 1	
48 49 50	Study selection	<u>#9</u>	State the process for selecting studies (i.e., for	4, Figure 1	2 2227
51 52			screening, for determining eligibility, for inclusion in the	at Dep	1
53 54 55			systematic review, and, if applicable, for inclusion in the	artme	
56 57			meta-analysis).	יידי איז איז איז איז איז איז איז איז איז אי	100
58 59 60		For	oeer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		- + >

1 2	Data collection	<u>#10</u>	Describe the method of data extraction from reports	4
3 4 5	process		(e.g., piloted forms, independently by two reviewers)	
5 6 7			and any processes for obtaining and confirming data	
8 9 10			from investigators.	
11 12	Data items	<u>#11</u>	List and define all variables for which data were sought	3
13 14			(e.g., PICOS, funding sources), and any assumptions	
15 16 17 18			and simplifications made.	
19 20	Risk of bias in	<u>#12</u>	Describe methods used for assessing risk of bias in	4
21 22	individual		individual studies (including specification of whether this	
23 24	studies		was done at the study or outcome level, or both), and	
25 26 27			how this information is to be used in any data synthesis.	
28 29 30	Summary	<u>#13</u>	State the principal summary measures (e.g., risk ratio,	N/A
31 32 33	measures		difference in means).	
34 35	Planned	<u>#14</u>	Describe the methods of handling data and combining	4,5
36 37	methods of		results of studies, if done, including measures of	
38 39 40	analyis		consistency (e.g., I2) for each meta-analysis.	
41 42 43	Risk of bias	<u>#15</u>	Specify any assessment of risk of bias that may affect	4
43 44 45	across studies		the cumulative evidence (e.g., publication bias, selective	
46 47 48			reporting within studies).	
49 50	Additional	<u>#16</u>	Describe methods of additional analyses (e.g.,	N/A
51 52 53	analyses		sensitivity or subgroup analyses, meta-regression), if	
53 54 55			done, indicating which were pre-specified.	
56 57 58	Results			
59 60		For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Study selection	<u>#17</u>	Give numbers of studies screened, assessed for	Figure 1
3 4			eligibility, and included in the review, with reasons for	ppen: f
5 6 7			exclusions at each stage, ideally with a flow diagram.	Figure 1 Figure 1 Figure 1 Figure 1 Figure 1 Frotected by copyright, including for uses related to to Appendix 2 N/A Figure 1 N/A
8 9 10	Study	<u>#18</u>	For each study, present characteristics for which data	5,6,7,8,9,10 5 ,6,7,8,9,10
11 12	characteristics		were extracted (e.g., study size, PICOS, follow-up	(Table 1) tote
13 14			period) and provide the citation.	l36/brr ed by
15 16	Dick of high	#10	Drepart data on rick of bigs of each study and if	copyr Annordiy 2
17 18	Risk of bias	<u>#19</u>	Present data on risk of bias of each study and, if	Appendix 2 right,
19 20	within studies		available, any outcome-level assessment (see Item 12).	9-0334 includ
21 22	Results of	<u>#20</u>	For all outcomes considered (benefits and harms),	rotected by copyright, including for uses (Table 1) Appendix 2 N/A
23 24 25	individual		present, for each study: (a) simple summary data for	12 Feb ' uses
26 27	studies		each intervention group and (b) effect estimates and	related
28 29			confidence intervals, ideally with a forest plot.	
30 31				Downl gescl (t and
32 33	Synthesis of	<u>#21</u>	Present the main results of the review. If meta-analyses	11,12,13,14,15 da lo la
34 35	results		are done, include for each, confidence intervals and	togeschool ed from htt 11,12,13,14,15 tand data mining, J
36 37			measures of consistency.	
38 39 40	Risk of bias	<u>#22</u>	Present results of any assessment of risk of bias across	ttp://bmjopen.bmj.com/ on May 12, 2 Al training, and similar technologies 10 N/A N
41 42 43	across studies		studies (see Item 15).	n.bmj.c and sim
44 45	Additional	<u>#23</u>	Give results of additional analyses, if done (e.g.,	illar tec N/A tec
46 47 48	analysis		sensitivity or subgroup analyses, meta-regression [see	May 1: hnolog
49 50			Item 16]).	2, 2025 Jies.
51 52 53 54	Discussion			p://bmjopen.bmj.com/ on May 12, 2025 at Department GEZ-LTA 1 training, and similar technologies. 10 N/A 16
55 56	Summary of	<u>#24</u>	Summarize the main findings, including the strength of	16 G
57 58	Evidence		evidence for each main outcome; consider their	EZ-LT
59 60		For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	>

			relevance to key groups (e.g., health care providers,
			users, and policy makers
Limitations		<u>#25</u>	Discuss limitations at study and outcome level (e.g., risk
			of bias), and at review level (e.g., incomplete retrieval of
			identified research, reporting bias).
Conclusions		<u>#26</u>	Provide a general interpretation of the results in the
			context of other evidence, and implications for future
			research.
Funding			
-			
Funding		<u>#27</u>	Describe sources of funding or other support (e.g.,
			supply of data) for the systematic review; role of funders
			for the systematic review.
Notes:			
•	8: 3, appendix	: 1	
•	9: 4, Figure 1		
• 18: 5,6,7,8,9,10 (Table 1)		0 (Tal	ble 1)
•	21: 11,12,13,1	4,15	
	The PRISMA checklist is distributed under the terms of the Creative Commons Attribution		
	License CC-BY. This checklist was completed on 13/11/2019		
		For p	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml